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Eine Eigenschaft chronischer Helmintheninfektionen ist die lange Verweildauer der Parasiten 
für Jahre oder Jahrzehnte im infizierten Wirtsorganismus. Um solche Lebensspannen zu 
erreichen, wirken Helminthen der Immunantwort ihrer Wirte durch Evasionsmechanismen 
entgegen, zum Beispiel durch die Sekretion immunmodulierender Moleküle. In diesem 
Zusammenhang wurde in Vorarbeiten gezeigt, dass Filarien-Cystatin (AvCystatin) Parameter 
allergischer Atemwegsentzündung in Mäusen in einer IL-10 abhängigen Weise signifikant 
reduzieren konnte (Schnoeller et al., 2008). Die Beobachtung, dass eine Depletion von 
Makrophagen diese Immunsuppression wieder aufhob, führte zu der Hypothese, dass ein 
Makrophagen-vermittelter Mechanismus für die Linderung von Krankheitssymptomen 
verantwortlich sein muss. Die vorliegende Arbeit hatte zum Ziel, AvCystatin-modulierte 
Makrophagen (AvCystatin-MФ) in zwei wesentlichen Ansatzpunkten zu analysieren. Erstens 
wurden Signalwege ermittelt, die in peritonealen Makrophagen nach Behandlung mit dem 
Immunmodulator zur Produktion von IL-10 führten. Zweitens sollten die suppressorischen 
Eigenschaften von AvCystatin-MФ und die molekularen Besonderheiten der Makrophagen-
vermittelten Immunsuppression in zwei Krankheitsmodellen der Maus untersucht werden.   
Die Stimulation von peritonealen Maus-Makrophagen mit AvCystatin führte zu einer frühen, 
jedoch transienten Expression von IL-10 in den Makrophagen und korrelierte mit einer 
Phosphorylierung der Mitogen-aktivierten Proteinkinasen (MAPK) p38 und ERK. Um die 
transiente IL-10-Expression in AvCystatin-MФ zu verstehen, wurde der Einfluss von dual-
spezifischen Phosphatasen (DUSPs) auf die MAPK-Aktivität und IL-10-Expression 
untersucht. Die Behandlung mit AvCystatin in vitro und in vivo führte zu einer Hochregulation 
der Phosphatasen DUSP-1, DUSP-2 und DUSP-5. Die erhöhte Expression von IL-10 und die 
Akkumulation von p38 in DUSP-1 defizienten Mäusen nach AvCystatin-Behandlung 
bekräftigte eine entscheidende Rolle der Phosphatase DUSP-1 für die Regulation der MAPK 
p38 und ERK und die damit verbundene IL-10-Expression. Diese Ergebnisse zeigen, dass 
AvCystatin Signalkaskaden in Makrophagen addressiert, um auf diese Weise die Produktion 
von IL-10 anzuregen. 
Die funktionelle Charakterisierung von AvCystatin-MФ in einem murinen Model der 
Ovalbumin-induzierten Atemwegsentzündung zeigte, dass suppressive Effekte unabhängig 
von der initialen IL-10-Expression der Makrophagen auf die inflammatorische Wirtsantwort 
vermittelt werden können. Bereits ein einmaliger Transfer von AvCystatin-MФ führte zu einer 
prominenten Reduktion von Gesamt- und Allergen-spezifischem Serum-IgE, verminderte die 




die systemische Th2 Zytokin-Antwort und milderte die Schleimproduktion in den Atemwegen. 
Die AvCystatin-MФ vermittelte Abschwächung entzündlicher Prozesse war mit signifikant 
erhöhten Mengen IL-10 in den Empfängertieren assoziiert. Um die Effekte von AvCystatin-
MФ in einem weiteren Krankheitsmodell zu untersuchen, wurden Makrophagen in Mäuse mit 
DSS-induzierter Kolitis transferiert. Die Auswertung von Kolonschnitten sowie die Analyse 
von inflammatorischen Zellen in der Submukosa des Kolons, Körpergewichtskontrollen und 
Messungen der Kolonlänge ergaben, dass die Behandlung mit AvCystatin-MФ Mäusen einen 
effizienten Schutz gegen intestinale Entzündung vermitteln konnte. 
In weiteren Untersuchungen wurde der Phänoptyp von in vitro und in vivo induzierten 
Makrophagen untersucht. Quantitative Real-time PCR von AvCystatin-MФ zeigte in beiden 
Fällen eine frühe und transiente Expression der pro- und anti-inflammatorischen Markergene 
iNOS, IL-12/23p40, TNF-α, IL-6 und IL-10. Dieser Phänotyp wechselte nach 18-20 Stunden 
zu einer M2a/M2b Hybrid-Signatur, charakterisiert durch die Expression der Markergene 
Arginase-1 (ARG-1), Sphingosinkinase-1 (SPHK-1) und LIGHT (TNFSF14). Eine 
durchflusszytometrische Analyse von Oberflächenmarkern der F4/80+CD11b+ AvCystatin-
MФ zeigte eine Hochregulation von MHC-II, kostimulatorischen Molekülen (CD40, CD80 und 
CD86), Fcγ-Rezeptoren (CD16/32), PD-L1 (CD274), PD-L2 (CD 273) und ICAM-1.    
Um den zugrunde liegenden Mechanismus der AvCystatin-MФ vermittelten Induktion von IL-
10 in T-Zellen besser zu verstehen, wurde eine in vitro Kokultur aus Makrophagen, 
dendritischen Zellen und Ovalbumin-spezifischen CD4+ T-Zellen etabliert. Dabei zeigte sich, 
dass AvCystatin-MФ die IL-2-, IFN-γ- und IL-13-Sekretion von CD4+ T-Zellen unterdrücken, 
gleichzeitig aber einen signifikanten Anstieg von IL-10 in diesen T-Zellen bewirken. Die 
Generierung von CD4+IL-10+ T-Zellen erfolgte zellkontaktunabhängig und war spezifisch für 
den in vivo induzierten Phänotyp der AvCystatin-MФ. Eine Blockade des IL-10 Rezeptors auf 
T-Zellen vor Kokultivierung mit dendritischen Zellen und Makrophagen führte zu keiner 
Umkehrung der durch AvCystatin-MФ vermittelten Effekte. 
Zusammenfassend konnte in der vorliegenden Arbeit eine durch das immunmodulierende 
Molekül AvCystatin induzierte suppressive Makrophagenpopulation charakterisiert werden, 
die unabhängig von der Anwesenheit des Immunomodulators gegen Entzündungsreaktionen 





A feature of chronic helminth infections is the long parasite persistence for years or decades 
in the infected vertebrate host. To achieve such life spans, helminths counteract host 
immune responses with a panel of evasion mechanisms, e.g. through the secretion of 
immunomodulatory molecules. In this context, previous studies reported on filarial cystatin 
(AvCystatin) which reduced clinical parameters of allergic airway inflammation in mice in an 
IL-10-dependent manner (Schnoeller et al., 2008). Since depletion of macrophages reversed 
the observed immunosuppression, a macrophage-mediated mechanism was hypothesized to 
be responsible for the amelioration of disease. The present study aimed to analyse 
AvCystatin-stimulated macrophages (AvCystatin-MФ) in two major steps. First, signalling 
events were investigated which led to IL-10 producion in macrophages after treatment with 
the immunomodulator. Second, the efficiency and molecular characteristics of AvCystatin-
MФ-induced immunosuppression was determined in two murine disease models. 
Stimulation of murine peritoneal macrophages with AvCystatin induced an early but transient 
IL-10 expression in macrophages and correlated with phosphorylation of mitogen-activated 
protein kinases (MAPK) p38 and ERK. To understand the transient nature of IL-10 
expression in AvCystatin-MФ, the impact of dual-specificity phosphatases (DUSPs) on MAPK 
activity and IL-10 expression was examined. Treatment of macrophages with AvCystatin in 
vitro and in vivo induced up-regulation of DUSP-1, DUSP-2 and DUSP-5. Increased IL-10 
expression and the accumulation of p38 in DUSP-1-deficient mice after treatment with 
AvCystatin confirmed a predominant role of DUSP-1 for the regulation of p38 and ERK and 
the associated IL-10 expression. These findings show that AvCystatin targets signalling 
pathways in macrophages to induce IL-10 production. 
Functional characterization of AvCystatin-MФ in a murine model of ovalbumin-induced airway 
inflammation showed that AvCystatin-MФ can mediate suppression on inflammatory host 
responses independent of the initial IL-10 expression by the macrophages. Single application 
of AvCystatin-MФ led to a prominent reduction of total and allergen-specifc serum IgE, 
reduced the amount of eosinophils and Th2 cytokines in the bronchoalveolar lavage fluid, 
suppressed systemic Th2 cytokine responses and mitigated mucus production in the 
airways. The resolution of allergic inflammation was associated with significantly increased 
levels of IL-10 in recipient mice. To asses the effects of AvCystatin-MФ in an additional 
disease model, AvCystatin-MФ were transferred into mice suffering from DSS-induced colitis. 
Intravenous treatment with AvCystatin-MФ efficiently protected mice against the development 




of inflammatory cell influx into the submucosal compartment, control of body weight and 
measurement of colon length.      
In subsequent studies the phenotype of in vitro- and in vivo-induced peritoneal AvCystatin-
MФ was analysed. Quantitative real-time PCR in both cases revealed an early and transient 
expression of pro- and anti-inflammatory marker genes such as iNOS, IL-12/23p40, TNF-α, 
IL-6 and IL-10 after contact with the immunomodulator. This phenotype changed towards a 
suppressive M2a/M2b hybrid signature after 18-20 hours which was characterized through 
the expression of arginase-1 (ARG-1), sphingosine kinase-1 (SPHK-1) and LIGHT 
(TNFSF14). Surface marker analysis of the F4/80+CD11b+ AvCystatin-MФ through flow 
cytometry showed an up-regulation of MHC-II, co-stimulatory molecules (CD40, CD80 and 
CD86), Fcγ receptors (CD16/32), PD-L1 (CD274), PD-L2 (CD273) and ICAM-1.  
To understand the underlying mechanism of IL-10 induction by AvCystatin-MФ, an in vitro co-
culture assay was established in which macrophages were incubated with dendritic cells and 
ovalbumin-specific CD4+ T cells. AvCystatin-MФ suppressed the secretion of IL-2, IFN-γ and 
IL-13 but induced significant amounts of IL-10 in CD4+ T cells. The induction of CD4+IL-10+ T 
cells was cell contact independent and specific for in vivo-stimulated AvCystatin-MФ. 
Blockade of the IL-10 receptor on CD4+ T cells prior to co-culture with dendritic cells and 
macrophages did not reverse the effects of AvCystatin-MФ.  
In summary, the present thesis characterized the molecular characteristics of a suppressive 
macrophage population induced by the helminth immunomodulator AvCystatin which 
transfers protection against unrelated inflammation in different disease contexts independent 









Helminths are multicellular organisms which live as extracellular parasites at the expense of 
other organisms. They obtain nourishment from and reproduce in their hosts thereby inflicting 
morbidity. Beyond that, helminth parasites enhance susceptibility to viruses, bacteria and 
protozoan parasites (Hotez et al., 2008) and thus constitute a big health problem. To date, 
approximately one quarter of the world population is infected with helminth parasites. 
However, while helminth infections are rare in the western world, they are highly prevalent in 
developing and tropical countries. Helminths are usually divided into nematodes 
(roundworms), trematodes (flukes) and cestodes (tapeworms). Among these, nematodes are 
especially abundant. Parasitic nematodes are transmitted through arthropod vectors, faeco-
orally or actively penetrate the vertebrate host. Prominent gastrointestinal nematodes are 
Trichuris trichiura and hookworms such as Ancylostoma duodenale or Necator americanus. 
Important tissue-dwelling nematodes are represented by Brugia malayi, Wuchereria 
bancrofti, Onchocerca volvulus and Loa loa. Although nematodes can cause pathology (e.g. 
river blindness, elephantiasis or sowda), many chronically infected patients remain 
asymptomatic (van Riet et al., 2007). This means that helminth infections do not necessarily 
have to be accompanied by severe illness but rather suggests that well-adapted parasites 
prevent impetuous immune responses by tolerizing the host immune system and thereby 
avert damage to the parasitized host.    
3.1 Helminth infections and the modulation of immune disorders 
In recent years, epidemiological and laboratory studies confirmed that helminth parasites 
modulate the host immune system to ensure their survival and thereby exert spillover effects 
on unrelated immune dysfunctions such as atopy. This shows that besides many negative 
aspects of helminth infections, parasites also exhibit characteristics which can probably be 
exploited to treat aberrant immune reactions. Atopic diseases encompass a wide range of 
immunologic disorders. Among these, allergic asthma is a frequently occurring disease in 
westernized countries. It affects 200 to 300 million people worldwide (Braman, 2006) and is 
defined as a type I hypersensitivity chronic inflammatory disorder of the airways triggered by 
innocuous antigens that are usually well tolerated. Several risk factors are considered to 
influence the susceptibility of asthma such as genetic background, age, gender, nutritional 
condition, immune status and environmental factors, e.g. air pollution or stress (reviewed in 
Subbaro et al., 2009). The course of disease is divided into two phases (Holt et al., 1999). 
During the induction phase, an inhaled environmental allergen gets internalized and 




stromal lymphopoietin (TSLP) and directly equip dendritic cells with Th2-promoting capacity 
(Figure 3-1, b). The interaction between dendritic cells and CD4+ T cells leads to the 
development of Th2 effector T cells (Figure 3-1, c) which are key players for the 
establishment of Th2 immune responses. They secrete cytokines that favour disease 
induction and progression, namely IL-4, IL-5, IL-9 and IL-13. IL-5 induces recruitment and 
maturation of eosinophils (Figure 3-1, d). IL-4 promotes mast cell maturation (Figure 3-1, e) 
and, in combination with IL-13, triggers both isotype switching in B cells and the secretion of 
allergen-specific IgE by plasma cells (Figure 3-1, f). The secretion of IL-9 supports IL-5 in 
promoting eosinophilopoiesis and acts synergistically with IL-4 on mast cell development. In 
addition to Th2 cytokines, production of the stem cell factor (SCF) by epithelial cells supports 
mast cell recruitment (Figure 3-1, g). A number of activated CD4+ Th2 effector T cells 
develop into Th2 memory T cells which remain in a quiescent stage until they are activated 
through re-exposure to the same antigen (Figure 3-1, h). During the effector phase of 
asthma, the antigen binds to FcεRI-attached allergen-specific IgE on mast cells, basophils 
and eosinophils in a bivalent manner (Figure 3-1, i) which triggers the release of bioactive 
mediators (e.g. histamine, leukotrienes, prostaglandins etc.) from intracellular granules 
(Figure 3-1, j). Such factors cause smooth muscle contraction, increased bronchial mucus 
production and stimulation of sensory nerves that finally lead to clinical manifestation of 
asthma which is characterized through cardinal symptoms like itching, wheezing, coughing, 













Figure 3-1. Development of allergic airway inflammation. Allergic airway inflammation is induced 
through activation of dendritic cells by antigen (a) or TSLP (b). Interaction of dendritic cells with naïve 
CD4+ T cells evoke their differentiation into CD4+ Th2 effector T cells (c) that produce specific 
cytokines. Secreted IL-4, IL-5, IL-13 and IL-9 lead to eosinophilia (d), mast cell recruitment (e) and 
production of antigen-specific IgE by plasma cells (f). Secretion of SCF by epithelial cells further 
supports the recruitment and activation of mast cells (g). Moreover, Th2 memory cells are generated 
which remain in a quiescent state until there are re-activated through antigen-specific contact (h). 
Antigen binding to FcεRI-attached IgE on mast cells or eosinophils (i) leads to the release of mediators 
(j) which cause inflammation and pathophysiological modifications.      
In industrialized countries the prevalence of asthma and other allergy-related diseases has 
been remarkably rising in the last decades (ISAAC, 1998; Cooper, 2009). Formerly, this 
trend was explained by the “hygiene hypothesis” saying that an exposure to microbial 
infections during early childhood shifts the balance of Th1 and Th2 immune responses 
towards an anti-allergic Th1 response that counterbalance pro-allergic Th2 immunity and 
prevents the tendency to develop allergies (Strachan, 1989). Hence, reduced exposure to 
Th1-polarizing bacterial or viral infections in the western world as a result of improved public 
health, high hygiene standards and the early use of antibiotics or vaccinations could have 
given rise to an increased susceptibility to inappropriate immune responses to allergens. Two 
important observations, however, raised doubts against the model of Th1/Th2 counter 
regulation proposed by the hygiene hypothesis. First, not only did the incidence of allergic 
diseases rise dramatically in westernized countries, also Th1-biased autoimmune diseases, 
e.g. multiple sclerosis, type 1 diabetes or morbus crohn, considerably increased during the 




which are reminiscent to immunological responses in allergic disorders. Helminths could thus 
be expected to promote atopic disorders (Yazdanbakhsh et al., 2001), however, 
epidemiological studies found atopy to be less frequent in areas where helminth infections 
are endemic (Yazdanbakhsh et al., 2001; Nyan et al., 2001, Scrivener et al., 2001; Cooper et 
al., 2003; Dagoye et al., 2003). This inverse correlation raised a considerable interest in the 
question whether helminths ameliorate rather than exacerbate allergic diseases. Further 
laboratory studies verified protective effects of helminth infections in animal models of 
allergic inflammation and, by assuming that helminth immunosuppression might be a 
nonspecific process, addressed whether parasitic worms could also affect other dysregulated 
immune responses. Meanwhile beneficial effects of helminth parasites or secreted helminth 
molecules have successfully been evaluated in murine disease models for type 1 diabetes 
(Cooke et al., 1999; Saunders et al., 2007), arthritis (McInnes et al., 2003), experimental 
autoimmune encephalomyelitis (La Flamme et al., 2003) and colitis (Elliott et al., 2004; Smith 
et al., 2007). Furthermore, successful treatment of human inflammatory bowel disease 
patients with Trichuris suis or Necator americanus in clinical trials demonstrated that 
helminths can be used for therapeutic purposes (Summers et al. 2005; Croese et al., 2006). 
In consequence, a lively interest has emerged in particular in parasite-elicited 




3.2 Immunoregulation by helminth parasites 
Helminths are powerful immunoregulators that evade and modulate the immune system of 
their hosts (Maizels et al., 2004; Hewitson et al., 2009). Being in close contact with tissue, 
parasitic worms are directly exposed to the host`s immune response. The longevity of these 
pathogens for decades or even life-long in immunocompetent hosts, however, illustrates that 
they have shaped effective strategies to ensure their survival. 
3.2.1 Strategies of helminth immune evasion 
Helminth immune evasion includes a large repertoire of strategies. One such strategy is the 
migration through tissues and compartments in the host`s body or to dwell and hide in 
nodules. Moreover, parasitic worms are able to mask their surface with host-like molecules 
(molecular mimikry) or avoid antibody opsonisation and subsequent activation of the host`s 
immune system by either the secretion of antibody-degrading proteases or, mechanically, by 
moving and molting thereby peeling off the opsonising antibodies. Helminth parasites further 
modulate the host immune response towards a phenotype that has been designated as a 
“modified Th2 immune response” (Platts-Mills et al, 2001 a). Such immunomodulation is an 
important aspect of immune evasion and often associated with the induction of 
immunoregulatory cells that mediate cellular hyporesponsiveness. Regulatory T cells, for 
example, control innate and adaptive immune responses. They suppress immune reactions 
to allergens, prevent pro-inflammatory cytokine production by dendritic cells, convey 
suppressive activity to macrophages, inhibit proliferation of effector T cells and dampen both 
Th2 and Th1 cell responses (Hawrylowicz and O´Garra, 2005; McKee and Pearce, 2004; 
Kryczek et al., 2006; Grainger et al., 2010). Similarly, specific subpopulations of helminth-
derived B cells are described to exhibit suppressive functions either directly by the secretion 
of IL-10 or through the induction of Foxp3+ regulatory T cells (Mangan et al., 2004; Amu et 
al., 2010). In addition, antigen-presenting cells (APC) are important targets of helminth-
secreted products. The modulation of dendritic cell functions by helminths was shown to 
affect dendritic cell cytokine responses (Massacand et al., 2009), to influence the expression 
of co-stimulatory surface molecules on dendritic cells (Segura et al., 2007) and to support the 
induction of IL-10-producing regulatory T cells (van der Kleij et al., 2002). Helminth-induced 
macrophages show context-dependent functions. They are described as important mediators 
of tissue remodelling and either suppress T effector cells thereby promoting parasite survival 




The secretion of anti-inflammatory cytokines such as transforming growth factor β (TGF-β) or 
IL-10 by worm-induced regulatory cells is a key feature of helminth immunomodulation. TGF-
β has been shown to suppress cells of the innate immune system, to induce peripheral 
tolerance and to maintain the survival of regulatory T cells (Li et al., 2006). IL-10 was 
originally identified to suppress cytokine production by Th1 cells (Fiorentino et al., 1989) and 
therefore termed “cytokine synthesis inhibitory factor”. Meanwhile, it is known that IL-10 has 
multiple effects on different cell types. It down-regulates the activity of NK cells (Couper et 
al., 2008) and inhibits mast cell cytokine production, degranulation and IgE receptor 
expression (Arock et al., 1996; Royer et al., 2001; Norton et al., 2008). IL-10 further 
suppresses APC functions through the inhibition of major histocompatibility complex class II 
(MHC-II) or co-stimulatory molecule expression (de Waal Malefyt et al., 1991; Fiorentino et 
al., 1991) which, in turn, affects the development of Th1 and Th2 effector responses. In 
addition, IL-10 influences the balance of antibody isotypes by suppressing class switching to 
antigen-specific IgE and promoting the induction of IgG4 (Jeannin et al., 1998). While 
antigen-specific IgE is protective and involved in pathology, the IgG4 isotype suppresses 
complement activation (van der Zee et al., 1986) and counteracts IgE by competing for 
allergen binding sites thereby preventing IgE-mediated effector cell activation and 
degranulation. Such an uncoupling of specific IgG4 and IgE has been defined as a main 
feature of a modified Th2 response (Maizels and Yazdanbakhsh, 2003). Similar to IgG4, 
increased levels of parasite-induced polyclonal IgE have been considered to saturate IgE 
binding sites on effector cells which prevent degranulation through binding of allergen-
specific IgE (Holt et al., 1999; Erb, 2007). Since this so-called “IgE blocking” or “mast cell 
saturation hypothesis” had been postulated, it was used as a feasible explanation for the 
observation that anaphylactic reactions often occur in atopics but never or rarely in helminth-
infected individuals (Erb, 2007). The hypothesis was supported by early field studies showing 
that suppressive effects on atopy in helminth infections were associated with increased 
levels of polyclonal IgE (Godfrey, 1975; Merrett et al., 1976; Lynch et al., 1993). Additional 
findings, however, challenge the IgE-blocking theory, for example, by showing that 
Nippostrongylus brasiliensis-induced polyclonal IgE is able to block passive sensitization in 
rats but not hypersensitivity reactions mediated by actively produced IgE (Jarrett et al., 
1980). 
In brief, helminth immune evasion has emerged as an essential prerequisite for parasite 
survival and propagation. In particular the ability to actively modulate host immunity is 
suggested to be most likely effected through the secretion of mediators which target and 




3.2.2 Helminth immunomodulators 
The secretion of bioactive molecules is a hallmark of helminth immunomodulation. Once 
released, such mediators target host cells, interfere with signalling pathways and modify 
effector cell functions. Over the past few years, a couple of secreted factors have been 
identified and evaluated as important immunomodulators.  
Aminopeptidases. The leucine aminopeptidase ES-62 is the predominant ES product of the 
filarial nematode Acanthocheilonema viteae (Harnett et al., 2004). ES-62 is one of the best 
characterized immunomodulators and exerts its biological activity on a wide range of host 
immune cells through modifications of phosphorylcholine (Houston and Harnett, 2004; 
reviewed in Hewitson et al., 2009). ES-62 suppresses CD4+ T cell proliferation and T cell-
mediated secretion of IFN-γ and IL-4 (Marshall et al., 2005), promotes IL-10 production by 
B1 cells (Wilson et al., 2003) and affects B cell-T cell interactions (Marshall et al., 2008). ES-
62 was further shown to inhibit IL-12 production by dendritic cells and macrophages in 
response to lipopolysaccharide (LPS) (Goodridge et al., 2001 and 2003), prevented FcεRI-
mediated mast cell degranulation in a model of ovalbumin-induced airway inflammation 
(Melendez et al., 2007) and protected mice against collagen-induced arthritis (McInnes et al., 
2003). These findings show that ES-62 is a potent immunomodulatory molecule that holds 
great promise for therapeutical application. 
Cytokine homologues. Parasite-secreted cytokine homologues mimick biological functions 
of mammalian host cytokines. Brugia malayi homologues of the macrophage migration 
inhibitory factor (MIF) was shown to modify the activity of human monocytes and 
macrophages (Pastrana et al., 1998) and synergized with IL-4 for the induction of 
alternatively activated macrophages through up-regulation of the IL-4 receptor (Prieto-
Lafuente et al. 2009). TGF-β homologue 2 (TGH-2) of Brugia malayi was found to bind the 
mammalian TGF-β receptor and supposed to promote the induction of Foxp3+ regulatory T 
cells (McSorley et al., 2008). De novo expression of Foxp3 in T cells via the TGF-β pathway 
has been described for a TGF-β mimick of the gastrointestinal nematode Heligmosomoides 
polygyrus called Heligmosomoides polygyrus excretory-secretory antigen or HES (Grainger 
et al., 2010). Similarly, MIF homologues of Anisakis simplex (As-MIF) suppressed clinical 
parameters of Th2 inflammation in a murine model of allergic airway inflammation through 




C-type lectins and galectins. Parasite-derived C-type lectins were found to mimick different 
host molecules. TES-32 and TES-70 of the dog roundworm Toxocara canis show high 
homology to mammalian proteins like the low affinity receptor for IgE (CD23) or the mannose 
receptor (CD206) on macrophages. TES-70 was further determined to mask worm 
carbohydrates by binding mammalian carbohydrates (Loukas et al. 1999 and 2000; reviewed 
in Hewitson et al., 2009). Galectins are carbohydrates that have been discussed as 
“amplifiers, silencers or tuners of inflammatory responses” (Rabinovich et al., 2002). 
Galectins of Haemonchus contortus are capable of modulating eosinophil migration in vitro 
(Turner et al., 2008) and Onchocerca volvulus beta galactoside binding protein (OvGalBP) 
was found to bind IgE thus protecting the parasite from eosinophil-mediated damage (Klion 
and Donelson, 1994; reviewed in Johnston et al., 2009). 
Lipid molecules, glycanes and glycoproteins. Lysophosphatidylserine (lyso-PS) is a 
schistosomal lipid molecule that acts on dendritic cells through the activation of TLR-2 and 
thereby induces IL-10-producing regulatory T cells (van der Kleij et al., 2002). Lacto-N-
neotetraose (LNnT) and lacto-N-fucopentaose III (LNFPIII) are important glycans of the blood 
fluke Schistosoma mansoni. Intraperitoneal injection of LNnT-dextran (LNnT-dex) into mice 
was shown to induce a Gr1+CD11b+F4/80+ cell population which produces low levels of pro-
inflammatory cytokines but high amounts of IL-10 and TGF-β and suppresses T cell 
proliferation in vitro (Terrazas et al., 2001). LNFPIII was determined to promote APC 
maturation through the activation of NF-kappa B (Thomas et al., 2005) and to induce 
alternative activation of macrophages (Atochina et al., 2008). Symilarly, glycans of Taenia 
crassiceps metacestodes were found to induce alternatively activated macrophages through 
up-regulation of ARG-1, Ym1 and CD206 in murine peritoneal macrophages (Gómez-García 
et al., 2006). In 2003, a dimeric glycoprotein was purified from soluble egg antigen (SEA) of 
Schistosoma mansoni and named IL-4-inducing principle of Schistosoma mansoni eggs 
(IPSE) due to its ability to induce IL-4 in human basophils (Schramm et al., 2003). IPSE was 
shown to be identical with a formerly described antigen in SEA called alpha-1 (Dunne et al., 
1981) and since then designated as IPSE/alpha-1 (Schramm et al., 2006). IPSE/alpha-1 was 
determined to induce secretion of IL-4 and IL-13 by basophils thereby supporting alternative 
activation of macrophages.  
Protease inhibitors. Protease inhibitors such as cystatins constitute effective modulatory 
molecules which are widely spread and involved in various biological processes. They 
display a group of evolutionary related tight-binding but reversible inhibitors of papain-like 
cysteine proteases (Nicklin and Barrett, 1984). Parasite-derived cystatins interact with both 




in Klotz et al., 2011 a). They regulate endogenous physiological processes such as moulting 
or oogenesis, protect the parasite against host proteases, interfere with antigen 
processing/presentation thereby affecting T cell priming and further modulate host cytokine 
responses or nitric oxide (NO) production (reviewed in Klotz et al., 2011 a). Two systems are 
currently used to classify cystatins. The older system differentiates three major types of 
cystatins (Barrett, 1986). First, stefins (type 1 cystatins) which are unglycosylated and 
intracellularly located proteins. They have a single domain but lack a signal sequence and 
disulfide bonds. Second, cystatins (type 2 cystatins) that possess a signal sequence for 
extracellular targeting but no carbohydrate side chains. They have a single domain with two 
conserved disulfide bonds at the carboxy terminus, are secreted and thus detectable in 
almost all biological fluids. Finally, kininogens (type 3 cystatins) are glycosylated proteins 
which are synthesized in the liver and exported to the blood. They possess three type 2 
cystatin-like domains with eight disulfide bonds. A newer classification system is provided by 
the MEROPS peptidase database (http://merops.sanger.ac.uk) that is based on amino acid 
sequences and structural characteristics of molecules. According to this classification, 
cystatins belong to the inhibitor family I25 that comprises inhibitors of family C1 (papain like) 
cysteine proteases and is subdivided into I25A, I25B and I25C.  
The present thesis focused on AvCystatin, a cystatin C-like molecule (type 2 cystatin, I25B) 
secreted by all developmental stages of the tick-transmitted rodent filaria Acanthocheilonema 
viteae (Hartmann et al., 1997). In vitro stimulation of mouse splenocytes with recombinant 
AvCystatin suppressed CD4+ T cell proliferation and induced IL-10 production (Hartmann et 
al., 1997). Additional studies revealed host cell modulation to be specific for AvCystatin since 
cystatin of the free-living nematode Caenorhabditis elegans did not exert regulatory effects 
(Schierack et al., 2003). Moreover, by evaluating in vivo functions of the immunomodulator, 
application of AvCystatin significantly reduced airway inflammation in a murine model of 
ovalbumin-induced airway hyperreactivity. These protective effects were reversed after 
depletion of macrophages suggesting that macrophages are targets of AvCystatin and exert 
important immunoregulatory functions (Schnoeller et al., 2008). 
In summary, helminth parasites secrete factors which interfere with different arms of the host 
immune system and establish an environment which is beneficial for their survival and 
reproduction. In many cases, it has been shown that such immunomodulation can lead to 
spillover effects on unrelated inflammation. Hence, immune regulation by helminths can be 
advantageous for both parasite and host as it enables the maintenance of infection and 




3.3 Macrophage biology and function 
The term “macrophage” has been attributed to Elie Metchnikoff who originally described 
these cells as large and efficient phagocytic cells (Metchnikoff, 1905). They originate from 
myeloid progenitor cells in the bone marrow which develop into monoblasts, promonocytes 
and monocytes. Monocytes leave the marrow and circulate in the blood until they enter 
tissues and differentiate into macrophages. Macrophages reside in virtually all organs 
throughout the body. They appear as microglia in the central nervous system, Langerhans 
cells in the skin, Kupffer cells in the liver, alveolar macrophages in the lungs, osteoclasts in 
bones and histiocytes in connective tissue. The complete range of cells including bone 
marrow progenitors, blood monocytes and macrophages constitutes a family of cells that has 
been defined as the mononuclear phagocyte system or MPS (Hume, 2006).  
Besides their structural heterogeneity macrophages show high functional plasticity. Their 
primary role is to maintain homeostasis through cleaning the interstitial environment from 
cellular debris, erythrocytes and apoptotic cells (Mosser and Edwards, 2008). Another 
functional facet is their ability to mount immunological functions. Since macrophages are 
innate immune cells, they constitute the first line of defence and represent efficient detector 
cells for danger signals in early infection (Dunn et al., 1985). They recognize pathogen-
associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs) such 
as mannose, scavenger, toll-like or complement receptors (reviewed in Plüddemann et al., 
2007) and respond with phagocytic activity, antigen presentation and expression of co-
stimulatory molecules for T cell activation. Moreover, macrophages migrate to the site of 
inflammation and act as effector cells through the release of bioactive mediators, cytokines 
and chemokines. The capacity of macrophages to produce anti-inflammatory cytokines 
highlights their role as regulatory cells, especially in cancer and parasitic infections (Reyes 
and Terrazas, 2007). Thus, macrophages are important cells that hold a variety of functions 
and thereby bridge innate and adaptive immune responses.   
3.4 Polarization and classification of murine macrophages 
To identify and distinguish macrophage subsets, studies have been focusing on how different 
stimuli influence the functional phenotype of macrophages. In 1992, Stein and collaborators 
described IL-4-activated macrophages to differ from IFN-γ-treated macrophages by 
increased mannose receptor expression and activity (Stein et al., 1992; reviewed in Gordon, 
2003). In consequence, macrophages were divided along two axes into M1 and M2 
macrophages to describe two main extremes of activation with distinct functions thereby 




(Mills et al., 2000). The term M1 describes classical activation of macrophages that arises 
due to injury or infection. M1 macrophages are induced by IFN-γ in combination with a 
second signal such as microbial products or tumor necrosis factor α (TNF-α). After activation, 
M1 macrophages produce pro-inflammatory cytokines (IL-12, IL-1β, TNF-α, IL-6 and IL-23), 
chemokines (CXCL-9, 10, 11 and 16), NO, reactive oxygen species (ROS) and show 
increased tumoricidal and phagocytic activity. M1 macrophages play an important role in 
polarized Th1 immune responses and mediate resistance against intracellular pathogens 
(Mantovani et al., 2005). M2, on the contrary, was introduced as a generic term that includes 
all forms of macrophage activation other than M1 thus representing “alternative activation” of 
macrophages. M2 cells are less efficient in killing pathogens but promote tissue repair and 
remodelling. Furthermore, by producing anti-inflammatory cytokines they suppress M1 
macrophage activity and enhance anti-inflammatory responses (Martinez et al., 2008). 
Mantovanti et al. (2004) expanded the original M1/M2 axis classification by dividing M2 
macrophages into subpopulations according to their route of activation and the resulting 
phenotype (Figure 3-2, A). The most representative form of M2 polarization is M2a activation 
which is induced through stimulation with Th2 cytokines IL-4 and IL-13. Compared to M1 
macrophages, M2a-polarized cells are less efficient APCs and fail to activate CD4+ T cells or 
to induce CD4+ T cell proliferation (Edwards et al., 2006). They are poor in producing NO but 
instead express high levels of ARG-1 which skews L-arginine metabolism towards proline 
and polyamine production (Hesse et al., 2001; reviewed in Stempin et al., 2009). Other 
marker genes expressed by M2a macrophages are CD206 (mannose receptor), resistin-like 
molecule α (RELM-α) and Ym1 (Raes et al., 2002). M2b macrophages constitute a 
physiologically distinct subpopulation that corresponds to a phenotype that has been 
described by Anderson and Mosser (2002) as type 2 macrophages. M2b cells are induced by 
immune complexes (IC) in the presence of TLR ligands. They produce high levels of IL-10, 
sphingosine kinase-1 (SPHK-1) and LIGHT (TNFSF14). However, M2b macrophages are not 
per se anti-inflammatory. They still produce low amounts of IL-12, TNF-α, IL-1β, IL-6, present 
antigen to CD4+ T cells and induce CD4+ T cell proliferation (Edwards et al., 2006). M2c 
macrophages are elicited by IL-10, TGF-β or glucocorticoids. They down-regulate 
proinflammatory cytokines and can be regarded as deactivated macrophages (Martinez et 
al., 2008).  
Macrophage polarization towards a functional phenotype is not irreversible. They retain the 
ability to respond to changes in their environment and adapt their phenotype by shifting from 
M1 to M2 activation or back (Stout et al., 2005; Mosser and Edwards, 2008). As macrophage 




classification systems, Mosser and Edwards (2008) suggested a system based on three 
fundamental macrophage functions including host defense (classically activated 
macrophages), wound healing (wound healing macrophages) and immune regulation 
(regulatory macrophages) and illustrated these properties as the primary colours of a colour 
wheel (Figure 3-2, B). Since macrophages can show characteristics of different subtypes, 
this classification system describes macrophage heterogeneity more precisely by accounting 
for hybrid macrophages with overlapping transcription profiles analogous to secondary 
colours that arise through the combination of primary colours. 
Figure 3-2. Activation and classification of murine macrophages. Macrophage classification 
includes a wide spectrum of physiologically distinct macrophages. (A) According to the activation 
stimuli and the resulting phenotype, macrophages are divided into classically activated M1 or 
alternatively activated M2 macrophages. Alternatively activated macrophages can be further 
differentiated into M2a, M2b and M2c macrophages (Martinez et al., 2008). (B) A newer classification 
system illustrates the three macrophage functions “wound healing”, “host defense” and “immune 
regulation” as the primary colours of a colour wheel. Similar to secondary colours that derive through 
the combination of primary colours, macrophages can share features of different phenotypes (Mosser 
and Edwards et al., 2008). The illustrated figures are based on figures in Martinez et al. (2008) and 




3.5 Macrophages and disease 
Macrophages are critical for the initiation, maintenance or resolution of inflammatory 
processes (Fujiwara and Kobayashi, 2005) and thus show pathogenic but also protective 
activity in different disease settings.  
3.5.1 Macrophages in allergic airway inflammation 
Macrophages exhibit divergent functions in allergic responses and have long been assumed 
to promote or exacerbate allergic inflammatory processes in the airways of patients (Holgate, 
2008; Verstraelen et al., 2008). On the contrary, there is experimental evidence which 
demonstrates the ability of macrophages to suppress allergic inflammation. The depletion of 
alveolar macrophages (AM), for instance, has been shown to increase IgE levels in mice 
suggesting a major role of macrophages in the regulation of IgE responses to inhaled 
allergen (Thepen et al., 1992). Similarly, Bang et al. (2011) found that depletion of alveolar 
macrophages increased the number of eosinophils, lymphocytes and levels of IL-4, IL-5 and 
GM-CSF in the bronchoalveolar lavage fluid (BAL-fluid) of mice suffering from asthma. 
Transfer of unsensitized alveolar macrophages, however, reduced eosinophil and 
lymphocyte numbers as well as GM-CSF concentrations in the BAL-fluid. Moreover, adoptive 
transfer of alveolar macrophages from allergy-resistant into alveolar macrophage-depleted 
and allergy-susceptible rats ameliorated airway hyperresponsiveness (AHR), substantiating 
the idea of a macrophage-mediated protection against AHR (Careau and Bissonette, 2004). 
Lung interstitial macrophages were found to prevent LPS-induced airway allergy by 
suppressing maturation and migration of dendritic cells (Bedoret et al., 2009). In another 
study, intratracheal application of immortalized splenic macrophages (Mf4/4 cells) pulsed ex 
vivo with ovalbumin successfully inhibited allergic airway responses in mice through the 
recruitment of IFN-γ-producing Th1 cells demonstrating that macrophages can suppress 
Th2-driven inflammation through the induction of counter-regulating Th1 responses (Pynaert 
et al., 2003). In summary, a rising number of studies show that macrophages are able to 
suppress airway inflammation and thus constitute important cells not only for the induction 
but also for negative regulation of allergic responses.  
3.5.2 Macrophage functions in autoimmunity 
Experimental data account for protective macrophage functions in a number of autoimmune 
diseases. In vivo application of immune complexes to ligate Fcγ receptors in mice protected 
animals against experimental autoimmune encephalomyelitis (EAE) (La Flamme et al., 




macrophages, La Flamme and colleagues examined the influence of in vitro-generated and 
intraperitoneally injected M2b or M1 macrophages on EAE in mice. Animals treated with M2b 
macrophages showed less severe signs of EAE whereas the administration of M1 
macrophages had no effect on EAE development (Tierney et al. 2009). In another context, 
murine macrophages successfully protected against T cell-dependent arthritis by secreting 
ROS which suppressed T cell proliferation (Gelderman et al., 2007). Moreover, expression of 
RANTES on ocular-infiltrating macrophages abrogated clinical parameters in a murine model 
of experimental autoimmune uveoretinitis (EAU) whereas neutralization of RANTES impaired 
EAU by changing ocular-infiltrating T cell subsets (Sonoda et al., 2003). The peroxisome 
proliferator-activated receptor-γ (PPARγ) has been correlated with alternative activation of 
murine macrophages in obesity (Heilbronn and Campbell, 2008) and is supposed to control 
immune responses (reviewed in Nencioni et al., 2003). Shah et al. (2007) elucidated a 
protective role of PPARγ in a model of dextran sodium sulfate (DSS)-induced colitis by 
showing that mice with PPARγ-null macrophages but not wildtype animals developed 
aggravated symptoms of intestinal inflammation. Thus, macrophage suppressive activity is 
not restricted to atopic disorders but can also protect against diverse forms of autoimmunity.  
3.5.3 Tumor-associated macrophages (TAM) 
In cancer, macrophages exert tumoricidal functions or contribute to tumor growth and 
disease progression. Since M1 macrophages are known to perform tumoricidal activity it 
comes as no surprise that tumor cells promote pro-tumoral macrophage activation by driving 
an M2-like phenotype of human and murine macrophages (Biswas and Mantovani, 2010). 
Tumor-associated macrophages (TAM) are ineffective in presenting antigens and 
characterized by low expression levels of NO and pro-inflammatory cytokines IL-12, IL-6, 
TNF-α and IL-1β (Mantovani et al., 2002). On the contrary, they produce high amounts of IL-
10 and TGF-β (Sica et al., 2002), express CD206 (Allavena et al., 2010), scavenger receptor 
A (Biswas et al., 2006) and promote angiogenesis (Sica et al., 2002). Neovascularisation is 
important for tumor progression and has been associated with TAM-mediated release of 
proangiogenic factors, e.g. vascular endothelial growth factor or thymidine phosphorylase 
(Hotchkiss et al., 2003). Tumor-derived agents that drive M2 macrophage polarization are 
not fully determined yet but depletion of TAM has been shown to successfully reduce tumor 
progression and angiogenesis (De Palma et al., 2005; Zeisberger et al., 2006) suggesting 





3.6 Macrophage functions in helminth infections 
Infections with parasitic worms are usually associated with macrophages that show high 
phenotypic similarity to those exposed to Th2 cytokines IL-4 and IL-13 (M2a activation). Such 
macrophages have increasingly become an active field of scientific interest and research 
(Jenkins and Allen, 2010). Literature research on murine macrophages in helminth infections 
shows that they exert diverse but sometimes also contradicting biological functions 
depending on the infection stage, infection site and the respective parasite species (Jenkins 
and Allen, 2010). 
3.6.1 Regulation of Th2 responses by helminth-induced macrophages 
Helminth-induced macrophages are important regulators of Th2 immune responses. They 
either support the recruitment of Th2 effector cells thereby mediating parasite clearance and 
host protection (positive regulation) or suppress CD4+ T cell functions and promote parasite 
survival (negative regulation). 
3.6.1.1  Positive regulation of Th2 responses and host protection 
A couple of studies suggested that helminth-induced macrophages promote the development 
of CD4+ Th2 cells and contribute to the recruitment of Th2 effector cells such as eosinophils 
(Hayashi et al., 1999; Mills et al., 2000). It was shown, that the induction of alternatively 
activated macrophages during Nippostrongylus brasiliensis infection correlated with the 
recruitment of eosinophils to the peritoneal cavity of mice whereas markedly reduced 
eosinophils numbers were detected in infected macrophage-deficient op/op mice (a mouse 
strain with impaired development of mononuclear phagocytes due to an inactivating mutation 
in the colony-stimulating factor 1 gene) and macrophage-depleted animals (Voehringer et al., 
2007). These results were supported by studies that describe alternatively activated 
macrophages to participate in the recruitment of eosinophils to the lungs of mice in a model 
of ovalbumin-induced airway inflammation (Ford et al., 2009; Ford et al., 2012) and by the 
finding that eosinophils appear to direct development of alternatively activated macrophages 
in intestinal helminth infection models (Loke et al., 2007; Byers and Holtzmann, 2010).  
Macrophage function in host protection was first reported by investigating early events in the 
memory response to larvae of the gastrointestinal parasite Heligmosomoides polygyrus. After 
primary infection, Th2 memory cells prevented parasite re-infection by inducing alternatively 
activated macrophages in an IL-4- and STAT6-dependent manner. Blockade of ARG-1 




important effector molecule in mediating host protection against helminth re-infection 
(Anthony et al., 2006). Similar findings were obtained for intestinal macrophages of mice 
infected with Nippostrongylus brasiliensis. Both the depletion of macrophages by clodronate 
liposomes and the blockade of ARG-1 in macrophages reduced intestinal smooth muscle 
hypercontractility suggesting a macrophage-dependent and again, ARG-1-mediated 
mechanism to be responsible for parasite clearance (Zhao et al., 2008). Hymenolepis 
diminuta infection was associated with the expression of ARG-1, FIZZ-1 (RELM-α) and Ym1 
in the intestine of mice as early as 8 days post infection suggesting the induction of 
alternatively activated macrophages. Since the appearance of these macrophages correlated 
with the peak of worm expulsion, the authors hypothesized the macrophages to mediate 
protection against worm infection (Persaud et al., 2007).  
3.6.1.2 Negative regulation of Th2 responses and parasite survival 
Contrariwise, recent data illustrate that helminth-modulated macrophages also act as 
negative regulators of Th2 immune responses thereby protecting the parasite from clearance 
rather than inducing worm expulsion. In vivo depletion of Taenia crassiceps-induced 
macrophages drastically reduced worm burdens in infected mice and favoured resistance to 
Taenia crassiceps (Reyes et al., 2010). STAT6-deficient but not wildtype mice were shown to 
develop strong Th1 immune responses associated with high levels of IFN-γ, IL-12 and NO 
post infection with Taenia crassiceps cysticerci. Thus, STAT6 signalling-dependent 
expansion of macrophages is essential for mediating susceptibility to Taenia crassiceps 
(Rodríguez-Sosa et al., 2002 a and b). 
The suppression of effector cell functions is an important mechanism to negatively regulate 
Th2 responses. First evidence for a suppressive activity of helminth-derived macrophages 
was found when mice were intraperitoneally implanted with adult Brugia malayi or injected 
with Brugia malayi ES products. Peritoneal macrophages were in vitro co-cultured with 
polyclonal or antigen-specific stimulated CD4+ T cells and successfully suppressed T cell 
proliferation in a cell contact and IL-4-dependent manner (Loke et al., 2000; MacDonald et 
al., 1998). Similar activity was found for macrophages induced by ES products from the 
rodent hookworm Nippostrongylus brasiliensis and the dog roundworm Toxocara canis (Allen 
and MacDonald, 1998). Moreover, experimental infection with Litomosoides sigmodontis 
induced ARG-1-expressing F4/80+ macrophages in mice which suppressed antigen-specific 
CD4+ T cell proliferation in an IL-10- and CTLA-4-independent but partially TGF-β-dependent 
manner (Taylor et al., 2006). Successional studies verified macrophages to exert 




model of Schistosoma mansoni infection, splenic macrophages induced CD4+ T cell anergy 
in vitro in a cell contact-dependent manner through the up-regulation of programmed death 
ligand 1 (PD-L1) (Smith et al., 2004). Taenia crassiceps-elicited peritoneal macrophages 
similarly prevented CD4+ T cell proliferation through the up-regulation of both PD-L1 and PD-
L2 (Terrazas et al., 2005). In a study by Mejri and Gottstein (2006), peritoneal macrophages 
of Echinococcus multilocularis-infected mice were stimulated with ovalbumin and suppressed 
the activity of in vitro co-cultured CD4+ T cells of ovalbumin immunized mice. Together, these 
findings identify T cells as an important target of helminth-induced macrophages in order to 
suppress Th2 responses. 
In recent studies, two molecules in particular were described as critical regulators of Th2 
immunity: RELM-α and ARG-1. RELM-α is a cysteine-rich protein which was originally 
detected in the BAL-fluid of mice suffering from allergic airway inflammation and thought to 
modulate the local tissue response to allergic inflammation (Holcomb et al., 2000). However, 
experimental findings of Nair et al. (2009) demonstrated RELM-α expression in macrophages 
to inhibit pulmonary inflammation in a murine model of Schistosoma mansoni infection. In the 
respective study, RELM-α was shown to bind CD4+ Th2 cell effector cells thereby 
suppressing cytokine production in a Bruton`s tyrosine kinase-dependent manner. 
Macrophages from RELM-α-deficient mice, on the other side, induced massive airway 
inflammation after challenge with Schistosoma mansoni eggs. Since RELM-α also bound 
macrophages and dendritic cells, the protein was suggested to exert other, non T cell-
mediated functions as well (reviewed in Jenkins and Allen, 2010). Studies by another group 
showed that RELM-α-deficient mice developed stronger Th2 responses and increased worm 
expulsion following Nippostrongylus brasiliensis infection in comparison to infected wildtype 
mice. Moreover, Schistosoma mansoni egg-induced granuloma formation in the airways of 
mice was aggravated in the absence of RELM-α and associated with high serum IgE and 
increased eosinophil numbers. The investigators thus hypothesized RELM-α to act as an 
important feedback mechanism to suppress helminth-induced Th2 responses (Pesce et al., 
2009 a). Similarly, ARG-1 has been described to exert suppressive activity on Th2 
inflammation in chronic schistosomiasis. Conditional deletion of ARG-1 in macrophages of 
Schistosoma mansoni-infected mice led to increased liver fibrosis, portal hypertension and 
granulomatous inflammation. In addition, IL-4/IL-13-induced but not ARG-1-deleted 
macrophages were able to suppress CD4+ T cell proliferation in vitro (Pesce et al., 2009 b) 




3.6.2 Wound healing 
An important feature of helminth-derived macrophages is their ability to orchestrate wound 
healing. At the site of injury, they remove dead cells, recruit fibroblasts, dissolve fibrin and 
further regulate angiogenesis and remodelling of connective tissue (Gordon, 2003). Tissue-
dwelling worms are large metazoan organisms that release proteolytic enzymes to pass 
through tissues thereby causing cellular damage and organ injury accompanied by 
inflammatory host responses (Kreider et al., 2007). Tissue repair by macrophages thus 
exhibits an effective strategy of parasites to minimize tissue injury and to prevent 
inflammation. In a study by Herbert et al. (2004), macrophage-mediated wound repair was 
found to be critical for host survival during infection with Schistosoma mansoni. Compared to 
infected control animals, IL-4Rα-deficient mice were inefficient in inducing tissue remodelling 
macrophages and therefore died from excessive intestinal inflammation caused by egg 
penetration trough the intestine. The expression of ARG-1, which converts L-arginine to 
proline for collagen production, plays a key role in tissue remodelling (Albina et al., 1990). 
However, other markers might also contribute to this function. RELM-α was found to promote 
vascularization through the induction of angiogenic factors and thereby could promote 
fibroblast recruitment, differentiation and activation (Chung et al., 2007; Nair et al., 2009). 
Another candidate is Ym1, a secretory 45 kDa heparin-binding lectin that shows sequence 
similarities to chitinases (Hung et al., 2002). Although lacking chitinase activity, Ym1 can 
effectively bind to chitin or the extracellular matrix and thereby mediate the recruitment of 
cells which support tissue remodelling (Reece et al., 2006). In a study by Kzhyshkowska et 
al. (2006), the expression of scavenger-like receptor stabilin-1 on IL-4-stimulated murine 
macrophages led to binding and uptake of secreted protein acidic and rich in cysteine 
(SPARC), a matricellular glycoprotein which, among other functions, exerts anti-adhesive 
and anti-proliferative effects on diverse cell types. Removal of SPARC from the extracellular 
space by alternatively activated macrophages was suggested to regulate tissue remodelling 
and the synthesis of extracellular matrix components by cells which respond to SPARC 
(Kzhyshkowska et al., 2006). 
In conclusion, helminth-derived macrophages bear diverse and sometimes opposing 
activities. They promote host Th2 immune responses and worm expulsion or suppress Th2 
effector mechanisms and mediate parasite survival. Such functional discrepancy, however, 
might simply reflect the diversity of helminth infections and the complexity of the parasite-
induced Th2 immune response (Jenkins and Allen, 2010). Thus, a single well-defined 




3.7 Aims of the thesis 
The finding that helminth-secreted molecules interfere with unrelated inflammation suggests 
the possibility to use such factors for the treatment of immune-related diseases. Former 
studies showed that in vivo application of the immunomodulator AvCystatin significantly 
suppressed important parameters of ovalbumin-induced airway hyperreactivity in mice such 
as eosinophilia, allergen-specific IgE and mucus production (Schnoeller et al., 2008). The 
protective effects were associated with increased levels of IL-10 and reversed either through 
the depletion of macrophages or blockade of the IL-10 receptor. Thus, macrophages were 
hypothesized to be critically involved in the amelioration of disease possibly through the 
secretion of IL-10 (Schnoeller et al., 2008). The present study aimed (a) to pinpoint the 
molecular mechanism for the induction of suppressive macrophages by AvCystatin and (b) to 
further evaluate the ability of AvCystatin-modulated macrophages (AvCystatin-MФ) to 
transfer protective effects in unrelated disease settings. The first part of the present 
investigation determined signalling events in macrophages which led to IL-10 production 
after treatment with AvCystatin. In the second part, the protective potential of AvCystatin-MФ 
was examined by adoptive transfer experiments using murine disease models of allergic 
airway and intestinal inflammation. To gain further insights into the underlying mechanism of 
immunosuppression, transcriptional profiling of AvCystatin-MФ was performed by quantitative 





4.1 Macrophages are target cells of AvCystatin 
In order to identify the primary target cell of AvCystatin, the fate of DyLight549-labelled 
AvCystatin was analysed after application to the peritoneal cavity of BALB/c mice. Peritoneal 
exudate cells (PEC) were isolated 20 minutes after intraperitoneal administration of the 
protein, stained for surface marker molecules of specific cell populations (CD4, CD19, 
CD11c, CD11b and F4/80) and analysed by flow cytometry. AvCystatin was detected in 
F4/80+CD11b+ macrophages and CD11c+F4/80- dendritic cells (Figure 4-1, A). Macrophages 
accounted for 35% and dendritic cells for 1.5% of the total PEC population suggesting 
resident macrophages to constitute the predominant target cells of AvCystatin within the 
peritoneal cavity (data not shown). AvCystatin was not determined in Gr1high cells excluding 
infiltrating monocytes or granulocytes as target cells (data not shown). Neither CD4+ T cells 
nor CD19+ B cells showed binding or uptake of the helminth immunomodulator (Figure 4-1, 
A). Confocal microscopy further determined AvCystatin to be taken up into the 
endolysosomal compartment of CD11b+ phagocytes as revealed by the punctuate signal of 
the labelled molecule (Figure 4-1, B). To differentiate between specific binding and active 
uptake, PEC were incubated with labelled AvCystatin for 30 minutes at either 4°C or 37°C. 
Flow cytometry analysis revealed an uptake of AvCystatin by F4/80+ cells at 37°C but 
minimally at 4°C. Incubation of PEC with labelled AvCystatin in the presence of actin 
polymerization-blocking cytochalasin D reduced protein uptake by macrophages (Figure 4-1, 
C). Furthermore, the kinetics of AvCystatin uptake by macrophages was determined by 
western blot analyses which showed a rapid and prolonged uptake between 0 and 24 hours 
at 37°C. Incubation at 4°C or 37°C in the presence of cytochalasin D for 15-60 minutes, 
however, reduced the uptake of AvCystatin (Figure 4-1, D). In conclusion, these findings 
confirm macrophages as the primary target cells of AvCystatin within the PEC population and 





Figure 4-1. AvCystatin is actively taken up by peritoneal macrophages. (A) AvCystatin was 
labelled with DyLight549 and intraperitoneally injected into mice (40 µg/mouse). Peritoneal exudate 
cells were isolated from untreated (grey shaded area) and labelled AvCystatin-treated (white area) 
animals 20 minutes post application, stained with antibodies against CD4, CD19, CD11c, CD11b and 
F4/80 and analysed by flow cytometry. Numbers represent the mean fluorescence intensity. (B) 
Confocal microscopy of CD11b+ cells (green) from the peritoneum of mice treated with DyLight594-
labelled AvCystatin (red, upper panel) or untreated control mice (lower panel). (C) PEC were in vitro 
incubated with DyLight549-labelled AvCystatin for 30 min at either 37°C (solid line) or 4°C (long 
dashes). PEC were in addition treated with 10 µM cytochalasin D in combination with DyLight-
AvCystatin for 30 minutes at 37°C (dotted line). Cells were stained against F4/80 and analysed for 
DyLight549 signals by flow cytometry. The shaded area represents untreated control cells. (D) 
Western blot analysis of cell extracts from AvCystatin-treated PEC at 37°C and 4°C. Some samples 
were additionally pre-treated with cytochalasin D to block endocytosis. Data are representative of 2-3 




4.2 Part I:  Signalling events in AvCystatin-MФ 
IL-10 has been described as an important mediator in allergy and asthma (Hawrylowicz and 
O`Garra, 2005). Since previous studies demonstrated the importance of macrophages and 
IL-10 to mediate AvCystatin effects in vivo, the induction of immunosuppressive 
macrophages by AvCystatin was hypothesized (Schnoeller et al., 2008). The first part of the 
present thesis investigated molecular mechanisms of IL-10 induction in macrophages by 
dissecting signalling events leading to cytokine production after treatment with the 
immunomodulator.    
4.2.1 MAPK activation by AvCystatin is associated with IL-10 production 
The activation of mitogen-activated protein kinases (MAPK) ERK and p38 has been shown to 
correlate with IL-10 production in M2b macrophages (Lucas et al., 2005). In order to analyse 
signalling pathways involved in the AvCystatin-induced IL-10 production by macrophages, 
murine peritoneal macrophages were cultured in the presence of specific inhibitors for the 
MAPK extracellular signal-regulated kinase (ERK), p38, C-Jun N-terminal kinase (JNK) and 
the phosphatidylinositol-3-kinase (PI3K)-AKT pathway. First, the induction of IL-10 in 
macrophages was validated after incubation with AvCystatin or control treatments (denatured 
AvCystatin or the unrelated control protein SNAP-tag which constitutes a 20 kDa mutant of 
the DNA repair protein O6-alkylguanine-DNA alkyltransferase). IL-10 was found to be 
significantly increased in culture supernatants of AvCystatin- but not control-stimulated 
macrophages 18-20 hours after treatment (Figure 4-2, A). Real-time PCR analysis of IL-10 
transcript revealed an early and transient expression of IL-10 in AvCystatin-MФ that peaked 
one hour after treatment and decreased afterwards to background levels (Figure 4-2, B). 
Inhibition of PI3K activation through treatment with different concentrations of the inhibitor 
Ly294002 prevented IL-10 production in macrophages in a dose-dependent manner (Figure 
4-2, C). Similarly, blockade of p38 and ERK through treatment with the inhibitors SB203580 
(inhibition of p38) and U0126 (inhibition of MEK1/2) markely reduced levels of IL-10 in the 
culture supernatants (Figure 4-2, D and E). Incubation of macrophages with JNK-inhibitor II, 
however, had no effect on IL-10 production (Figure 4-2, F). To investigate the influence of 
tyrosine kinases on IL-10 production in macrophages, peritoneal macrophages were 
incubated with AvCystatin in the presence of the tyrosine kinase inhibitor genistein. 
Treatment with the inhibitor led to a dose dependent reduction of macrophage-secreted IL-10 
(Figure 4-2, G). In conclusion, AvCystatin-mediated induction of IL-10 in macrophages 
involves p38, ERK and PI3K-dependent signalling events in a tyrosine kinase-sensitive 




Figure 4-2. Induction of IL-10 involves ERK-, p38- and PI3K-dependent signalling. Induction of IL-
10 in murine peritoneal macrophages after in vitro stimulation with AvCystatin for 18-20 hours in the 
absence or presence of specific inhibitors. (A) IL-10 production by macrophages after treatment with 
AvCystatin or control applications for 18 hours. (B) Real-time PCR analysis of IL-10 transcript in 
macrophages after incubation with AvCystatin or control treatment for 1, 4 and 18 hours. Normalized 
data is presented as fold induction compared to untreated macrophages (medium control). (C-G) 
Incubation of macrophages with AvCystatin and different concentrations of Ly294002 (PI3K-inhibitor), 
SB203580 (p38-inhibitor), U0126 (MEK1/2-inhibitor), JNK inhibitor II (JNK-inhibitor) and genistein 
(tyrosine kinase-inhibitor). One representative of 2-4 experiments is shown (A-G) and data (mean ± 
SEM) presented as percent cytokine production compared to AvCystatin treatment (C-G). *, P < 0.05; 




4.2.2 AvCystatin leads to phosphorylation of MAPK p38 and ERK 
Next, the phosphorylation of ERK, p38 and AKT was examined by western blot analysis of 
cell lysates from AvCystatin- or control-treated peritoneal macrophages. Phosphorylation of 
p38 was determined by 15 minutes after application of AvCystatin, peaked at 60 minutes and 
decreased between 60 and 360 minutes (Figure 4-3, A). The ERK phosphorylation signal 
emerged as early as 15 minutes after treatment with the immunomodulator, remained 
elevated between 30 and 120 minutes and decreased from 120 minutes onwards (Figure 
4-3, B). Although inhibition of PI3K affected IL-10 production in macrophages (Figure 4-2, 
C), no specific phosphoryIation of AKT by AvCystatin was detectable (Figure 4-3, C). These 
findings show that treatment with AvCystatin induces transient phosphorylation of p38 and 
ERK in macrophages but does not affect phosphorylation of AKT. 
Figure 4-3. AvCystatin activates MAPK in peritoneal macrophages. Peritoneal macrophages were 
stimulated in vitro with 0.5 µM AvCystatin or denatured AvCystatin for various time points. Total cell 
extracts were analysed by western blotting of phospho- and total-p38, phospho- and total-ERK, 
phospho- and total-AKT. (A) Representative blot of phosho- and total p38 from AvCystatin- or control-
treated cell extracts and densitometric blot analysis. (B) Blot of phospho- and total-ERK and 
densitometric analysis of protein expression. (C) Blot of phospho- and total AKT and densitometric 
analysis. Densitometric analysis data from one of 2-3 experiments is presented as mean ± SEM and 
expressed as fold induction relative to medium control. Phospho-p38, phospho-ERK and phospho-




4.2.3 AvCystatin induces in vitro and in vivo expression of DUSPs 
Since treatment with AvCystatin induced transient IL-10 expression and MAPK activation in 
macrophages, the involvement of a negative feedback mechanism on MAPK was 
hypothesized. Dual-specificity phosphatases (DUSPs) constitute a group of protein tyrosine 
phosphatases which dephosphorylate both tyrosine and threonine residues on MAPK 
thereby acting as negative regulators of MAPK activity (Jeffrey et al., 2007; Liu et al., 2007). 
In order to assess whether DUSPs influence the macrophage IL-10 response to AvCystatin, 
quantitative real-time PCR was performed for early expression of DUSPs which regulate p38 
and ERK activity in macrophages (DUSP-1, DUSP-2, DUSP-3, DUSP-5, DUSP-6 and 
DUSP-10). In vitro stimulation of peritoneal macrophages with 0.5 µM AvCystatin induced an 
up-regulation of DUSP-1, DUSP-2 and DUSP-5 (Figure 4-4, A). Increased transcript levels 
were detected as early as 30 minutes post treatment for all three phosphatases. Expression 
of DUSP-1 reached its peak at 60 minutes and dropped between 60 and 240 minutes. 
DUSP-2 transcript levels were constant for indicated timepoints. A lower expression of 
DUSP-5 was detectable between 30 and 120 minutes after treatment with AvCystatin. 
Transcript levels of DUSP-3, DUSP-4 and DUSP-10 RNA remained unaltered (Figure 4-4, 
A). Next, DUSP-1 expression and phosphorylation was examined in total cell extracts by 
western blot analysis. Increased protein levels were detected by 60 and 90 minutes after 
treatment with AvCystatin. DUSP-1 phosphorylation was strongest after 60 minutes and 
again lowered after 90 minutes (Figure 4-4, B). To determine the in vivo effect of AvCystatin 
on DUSP expression, animals were intraperitoneally injected with 20 µg/mouse recombinant 
AvCystatin or denatured protein. Real-time PCR analyses of ex vivo purified peritoneal 
macrophages showed transient expression of DUSP-1 and DUSP-2 which both peaked 60 
minutes after AvCystatin treatment and declined afterwards. DUSP-1 was found to be most 
prominently expressed whereas lower expression levels were detected for DUSP-2 (Figure 
4-4, C). In summary, these findings show DUSPs to be expressed on RNA and protein level 
in AvCystatin-MФ in vitro and in vivo suggesting that DUSPs regulate MAPK activity and IL-




Figure 4-4. AvCystatin induces expression of DUSPs. In vitro and in vivo expression of dual-
specificity phosphatases (DUSPs) in AvCystatin- or control-treated macrophages. (A) Peritoneal 
macrophages were analysed for expression of DUSP-1, DUSP-2, DUSP-3, DUSP-5, DUSP-6 and 
DUSP-10 after in vitro incubation with AvCystatin or control treatments by real-time PCR. (B) Western 
blot kinetics of phospho-DUSP-1 and DUSP-1 from total cell extracts after in vitro stimulation with 
AvCystatin or denatured AvCystatin. (C) Real-time PCR for DUSP expression in macrophages of 
AvCystatin- or control-treated animals. Results (mean ± SEM) represent one of 2-3 experiments. 
Normalized data is expressed as fold induction compared to untreated control mice. Cells were pooled 




4.2.4 IL-10 expression in AvCystatin-MФ is regulated by DUSP-1 
To elucidate the inhibitory role of DUSPs on MAPK activation and IL-10 expression in 
peritoneal macrophages, the experimental findings on AvCystatin-induced DUSP expression 
were compared to the predictions of a mathematical model published by cooperation 
partners in Figueiredo et al. (2009). This model was used to perform in silico analysis on the 
relevance of MAPK and DUSPs for IL-10 expression in AvCystatin-MФ and predicted that an 
inhibition of p38 would suppress the AvCystatin-induced IL-10 production (Klotz et al., 2011 
b). DUSPs exhibit preferences for specific MAPK. Whereas DUSP-1 shows preferential 
activity for MAPK p38, DUSP-2 appears to hold highest substrate specificity for ERK (Jeffrey 
et al., 2007; Liu et al., 2007). The experimental findings demonstrated elevated DUSP-1 
expression in AvCystatin-MФ, while the mathematical model predicted IL-10 suppression 
through inhibition of p38. Thus, MAPK phosphorylation and IL-10 gene expression were 
analysed in macrophages of DUSP-1-deficient mice and wildtype littermates. Control animals 
showed transient IL-10 expression after treatment with AvCystatin. In DUSP-1-deficient mice, 
however, the IL-10 expression was increased and sustained (Figure 4-5, A). Western blot 
analysis determined an accumulation of phospho-p38 and slightly reduced levels of 
phospho-ERK in DUSP-1-deficient mice (Figure 4-5, B). In summary, these findings 
demonstrate an important role for DUSP-1 in regulating MAPK activation and IL-10 
expression in AvCystatin-MФ.    
Figure 4-5. DUSP-1 regulates MAPK activation and IL-10 expression in AvCystatin-MФ. (A) IL-10 
expression in macrophages of DUSP-1-deficient mice and wildtype littermates after intraperitoneal 
injection of 20 µg AvCystatin or denatured AvCystatin. (B) Western blot analysis of phospho-p38 and 
phospho-ERK in DUSP-1-deficient mice and wildtype littermates. Results are shown as mean ± SEM 
for one of 2-3 experiments and normalized data is expressed as fold induction compared to untreated 




4.3 Part II:  Functional and molecular characteristics of AvCystatin-MФ 
In part II, the functional relevance of AvCystatin-MФ was examined by addressing whether 
adoptive transfer of AvCystatin-primed cells interferes with inflammation in two murine 
disease models and by further evaluating the mechanism of immunosuppression.   
4.3.1 Effects of AvCystatin-MФ in allergic airway hyperreactivity 
The induction of airway inflammation with the model allergen ovalbumin is a commonly used 
method to reflect symptoms of asthma in mice. In contrast to C57BL/6 mice, the BALB/c 
mouse strain has a genetically determined tendency to develop Th2 responses and is most 
commonly used to investigate different facets of allergic inflammation (Schröder and Maurer, 
2007). By using the model of ovalbumin-induced airway hyperreactivity on a female BALB/c 
mouse background the present investigation aimed to address whether (a) protective effects 
of AvCystatin can be transferred by modulated cells through adoptive transfer experiments 
and (b) whether such effects are dependent on the IL-10 production of transferred cells. 
4.3.1.1 Adoptive transfer of AvCystatin-stimulated peritoneal exudate cells    
To address whether AvCystatin-primed cells exert beneficial effects on allergic airway 
inflammation in vivo, total PEC were transferred from mice that have been intraperitoneally 
treated with AvCystatin or control applications. Airway inflammation was induced in female 
BALB/c mice by using a sensitization and provocation scheme including two intraperitoneal 
sensitizations with ovalbumin in Imject Alum adjuvant and two intranasal allergen challenges 
on two consecutive days. PEC were isolated from donor animals 18-20 hours after 
intraperitoneal administration of 20 µg recombinant AvCystatin or control applications and 
transferred 4 days prior to intranasal challenge (Figure 4-6). Transfer of control-treated cells 
(stimulated with denatured AvCystatin or SNAP-tag) was performed to exclude possible side 
effects by the cell transfer alone. Preliminary studies confirmed that transfer of control-
treated PEC in ovalbumin-sensitized mice established similar immune responses after 
antigen-challenge as ovalbumin-sensitized mice without cell transfer (Figure 4-7). Compared 
to control treatments, single intravenous injection of 3x106 AvCystatin-primed PEC 
(AvCystatin-PEC) significantly reduced total and ovalbumin-specific IgE. However, 
ovalbumin-specific IgG1 and IgG2a responses were not altered by the cell transfer (Figure 
4-8, A). Levels of IL-4, IL-5 and IL-13 in both the BAL-fluid and in culture supernatants of 
antigen-restimulated splenocytes were drastically reduced in animals treated with 
AvCystatin-PEC. In contrast, these animals responded with significantly increased levels of 




fluid revealed a strong reduction of eosinophil numbers by approximately 40-50% in animals 
which were treated with AvCystatin-PEC (Figure 4-8, D). Moreover, histological analysis of 
lung sections through periodic acid-Schiff (PAS) and hematoxylin/eosin (HE) staining 
showed that transfer of AvCystatin-PEC reduced mucus production in the bronchioles and 
lowered airway cell infiltration (Figure 4-8, E). To elucidate whether IL-10 production by cells 
within the PEC population was responsible for the protective effects, AvCystatin-PEC of 
IL-10-deficient mice were transferred in parallel. Strikingly, single tail-vein injection of 3x106 
AvCystatin-PEC from IL- 10-deficient mice into recipient mice resulted in similar suppression 
of all analysed parameters compared to the transfer of wildtype AvCystatin-PEC (Figure 4-8, 
A-E). Collectively, these results demonstrate a strong suppressive effect of AvCystatin-PEC 





Figure 4-6. Scheme of ovalbumin-induced airway hyperreactivity and cell transfer. BALB/c mice 
were sensitized with two intraperitoneal (i.p.) injections of 20 µg ovalbumin in Imject Alum adjuvant on 
day 0 and 14 followed by two intranasal (i.n.) allergen challenges with 50 µg/animal ovalbumin on day 
28 and 29. Cells were isolated from mice treated with AvCystatin or denatured AvCystatin 18-20 hours 
after intraperitoneal injection and adoptively transferred through tail-vein administration into 
ovalbumin-sensitized mice 4 days (day 24) prior to intranasal provocation with the allergen. 
Figure 4-7. Establishment of positive controls for transfer experiments. Female BALB/c mice 
were sensitized with PBS/Imject Alum and challenged with PBS (healthy control) or sensitized with 
ovalbumin/Imject Alum and challenged with ovalbumin. For the latter treatment, animals either 
received no cell transfer (ovalbumin positive control) or were intravenously treated with AvCystatin- or 
denatured AvCystatin-stimulated peritoneal exudate cells. (A) Total serum IgE. (B) Ovalbumin-specific 
serum IgE. (C) Percentage of eosinophils in the BAL-fluid. (D-F) Local cytokine response in the BAL-
fluid. The figure shows one initial experiment which was performed to establish positive controls for 
cell transfer experiments. Since no significant differences were detected between the ovalbumin 
positive control without cell transfer and transfer of control-treated (denat. AvCystatin-PEC) cells, only 




Figure 4-8. AvCystatin-primed PEC protect against airway inflammation. Peritoneal exudate cells 
were isolated from BALB/c wildtype or IL-10-deficient mice 18-20 hours after intraperitoneal injection 
of AvCystatin or denatured AvCystatin. 3x106 cells were intravenously transferred into ovalbumin-
sensitized mice prior to intranasal challenge with ovalbumin. (A) Total and allergen-specific levels of 
serum IgE and ovalbumin-specific IgG1 and IgG2a in recipient mice. (B) Systemic cytokine response 
in culture supernatants of allergen-restimulated recipient splenocytes. (C) Local cytokine response in 
the BAL-fluid of recipients measured by quantification of IL-4, IL-5, IL-13 and IL-10. (D) Cell counts for 
inflammatory cells in the BAL-fluid. (E) Histological staining of lung bronchioles with PAS and HE. 
Bars, 100 µm. Results are presented as mean ± SEM for two independent experiments with 5-6 




4.3.1.2 Transfer of AvCystatin-MФ abrogates allergic airway inflammation 
To determine the suppressive potential of AvCystatin-MФ on airway inflammation, 
macrophages were purified from the PEC population of donor mice 18-20 hours after 
treatment with AvCystatin or denatured AvCystatin. Purity of untouched macrophages was > 
95% as revealed by flow cytometry analysis for the expression of macrophage markers 
F4/80 and CD11b (Figure 4-9, A). Single intravenous transfer of 2x106 macrophages 4 days 
prior to intranasal provocation (Figure 4-6) reduced the total and ovalbumin-specific IgE 
response of recipient mice but did not affect antigen-specific serum IgG1 and IgG2a (Figure 
4-9, B). Local and systemic levels of IL-4, IL-5 and IL-13 were significantly reduced by 
treatment with AvCystatin-MФ. On the contrary, elevated levels of IL-10 in the BAL-fluid and 
in splenocyte culture supernatants were detected (Figure 4-9, C and D). Eosinophil 
infiltration was significantly hampered through the treatment with AvCystatin-MФ (Figure 4-9, 
E) and associated with reduced expression of eotaxin-1, eotaxin-2, CCR3 and MCP-5 in lung
homogenates (Figure 4-9, F). The expression of other chemokines such as MCP-1 (CCL2), 
VCAM-1 (CD106) or RANTES (CCL5) was not altered by the transfer of AvCystatin-MФ (data 
not shown). Histological analysis of lung sections by PAS and HE staining revealed mitigated 
mucus production and inflammatory cell infiltration after treatment with AvCystatin-MФ 
(Figure 4-9, G). To assess whether AvCystatin-MФ survive in recipient animals, 2-3x106 
carboxyfluorescein succinimidyl ester (CSFE)-labelled macrophages were intravenously 
transferred on day 24 into ovalbumin-sensitized animals prior to challenge and their 
distribution analysed in the lung, BAL-fluid, peribronchial lymph nodes (PBLNs) and the 
spleen of recipient animals on day 31 by flow cytometry. Labelled macrophages were 
detected in the spleen (AvCystatin-MФ: 194491 ± 27549 cells; control-treated MФ: 94680 ± 
10013 cells; mean ± SEM) and to a lower amount in the PBLNs (AvCystatin-MФ: 3985 ± 
2870; control-treated MФ: 1824 ± 202; mean ± SEM) of recipient mice (Figure 4-9, H). 
Hence, these findings show that AvCystatin-MФ efficiently protect against allergic airway 




Figure 4-9. AvCystatin-MФ ameliorate allergic airway inflammation. Macrophages were purified 
from peritoneal exudate cells of AvCystatin- or control-treated BALB/c mice 18-20 hours after 
intraperitoneal injection and intravenously transferred (2x106) in ovalbumin-sensitized mice prior to 
airway challenge. (A) Purity of enriched AvCystatin-MФ was determined by expression of F4/80 and 
CD11b (both > 95%). Similar values were detected for control-treated macrophages (data not shown). 
(B) Levels of total and allergen-specific IgE, ovalbumin-IgG1 and -IgG2a in recipient mice. (C) 
Concentrations of IL-4, IL-5, IL-13 and IL-10 in the BAL-fluid. (D) Antigen-specific cytokine response in 
splenocyte culture supernatants. (E) Analysis of total cell numbers, eosinophils, 
monocytes/macrophages and lymphocytes in the BAL-fluid. (F) Analysis of chemokine expression in 
lung homogenates by quantitative real-time PCR. Gene expression was analysed in triplicate values 
and expressed as fold induction compared to untreated control mice. (G) Histological analysis of 
mucus production and inflammatory cell influx in bronchioles by PAS and HE staining. Bars, 100 µm. 
(H) Detection of CFSE-labelled macrophages in the spleen and in the PBLNs of recipient mice by flow 
cytometry analysis on day 31. Values are presented as mean ± SEM of two independent experiments 




4.3.1.3 B cell transfer does not suppress airway inflammation 
Recent publications show helminth-induced regulatory B cells to be capable of abrogating 
symptoms of airway inflammation by adoptive cell transfer (Mangan et al., 2004; Amu et al., 
2010; Wilson et al., 2010). After intraperitoneal application of AvCystatin, B cells accounted 
for 30-40% of the PEC population. In order to evaluate whether AvCystatin-stimulated B cells 
within the peritoneal cell population mediated immunosuppression, 2x106 purified B cells 
(purity 90-95%) of AvCystatin- or control-treated mice were intravenously administered into 
ovalbumin-sensitized animals by using the same transfer protocol as described previously 
(Figure 4-6). Compared to intravenous application of AvCystatin-PEC or AvCystatin-MФ, the 
administration of B cells did not transfer protective effects on any of the investigated 
parameters such as IgE levels (Figure 4-10, A), local and systemic cytokine responses 
(Figure 4-10, B and C), the cell composition in the BAL-fluid (Figure 4-10, D) or mucus 
production (Figure 4-10, E). 
Figure 4-10. Transfer of B cells does not protect against airway inflammation. 2x106 purified B 
cells of AvCystatin- or control-treated mice were intravenously transferred into ovalbumin-sensitized 
mice 18-20 hours after injection of the immunomodulator. (A) Total and allergen-specific IgE, 
ovalbumin-IgG1 and -IgG2a. (B) Th2 cytokine and IL-10 response in BAL-fluid. (C) Antigen-specific 
cytokine response of recipient splenocytes. (D) Analysis of inflammatory cells in the BAL-fluid. (E) 
PAS and HE staining of lung sections. Bars, 100 µm. Results are presented as mean ± SEM for one 




4.3.1.4 AvCystatin-MФ in vivo and in vitro induce IL-10-producing T cells 
The induction of IL-10-secreting immunoregulatory cells is a common feature of helminth 
immunomodulation. Previous studies determined AvCystatin to reduce airway hyperreactivity 
in a macrophage-mediated and IL-10-dependent manner (Schnoeller et al., 2008). In the 
present study, AvCystatin-MФ significantly increased local and systemic IL-10 in recipient 
mice. However, elevated IL-10 levels were detected after transfer of AvCystatin-primed cells 
from IL-10-deficient mice as well. Thus, an indirect suppressive effect of AvCystatin-MФ 
through the induction of an IL-10-producing cell type was hypothesized. CD4+ T cells have 
been described as important producers of IL-10 in diverse contexts of helminth infections or 
after treatment with helminth-secreted products. Therefore, CD4+ T cells were purified by 
negative depletion (purity ≥ 95%) from the spleen of healthy control mice or ovalbumin-
sensitized and -challenged animals that had been treated with AvCystatin- or control-
stimulated macrophages prior to intranasal provocation. ConA stimulation of purified CD4+ T 
cells significantly up-regulated the expression of IL-10 transcript in CD4+ T cells (Figure 
4-11, A upper panel) and increased levels of IL-10 in CD4+ T cell culture supernatants 
(Figure 4-11, A lower panel). Analysis of Foxp3 expression in IL-10-producing CD4+ T cells 
showed no differences between experimental groups (data not shown). To verify the 
induction of IL-10-producing CD4+ T cells by AvCystatin-MФ, an in vitro system was 
established reflecting the in vivo situation by incubating macrophages with ovalbumin-
specific CD4+ T cells of DO11.10 mice and bone marrow-derived dendritic cells pre-treated 
with the ovalbumin-peptide 323-339 (OVA-DC). To investigate whether IL-10 induction in 
CD4+ T cells is cell contact-dependent or mediated through soluble factors, in vitro assays 
were performed in a mixed population and transwell approach separating the macrophages 
from T cells and dendritic cells. In both cases AvCystatin- but not control-treated 
macrophages clearly induced IL-10 in CD4+ T cells (Figure 4-11, B upper and middle panel). 
Moreover, CD4+ T cell and OVA-DC co-cultures in the presence of AvCystatin- but not 
control-treated macrophage-supernatants (MФ-S) showed significantly increased IL-10 levels 
in the culture supernatants (Figure 4-11, B lower panel) suggesting a cell contact-
independent mechanism for the observed IL-10 induction. IL-10 was not detected in co-
cultures of CD4+ T cells, macrophages and untreated dendritic cells (Figure 4-11, B upper 
and middle panel). Moreover, incubation of CD4+ T cells with ovalbumin-peptide-treated 
AvCystatin-MФ in the absence of dendritic cells did not induce IL-10 production in CD4+ T 
cells (data not shown). Intracellular staining of IL-10 finally verified CD4+ T cells as the 




Figure 4-11. AvCystatin-MФ induce CD4+IL-10+ T cells. (A) Splenic CD4+ T cells were purified from 
healthy mice or allergic animals after treatment with AvCystatin-MФ or denatured AvCystatin-treated 
macrophages (control-MФ). IL-10 transcript (upper panel) and IL-10 protein (lower panel) was 
analysed after stimulation with ovalbumin or ConA. Results (mean ± SEM) are shown for one of two 
independent experiments with 5-6 mice per group. Normalized data is expressed as fold induction 
compared to healthy control mice. ***, P < 0.001. (B) Detection of IL-10 in culture supernatants after 
incubation of in vivo-generated AvCystatin-MФ or control-MФ with CD4+ T cells and dendritic cells. 
Assays were performed in a mixed population and transwell approach or CD4+ T cells and dendritic 
cells were alternatively incubated with macrophage supernatants (MФ-S). (C) Intracellular staining of 
IL-10 in CD4+ T cells after in vitro co-culture with dendritic cells and macrophages. Data represents 
mean ± SEM for one of at least three independent experiments. Triplicate analysis was performed for 




4.3.1.5 AvCystatin-MФ impair CD4+ T cell cytokine production 
To evaluate the impact of AvCystatin-MФ on other ovalbumin-specific CD4+ T cell cytokines, 
levels of IL-2, IFN-γ and IL-13 were assessed in co-culture supernatants of macrophages, 
dendritic cells and CD4+ T cells. Incubation of dendritic cells and CD4+ T cells in the absence 
of macrophages induced elevated levels of IL-2 (Figure 4-12, B), IFN-γ (Figure 4-12, C) and 
IL-13 (Figure 4-12, D). IL-10, however, was not detectable (Figure 4-12, A). Compared to 
control-treated macrophages which did not affect cytokine induction through dendritic cell-
mediated T cell activation, AvCystatin-MФ significantly suppressed levels of IL-2, IFN-γ and 
IL-13 (Figure 4-12, B-D) but increased the amount of IL-10 (Figure 4-12, A). To examine 
whether the CD4+ T cell-derived IL-10 affects T cell cytokine responses through an autocrine 
feedback, ovalbumin-specific CD4+ T cells were pre-treated with 10 µg/ml anti-IL-10 receptor 
antibody (clone 1B1; DRFZ, Berlin, Germany) for one hour to ensure that IL-10 cannot bind 
to and signal through its receptor on T cells. Thereafter, CD4+ T cells were co-cultured with 
ovalbumin-peptide-treated dendritic cells and AvCystatin- or control-treated macrophages in 
a mixed population approach. Pre-treatment of CD4+ T cells with the anti-IL-10 receptor 
antibody had no effect on the suppression of IFN-γ and IL-13 (Figure 4-12, C and D). IL-2 
secretion, however, was significantly restored but did not reach the initial level determined in 
supernatants of CD4+ T cell and dendritic cell co-cultures in the absence of macrophages 
(Figure 4-12, B). Together, these findings show that AvCystatin-MФ modulate ovalbumin-
specific CD4+ T cell responses but exclude an IL-10 autocrine feedback mechanism for the 
observed suppression of IFN-γ and IL-13 in CD4+ T cells. However, IL-10 seems, at least in 




Figure 4-12. Effect of AvCystatin-MФ on CD4+ T cell cytokine production in vitro. In vivo-
generated macrophages were purified from BALB/c mice and in vitro co-cultured with ovalbumin-
peptide-treated dendritic cells (OVA-DC) and ovalbumin-specific CD4+ T cells. In parallel, CD4+ T cells 
were pre-treated with 10 µg/ml anti-IL-10 receptor antibody for one hour and thereafter incubated with 
dendritic cells and macrophages. Supernatants were collected and analysed by ELISA for IL-10 (A), 
IL-2 (B), IFN-γ (C) and IL-13 (D). Data is presented as mean ± SEM for one of two independent 
experiments. Triplicate analysis was performed with pooled macrophages of 5 animals per treatment, 
purified splenic CD4+ T cells of 3 DO11.10 mice and bone marrow-derived dendritic cells of one 




4.3.2 Effects of AvCystatin-MФ in a model of DSS-induced colitis 
To address whether AvCystatin-MФ transfer protection in another disease setting, 
macrophages were evaluated in a murine model of dextran sodium sulfate (DSS)-induced 
colitis. DSS directly exerts toxic effects on colonic epithelial cells of the basal crypts and is 
commonly used to study innate immune mechanisms in colitis (Wirtz et al., 2007). Disruption 
of the mucosal barrier by DSS leads to severe histological damage associated with high 
levels of pro-inflammatory cyokines and the infiltration of granulocytes such as neutrophils 
and eosinophlis. In the present study, animals were treated with 3% DSS in drinking water 
for a total of 8 days and 3x106 AvCystatin- or control-treated macrophages were 
intravenously transferred one day after access to DSS (Figure 4-13, A). Single transfer of 
AvCystatin-MФ protected recipient mice against body weight loss (Figure 4-13, B) and colon 
shortening, a hallmark symptom of colitis wich arises from longitudinal muscle spasm or 
irreversible fibrosis (Figure 4-13, C). Histological analysis of distal colon sections revealed 
significantly lowered scores for tissue damage and inflammation after transfer of AvCystatin-
MФ (Figure 4-13, D and E). Compared to control-treated macrophages, injection of 
AvCystatin-MФ suppressed the influx of neutrophils (MPO7+) and eosinophils (SiglecF+) to 
the submucosa of distal colon (Figure 4-13, F and G) but did not induce Foxp3+ regulatory T 
cells or IL-10 (data not shown). Hence, transfer of AvCystatin-MФ not only protects against 




Figure 4-13. AvCystatin-MФ protect against DSS-induced colitis. 3x106 AvCystatin- or control-
treated macrophages of C57BL/6 donor mice were transferred into C57BL/6 recipient animals one day 
after access to dextran sodium sulfate (DSS) and animals sacrificed on day 8. (A) Scheme of DSS-
induced colitis. (B) Body weight curve. (C) Analysis of colon length on day 8. (D) Histological images 
of HE-stained colon sections. Bars, 100 µM. (E) Histopathology (includes analysis of inflammatory cell 
influx and scoring of tissue damage). (F) Cell counts of neutrophils (MPO7+) in the submucosal 
compartment. (G) Flow cytometry analysis of eosinophils (SiglecF+) in the submucosa of distal colon. 
Pooled data of two independent experiments with 5-9 mice per group is presented as mean ± SEM. *, 




4.3.3 Phenotyping of AvCystatin-MФ 
In order to characterize the AvCystatin-induced macrophage population and its suppressive 
activity in more detail, AvCystatin-MФ were phenotypically examined for gene and surface 
marker expression.  
4.3.3.1 Analysis of the transcriptional macrophage signature 
Transcriptional macrophage profiling was performed by analysing selected differentiation 
markers for murine M1 (iNOS, IL-12/23p40, TNF-α, IL-6), M2a (TGF-β, ARG-1, Ym1, RELM-
α), M2b (IL-10, SPHK-1, LIGHT, CCL1) and M2c (TLR-8, IL-21R) activation by quantitative 
real-time PCR. To elucidate the in vitro effect of AvCystatin on macrophage gene expression, 
enriched macrophages were stimulated with 0.5 µM recombinant or denatured AvCystatin. 
Analysis of marker gene expression revealed an early and transient expression of pro- and 
anti-inflammatory marker genes such as inducible nitric oxide synthase (iNOS), IL-12/23p40, 
TNF-α, IL-6 and IL-10 by macrophages treated with AvCystatin. These markers were down-
regulated to background levels 10-18 hours after treatment. Instead, AvCystatin-MФ 
changed their phenotype and expressed elevated levels of SPHK-1, LIGHT and ARG-1 
(Figure 4-14, A). However, treatment with AvCystatin did not induce expression of M2c 
marker genes (data not shown). To confirm the AvCystatin effect in vivo, 20 µg/animal 
AvCystatin or denatured AvCystatin was intraperitoneally injected into mice. Real-time PCR 
analysis of purified macrophages reflected the in vitro results by showing an early and 
transient expression of pro- and anti-inflammatory markers followed by expression of SPHK-
1, LIGHT and ARG-1 between 5-18 hours after stimulation (Figure 4-14, B). Thus, 
stimulation of peritoneal macrophages with AvCystatin in vitro and in vivo induces a specific 
phenotype characterized by an early and transient expression of pro- and anti-inflammatory 





Figure 4-14. Transcriptional characterization of AvCystatin-MФ. Macrophages were stimulated in 
vitro (0.5 µM) or in vivo (20 µg/mouse) with AvCystatin or control treatments. (A) Real-time PCR 
analyses for the expression of selected macrophage activation markers after in vitro stimulation. 
Results (mean ± SEM) are representative for one of three independent experiments. (B) Analysis of 
marker expression in macrophages after in vivo stimulation. Results (mean ± SEM) are representative 
for one of two independent experiments. Normalized data is expressed as fold induction compared to 
untreated control animals. For each group, macrophages of 8-10 animals were pooled and gene 




4.3.3.2 Phenotypic conversion of AvCystatin-MФ is IL-10 independent 
It was formerly shown that M2 macrophages can inhibit M1 macrophage activation through 
the secretion of IL-10 (Katakura et al., 2004). To assess whether an autocrine effect of 
AvCystatin-MФ-secreted IL-10 induces a phenotypic shift from M1 to M2a/M2b activation, the 
expression of selected marker genes was examined in macrophages of wildtype and IL-10-
deficient mice at an early and late timepoint after treatment with AvCystatin or denatured 
protein. No significant differences were observed between macrophages of wildtype and IL-
10-deficient mice. In vivo stimulation with AvCystatin induced early up-regulaton of iNOS, 
IL12/23p40, TNF-α and IL-6 in macrophages of wildtype and IL-10-deficient mice. As 
expected, IL-10 was only induced in wildtype but not in IL-10-deficient macrophages. Early 
marker genes were down-modulated to background levels 18-20 hours post stimulation. 
Instead, the expression of SPHK-1, LIGHT and ARG-1 was detectable in both wildtype and 
IL-10-deficient macrophages (Figure 4-15). These results show that the phenotypical 
conversion of AvCystain-MФ from M1 activation towards an M2a/M2b signature does not 
depend on an autocrine IL-10 effect. 
Figure 4-15. IL-10 does not induce phenotypic conversion of AvCystatin-MФ. Macrophages of 
wildtype (wt) or IL-10-deficient (IL-10-/-) mice were analysed for their marker expression after in vivo 
treatment with AvCystatin or denatured AvCystatin. Results (mean ± SEM) are shown for one 
experiment. Normalized data is expressed as fold induction compared to untreated control mice. 
Macrophages of 5-6 animals per group were pooled and gene expression analysed in triplicate values. 




4.3.3.3 AvCystatin-MФ surface marker profile 
To assess the effect of AvCystatin on macrophage surface molecules, the expression of 
surface markers of in vivo-generated AvCystatin-MФ was determined 18-20 hours after 
intraperitoneal treatment with the immunomodulator. Flow cytometric analysis of peritoneal 
F4/80+CD11b+ AvCystatin-MФ revealed up-regulation of MHC-II, CD40, CD80, CD86, Fcγ 
receptor (FcγR) III and II (CD16/32), PD-L1 (CD274), PD-L2 (CD273) and intercellular 
adhesion molecule 1 (ICAM-1) (Figure 4-16). Thus, AvCystatin-MФ express a surface 
marker pattern which, in this specific combination, has not yet been described for any other 
murine macrophage population.  
Figure 4-16. Surface marker expression of AvCystatin-MФ. PEC were isolated from the peritoneal 
cavity of mice 18-20 hours after intraperitoneal application of 20 µg AvCystatin or control treatment. 
AvCystatin-stimulated F4/80+CD11b+ peritoneal macrophages show an up-regulation of MHC-II, co-
stimulatory molecules (CD40, CD80, CD86), FcγRIII/FcγRII (CD16/32), PD-L1, PD-L2 and ICAM-1. 




4.3.4 Analyses of the AvCystatin-MФ suppressive mechanism 
4.3.4.1 Specificity of IL-10 induction by AvCystatin-MФ 
Since macrophage treatment with AvCystatin induced a phenotype similar to murine M1, 
M2a and M2b macrophage activation, AvCystatin-MФ were examined for their specific 
characteristics in inducing CD4+IL-10+ T cells. M1, M2a and M2b macrophages were in vitro 
generated through stimulation of murine peritoneal macrophages with 100 U/ml IFN-γ and 10 
ng/ml LPS (M1-MФ) for 18-20 hours, through pre-treatment with 20 ng/ml IL-21 for 6 hours 
and subsequent incubation with 20 ng/ml IL-4/IL-13 for 18-20 hours (M2a-MФ) or by 
stimulation with 150 µg ovalbumin immune complexes (OVA-IC) in combination with 10 ng/ml 
LPS for 18-20 hours (M2b-MФ). Successful generation of the respective macrophage 
populations was determined by quantitative real-time PCR for the expression of selected M1 
(iNOS, IL-12/23p40), M2a (ARG-1, RELM-α, Ym1) and M2b (IL-10, SPHK-1, LIGHT) 
activation markers (Figure 4-17, A). The ability of M1, M2a and M2b macrophages to induce 
IL-10 in CD4+ T cells was evaluated by using the established co-culture assay of 
macrophages, ovalbumin-peptide-treated dendritic cells and ovalbumin-specific CD4+ T cells. 
This was compared to the IL-10-inducing capacity of in vitro- and in vivo-stimulated 
AvCystatin-MФ. M2b but not M1 or M2a macrophages showed increased IL-10 production 
18-20 hours after stimulation with the respective stimulus. However, IL-10 levels in the 
culture supernatant of M2b macrophages incubated with ovalbumin-peptide-treated dendritic 
cells and CD4+ T cells did not significantly differ from IL-10 levels produced by M2b 
macrophages alone (Figure 4-17, B). AvCystatin-MФ showed no IL-10 self-production 18-20 
hours after treatment with AvCystatin but significantly elevated levels of IL-10 were detected 
in culture supernatants of in vivo-stimulated AvCystatin-MФ incubated with ovalbumin-
peptide-treated dendritic cells and CD4+ T cells. In vitro-generated AvCystatin-MФ, however, 




Figure 4-17. Macrophage-specific IL-10 induction. M1 macrophages (M1-MФ), M2a macrophages 
(M2a-MФ), M2b macrophages (M2b-MФ), AvCystatin-stimulated macrophages (AvCystatin-MФ) and 
denatured AvCystatin-treated macrophages (control-MФ) were generated and in vitro evaluated for 
their ability to induce IL-10 in CD4+ T cells. (A) Determination of macrophage activation by quantitative 
real-time PCR analysis for macrophage-specific marker expression 18-20 hours after treatment with 
the respective stimuli (M1-MФ: 100 U/ml IFN-γ and 10 ng/ml LPS; M2a-MФ: 20 ng/ml IL-21 and 20 
ng/ml IL-4/IL-13; M2b-MФ: 150 µg OVA-IC and 10 ng/ml LPS; in vivo-generated AvCystatin-MФ: 20 µg 
AvCystatin/mouse; in vitro-generated AvCystatin-MФ: 0.5 µM AvCystatin; control-MФ were generated 
in an analogous manner by using denatured AvCystatin). Normalized data (mean ± SEM) of one 
representative experiment is shown and expressed as fold induction compared to untreated 
macrophages (M0). Macrophages of 5 mice per treatment were pooled and gene expression analysed 
in duplicate values. (B) Macrophage subpopulations were cultured alone (black bars) or with 
ovalbumin-specific CD4+ T cells and ovalbumin-peptide-treated dendritic cells (OVA-DC) (white bars). 
Culture supernatants were analysed for IL-10 by ELISA. Pooled data of 3 independent experiments is 




4.3.4.2 Role of macrophage markers for the induction of CD4+IL-10+ T cells 
SPHK-1, ARG-1, PD-L1 and PD-L2 have formerly been reported to directly or indirectly 
interfere with CD4+ T cell responses (Wang et al., 2005; Pesce et al., 2009 b; Francisco et 
al., 2009). To address whether these marker genes are involved in the induction of CD4+IL-
10+ T cells, either chemical inhibitors and blocking antibodies for ARG-1, PD-L1, PD-L2 or 
antagonists for target receptors of AvCystatin-MФ-secreted factors (S1P) were used. 
AvCystatin-MФ were pre-treated with different concentrations of the ARG-1 inhibitor S-(2-
boronoethyl)-l-cysteine (BEC) (Figure 4-18, A) or with anti-PD-L1 and anti-PD-L2 antibodies 
in a dose-dependent manner for one hour (Figure 4-18, E) and thereafter cultured with 
ovalbumin-petide-treated dendritic cells (OVA-DC) and ovalbumin-specific CD4+ T cells. The 
efficiency of ARG-1 inhibition by BEC was determined through measuring urea production by 
M2a macrophages in the absence of BEC or in the presence of different BEC concentrations 
(Figure 4-18, B). Since SPHK-1 converts sphingosine to sphingosine-1-phosphate (S1P) 
which can bind to sphingosine 1 phosphate receptors (S1PR) on T cells, ovalbumin-specific 
CD4+ T cells were pre-treated with the S1PR1 antagonist VPC23019 for one hour in a dose-
dependent manner and further incubated with AvCystatin- or control-treated macrophages 
and ovalbumin-peptide-treated dendritic cells (Figure 4-18, C). In addition, co-cultures of 
ovalbumin-peptide-treated dendritic cells and ovalbumin-specific CD4+ T cells were 
supplemented with various concentrations of S1P to analyse whether addition of the 
lysosphingophospholipid itself induces IL-10 production in ovalbumin-specific CD4+ T cells 
(Figure 4-18, D). None of the inhibitors, blocking antibodies or antagonists significantly 
reduced IL-10 levels in the supernatants of co-cultured AvCystatin-MФ, ovalbumin-peptide-
treated dendritic cells and ovalbumin-specific CD4+ T cells (Figure 4-18, A, C and E). 
Moreover, supplementation of CD4+ T cell and dendritic cells co-cultures with S1P did not 
increase IL-10 levels in the culture supernatants (Figure 4-18, D). Together, these findings 
argue for an additional, as yet undefined factor secreted by AvCystatin-MФ that conveys the 




Figure 4-18. Role of specific AvCystatin-MФ markers for the induction of IL-10 in T cells. 
(A) Macrophages were pre-treated for one hour with different concentrations of the ARG-1 inhibitor 
BEC and thereafter incubated with ovalbumin-specific CD4+ T cells and ovalbumin-peptide-treated 
dendritic cells (OVA-DC). (B) Validation of BEC activity was determined by measuring urea 
concentrations in the supernatants of M2a macrophage cultures after incubation with different 
concentrations of the inhibitor for 18-20 hours. (C) Ovalbumin-specific CD4+ T cells were pre-
incubated for one hour with the S1PR1 antagonist VPC23019 and subsequently incubated with 
AvCystatin- or control-treated macrophages and ovalbumin-peptide-treated dendritic cells. (D) Co-
cultures of ovalbumin-specific CD4+ T cells and ovalbumin-peptide-treated dendritic cells were 
supplemented with various concentrations of S1P. (E) Macrophages were pre-treated with anti-PD-L1 
and anti-PD-L2 for one hour in a dose-dependent manner and further incubated with ovalbumin-
specific CD4+ T cells and ovalbumin-peptide-treated dendritic cells. Data for one representative of 2-3 
independent experiments is presented as mean ± SEM in A, C, D and E. Pooled data from 3 
experiments is shown in B. For each experiment culture assays were performed with pooled 
macrophages of 5-6 animals per treatment, purified splenic CD4+ T cells of 3 DO11.10 mice and bone 




4.4 Proposed model of AvCystatin-induced macrophage activities 
In order to summarize the experimental findings of the present thesis, the following model of 
AvCystatin-induced macrophage activities is suggested (Figure 4-19).  
Figure 4-19. Modulation of murine macrophage activities by AvCystatin. Treatment of peritoneal 
macrophages with AvCystatin leads to an active endocytotic uptake of the immunomodulator into the 
endolysosomal compartment (a) and induces subsequent phosphorylation of MAPK p38 and ERK (b). 
The activation of transcription factors CREB and STAT3 by MAPK (c) gives rise to the expression of 
pro- and anti-inflammatory marker genes (d). In parallel to MAPK, dual specificity phosphatases 
(DUSPs) are expressed (e) which act as negative regulators on MAPK (f). As a result of DUSP-
mediated dephosphorylation of p38 and ERK, the early gene expression is down-modulated (g). 
Macrophages show an M2a/M2b hybrid phenotype 18-20 hours post stimulation with the 
immunomodulator, characterized by the expression of SPHK-1, LIGHT and ARG-1 (h). Adoptive 
transfer of this phenotype mitigates intestinal inflammation and symptoms of ovalbumin-induced 
airway hyperreactivity in mice. The amelioration of airway inflammation is associated with the 
secretion of a mediator (i) that induces CD4+ T cells which produce high amounts of IL-10 but reduced 





The immunomodulatory potential of parasitic worms and the suppression of unrelated 
pathology as a bystander effect of helminth infection has led to an increased interest in the 
interplay between parasite-induced evasion mechanisms and the immune system of their 
mammalian hosts. The present investigation studied the effects of the helminth-derived 
immunomodulatory protein AvCystatin on murine peritoneal macrophages and aimed to 
examine the therapeutic potential of AvCystatin-MФ in two murine disease models. 
5.1 Part I: Signalling events in AvCystatin-MФ 
In previous studies, AvCystatin was shown to affect the cytokine response of mouse 
macrophages by inducing an anti-inflammatory IL-10-secreting phenotype (Schierack et al., 
2003). Additional investigations demonstrated IL-10 to be the key mediator of the AvCystatin-
mediated immunosuppression in a model of ovalbumin-induced airway hyperreactivity. 
Administration of anti-IL-10 antibodies prior to allergen challenge ablated the protective 
AvCystatin effect in mice and the depletion of macrophages resulted in abrogated IL-10 
expression. These results suggested that AvCystatin ameliorates inflammatory responses 
through the induction of IL-10-producing macrophages (Schnoeller et al., 2008). To date, 
little is known about intracellular pathways and signalling events which are target of and 
triggered by AvCystatin. Part I of the present investigation thus aimed to analyse signalling 
events involed in the IL-10 induction of AvCystatin-MФ. 
5.1.1 Activation of MAPK affects IL-10 production in macrophages 
The importance of MAPK activation for cytokine production has been investigated in and 
demonstrated through different studies (Saccani et al., 2002; Mathur et al., 2004). To assess 
whether MAPK are involved in the AvCystatin-mediated induction of IL-10 in macrophages, 
the influence of specific MAPK inhibitors on IL-10 production in murine peritoneal 
macrophages was examined. In mammalian cells three important MAPK pathways are 
described: the p38, ERK and JNK pathway (Johnson and Lapadat et al., 2002). These MAPK 
are activated through phosphorylation of their tyrosine and threonine residues and target a 
large number of downstream elements such as kinases, transcription factors or proteins 
which control the stability and translation of mRNA (Lang et al., 2006). In the present study, 
inhibition of both p38 and ERK clearly affected IL-10 production by AvCystatin-MФ in a dose- 
and tyrosine kinase-dependent manner whereas blockade of JNK had no significant effect on 




argued for an involvement of PI3K-AKT in AvCystatin-induced IL-10 expression. MAPK 
activation through phosphorylation of tyrosine and threonine residues alters protein 
conformation and substrate accessibility (Cobb and Goldsmith, 2000). Therefore, additional 
western blot analysis was performed that supported the experimental outcome of the inhibitor 
study by confirming AvCystatin-induced phosphorylation of p38 and ERK. Surprisingly, 
phosphorylation of the PI3K downstream target AKT was not detectable although blockade of 
PI3K significantly inhibited IL-10 production. Together, these observations suggest that 
activation of p38 and ERK leads to IL-10 production in macrophages and endogenous 
phospho-AKT levels might be enough for sufficient cytokine production after treatment with 
AvCystatin.  
The AvCystatin-specific activation of MAPK and its positive correlation with IL-10 production 
in macrophages is in line with findings of Lucas et al. (2005) who determined the mechanism 
of IL-10 induction in regulatory M2b macrophages. The authors found up-regulation of IL-10 
to be associated with enhanced activation of p38 and ERK. Increased ERK activity led to 
histone modifications at the IL-10 locus resulting in higher IL-10 promotor accessibility to 
p38-activated transcription factors specificity protein 1 (Sp1) and signal transducer and 
activator of transcription (STAT) 3. Phosphorylation of transcription factors is an important 
feature of activated MAPK for the induction of gene transcription (Davis, 1993). Activation of 
transcription factor cAMP response element-binding protein (CREB) was shown to correlate 
with increased promotor binding and IL-10 expression in macrophages (Martin et al., 2005). 
In addition, CCAAT/enhancer-binding protein (C/EBP), nuclear factor-kappa B (NFkappaB), 
interferon regulatory factor-1 (IRF-1) and musculoaponeurotic fibrosarcoma (Maf) have been 
determined as important regulators of IL-10 production in macrophages (Liu et al., 2003; Cao 
et al., 2006; Ziegler-Heitbrock et al., 2003; Cao et al., 2005). In additional studies, which 
were not directly part of the present thesis, AvCystatin was found to induce MAPK-regulated 
phosphorylation of transcription factors CREB and STAT3 in murine peritoneal macrophages 
(Klotz et al., 2011 b). It remains to be analysed whether treatment of macropages with 
AvCystatin additionally promotes histone phosphorylation and IL-10 promoter accessibility 
similar to what has been described by Lucas et al. (2005).     
The activation of MAPK is not a mechanism specific to AvCystatin. Other helminth-derived 
molecules have been shown to exploit MAPK signalling in order to modulate APC maturation 
(reviewed in Carvalho et al., 2009). ES-62 of the rodent nematode Acanthocheilonema viteae 
activates ERK but suppresses p38 phosphorylation thereby directing the phenotype of 
dendritic cells towards low IL-12 production (Goodridge et al., 2005 b). Similar to ES-62, the 




promoting activity on dendritic cells by preferentially activating ERK (Thomas et al., 2003). 
This demonstrates that helminth parasites target and subvert well-established signalling 
pathways in host cells to modify their cytokine response. 
5.1.2 Dual-specificity phosphatases regulate MAPK activity 
Stimulation of macrophages with AvCystatin induced transient activation of both p38 and 
ERK. Analysis of IL-10 transcript further revealed early induction of IL-10 followed by a 
subsequent down-regulation to background levels. To explain this transient activation and 
expression, a negative feedback mechanism on MAPK was hypothesized. Inactivation of 
MAPK activity can be performed by serine-threonine phosphatases, tyrosine phosphatases 
or dual-specificity phosphatases (DUSPs) (Lang et al., 2006). DUSPs are particularly 
effective regulators of MAPK since they dephosphorylate both tyrosine and threonine 
residues (Liu et al., 2007). To date, approximately 11 of 30 DUSPs have been shown to 
contain a MAPK binding domain in addition to their DUSP domain and thereby exert 
inhibitory activity on MAPK (Lang et al., 2006). To elucidate whether DUSPs are responsible 
for transient phosphorylation of p38 and ERK, the AvCystatin-specific expression of selected 
DUSPs which have been reported to regulate p38 and ERK activity in macrophages in vitro 
and in vivo was determined. Real-time PCR analysis of AvCystatin-MФ revealed up-
regulation of DUSP-1, DUSP-2 and lower amounts of DUSP-5 in vitro. In vivo-stimulated 
macrophages showed prominent expression of DUSP-1 and moderate transcript levels of 
DUSP-2. DUSP expression was detectable as early as 30 to 60 minutes after treatment with 
AvCystatin. DUSPs can be divided into phosphatases which are predominantely localized in 
the nucleus and encoded by immediate-early genes and phosphatases which are not 
encoded by immediate-early genes and primarily reside in the cytoplasm or both the 
cytoplasm and the nucleus (Liu et al., 2007). The affiliation of DUSP-1, DUSP-2 and DUSP-5 
to phosphatases encoded by immediate-early genes might explain their early expression 
after stimulation with AvCystatin. DUSPs that belong to this group of phosphatases are 
normally induced by the same stimuli that lead to MAPK activation, e.g. stress signals or 
growth factors (Keyse, 2000).  
Phosphorylation is not essential for DUSP activation but mediates stabilization of DUSPs by 
increasing their half-life. The accumulation of DUSPs in consequence leads to higher DUSP 
activity (Brondello et al., 1999). To elucidate a possible stabilization effect on DUSPs, the 
phosphorylation kinetics of DUSP-1 was investigated in AvCystatin-MФ by western blot 
analysis. Increased DUSP-1 phosphorylation was detected after 60 minutes of stimulation 




possible that DUSP-1 stabilization might be an effect of the early IL-10 production by 
AvCystatin-MФ since an investigation by Hammer et al. (2005) showed that IL-10 can 
enhance and prolong the expression of DUSP-1. By using DUSP-1-deficient mice, DUSP-1 
was demonstrated to control phosphorylation of MAPK and IL-10 expression following 
AvCystatin treatment. Wildtype animals showed transient expression of IL-10 after 
stimulation with the immunomodulator whereas DUSP-1-deficient mice revealed increased 
and sustained IL-10 expression (chapter 4.2.4) but reduced levels of IL-12/23p40 (data not 
shown). This result is substantiated by studies showing that DUSP-1-deficient mice produce 
increased amounts of IL-10, TNF-α and IL-6 but reduced levels of IFN-γ and IL-12p40 in 
response to TLR stimulation (reviewed in Lang et al., 2006). Western blotting confirmed the 
substrate preference of DUSP-1 for p38 since treatment with AvCystatin led to an 
accumulation of phospho-p38 and slightly reduced levels of phospho ERK in DUSP-1-
deficient mice.  
5.1.3 Possible involvement of receptors in AvCystatin-mediated signalling  
AvCystatin was actively taken up into the endolysosomal compartment of peritoneal 
macrophages. The activation of MAPK following AvCystatin treatment, however, might be 
indicative for an additional, receptor-mediated mechanism. So far, no specific receptors have 
been identified for cystatins. Thus, it is still unclear whether AvCystatin effects result from 
receptor binding or from inhibitory effects on cysteine proteases (Klotz et al., 2011 b). Human 
cystatin C was shown to antagonize TGF-β signalling through interaction with the TGF-β 
receptor on mammary tumor cells (Sokol et al., 2005). By using a TGF-β reporter system 
described in Tesseur et al. (2006), AvCystatin was not determined to interfere with TGF-β 
signalling (data not shown). Another feasible scenario is that AvCystatin interacts with PRRs 
such as TLRs or C-type lectin receptors. Several helminth molecules have been described to 
induce anti-inflammatory responses by interference with PRRs (reviewed in Harnett and 
Harnett, 2010). The aminopeptidase ES-62, for example, signals through TLR-4 in a manner 
which is different from LPS (Goodridge et al., 2005 a). Moreover, products from 
schistosomes (e.g. lacto-N-fucopentaose, lysophosphatidylserine or phosphatidylserine) 
exert anti-inflammatory effects through the interaction with TLRs (van der Kleij et al., 2002; 
Harn et al., 2009; van Riet et al., 2009). In studies from our own group, Acanthocheilonema 
viteae-derived tropomyosin was found to up-regulate and bind TLR-2 on mouse 
macrophages (unpublished data). TLR-3, TLR-7, TLR-8, TLR-9 and TLR-13 are 
intracellularly expressed and described to act within the endosomal compartment (reviewed 
in Blasius and Beutler, 2012). Since AvCystatin is taken up into the endolysosomal 




astonishing that helminth parasites convey anti-inflammatory effects via TLRs however my 
be plausible if one takes into account that subversion of TLR signalling by filarial nematodes 
supports the generation of immature APCs which produce fewer pro-inflammatory cytokines 
(Harnett and Harnett, 2010). The precise mechanisms how helminths modulate TLR 
responses are not entirely known. In a study by Donnelly et al. (2010), two helminth cysteine 
proteases, Fasciola hepatica cathepsin L1 (FheCL1) and Schistosoma mansoni cathepsin 
B1 protease (SmCB1), were shown to successfully protect mice against the development of 
severe inflammation in response to TLR agonists through the suppression of TRIF-
dependent macrophage activation. In the respective study, the protease-specific inhibition of 
TLR signalling was mediated through degradation of TLR-3 within the endosome (Donnelly 
et al., 2010). Park et al. (2008) showed that cathepsin activity is necessary for TLR-9 
responses. The investigators blocked cathepsin activity by using the cysteine protease 
inhibitor benzyloxycarbonyl-Phe-Ala-fluoromethylketone (z-Phe-Ala-fmk) and thereby 
inhibited TNF-α production in RAW cells (a murine leukaemic monocyte-macrophage cell 
line) in response to CpG oligodeoxynucleotides but not LPS. Thus, it is likely that helminth-
secreted cysteine protease inhibitors such as AvCystatin interfere with TLR-9 responses in 
the endolysosomal compartment. Moreover, accessory PRRs, e.g. C-type lectins, might be 
recruited and crosstalk with TLRs in order to inhibit or synergistically enhance signals 
(reviewed in Harnett and Harnett, 2010). C-type lectins such as the mannan-binding lectin 
(MBL), macrophage galactose-type lectin (MGL) or dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN), have been shown to act as targets 
for SEA or different glycans (e.g. Lewisx antigen or α/β GalNAc) of Schistosoma mansoni 
(reviewed in Johnston et al., 2009). At present, the most promising receptor candidates for 
AvCystatin are Fcγ receptors. AvCystatin-MФ share remarkable similarities with M2b 
macrophages which are derived through crosslinking of Fcγ receptors by immune complexes 
in the presence of a pro-inflammatory co-stimulus. Moreover, AvCystatin targets signalling 
events in murine macrophages similar to those described for M2b macrophages (Lucas et 
al., 2005) and up-regulates the expression of Fcγ receptors on these cells. In vivo, 
AvCystatin induces high levels of IgG1 (data not shown) which is known to bind with high 
affinity to Fcγ receptors. These findings hint towards a possible involvement of Fcγ receptors 
in AvCystatin-mediated signalling. 
Together, the results of part I show for the first time that the helminth immuomodulator 
AvCystatin exploits activating and deactivating pathways of MAPK in murine macrophages 




5.2 Part II: Functional and molecular characteristics of AvCystatin-MФ 
In part I, AvCystatin was determined to interfere with signalling events leading to IL-10 
production in peritoneal macrophages. The aim of part II was to examine the potential of 
AvCystatin-MФ in transferring protection against aberrant inflammation independent of the 
immunomodulator`s presence and to gain more insights into the macrophage phenotype and 
the macrophage-mediated mechanism of immunosuppression. 
5.2.1 AvCystatin-MФ ameliorate ovalbumin-induced airway inflammation 
The model of ovalbumin-induced airway hyperreactivity in mice reflects important symptoms 
of asthma. After antigen-sensitization and -challenge, animals develop airway inflammation 
characterized by increased levels of Th2 cytokines, production of antigen-specific IgE, airway 
eosinophilia and goblet cell hyperplasia (Schröder and Maurer, 2007). The present study 
shows that single transfer of AvCystatin-MФ is sufficient to abrogate pathophysiological 
hallmarks of ovalbumin-induced airway hyperreactivity. Suppression of allergic inflammation 
either involves counteracting mechanisms such as driving the immune response towards a 
Th1 phenotype or results from unspecific suppression of immune responses and leucocyte 
activity (Peters-Golden, 2004). Adoptive transfer of AvCystatin-MФ did not instruct a counter-
regulatory Th1 response in recipient mice (data not shown) but correlated with high levels of 
local and systemic IL-10 through induction of CD4+IL-10+Foxp3- T cells. Previous studies 
demonstrated the necessity of IL-10 for the AvCystatin-mediated suppression of ovalbumin-
induced airway hyperreactivity in mice since in vivo blockade of the IL-10 receptor reversed 
protection (Schnoeller et al., 2008). IL-10 has been shown to exert suppression on APCs, 
eosinophils, mast cells, basophils and T cells thus representing an attractive candidate to 
control allergic diseases (Hawrylowicz and O´Garra, 2005; Saraiva and O´Garra, 2010). 
Compared to increased IL-10 production, AvCystatin-MФ-induced CD4+Foxp3- T cells 
showed a reduced capacity to produce other cytokines. Collectively, these results 
demonstrate that AvCystatin-MФ modulate the antigen-specific cytokine response of CD4+ T 
cells and thereby indirectly abrogate the main features of ovalbumin-induced airway 
hyperreactivity. However, the induction of IL-10-producing CD4+ T cells is not a feature 
specific to AvCystatin-MФ. A similar effect has been described by Atochina et al. (2008). In 
the respective study, murine peritoneal macrophages were treated in vivo with LNFPIII, a 
secreted glycan of the blood fluke Schistosoma mansoni. Macrophages were isolated after 
20 hours and exhibited an alternative activation status through up-regulation of ARG-1 and 
Ym-1. These macrophages were pulsed ex vivo with ovalbumin-peptide and adoptively 
transferred into the peritoneum of healthy DO11.10 mice. Splenocytes of recipient animals 




peptide. Thereby, LNFPIII- but not control-treated macrophages significantly increased levels 
of IL-10 but also induced the production of IL-13 in CD4+ T cells. Although not explicitly 
shown, the authors speculated that this effect could be mediated through macrophage 
soluble factors (Atochina et al., 2008).  
Th2 cytokines are key factors for the development of asthma pathogenesis. IL-5 plays an 
outstanding role for eosinophilopoesis, the recruitment of eosinophils to the site of 
inflammation, their degranulation and survival (reviewed in O´Byrne et al., 2004). IL-4 is a 
cytokine with pleiotropic effects on different cells and important for the initial phase of allergic 
inflammation. It increases Fcε receptor expression on B cells, promotes isotype switching to 
IgE (Bossie et al., 1987; Hudak et al., 1987), stimulates Th2 cell differentiation (Spellberg 
and Edwards, 2001), mediates tissue homing of inflammatory cells (Romagnani, 2004) and 
triggers mast cell growth and maturation (Paul, 1989). IL-13 has been shown to mediate 
airway hyperresponsiveness and mucus secretion (Wills-Karp et al., 1998; Walter et al., 
2001). IL-4 and IL-13 both recruit eosinophils, macrophages, monocytes and CD4+ T cells 
from the bloodstream by inducing expression of adhesion molecules in the airway epithelium 
(Bochner et al., 1995) and chemokines that regulate chemotaxis of inflammatory cells (Schuh 
et al., 2003; Zimmermann et al., 2003). Modulation of local and systemic Th2 responses after 
transfer of AvCystatin-MФ was associated with the induction of IL-10-producing CD4+ T cells. 
Since IL-10 inhibits Th2 cytokine production by the suppression of CD28-dependent 
signalling in T cells (Schandene et al., 1994; Akdis et al., 2000; Akdis and Blaser 2001), it is 
possible that the AvCystatin-MФ-induced IL-10 acts back on T cells in an autocrine manner 
thereby suppressing cytokine production. To test this hypothesis, ovalbumin-specific CD4+ T 
cells were incubated in vitro with an anti-IL-10 receptor antibody and thereafter co-cultured 
with ovalbumin-peptide-treated dendritic cells and AvCystatin-MФ. Blocking IL-10 signalling 
in T cells did not restore the AvCystatin-MФ-mediated suppression of IL-13 but significantly 
reversed the inhibition of IL-2. These findings exclude an autocrine IL-10 feedback to be 
responsible for the observed suppression of Th2 cytokines in CD4+ T cells but indicate that 
IL-10 might suppress T cell proliferation through the inhibition of IL-2 production and thereby 
indirectly limit Th2 cytokine production. The main source of Th2 cytokines are CD4+ Th2 T 
cells. Eosinophils, basophils and mast cells, however, mobilize IL-4 and IL-13 transcripts for 
instantaneous translation and can therefore act as early sources of Th2 cytokines (Gessner 
et al., 2005). This leads to the question whether such cells can compensate the AvCystatin-
MФ-mediated Th2 cytokine suppression. It has been shown that intranasal allergen 
challenge is important for the recruitment of basophils, mast cells and eosinophils to the 
airways (reviewed in Kim et al., 2010). AvCystatin-MФ were transferred 4 days prior to 




with the recruitment of inflammatory cells, e.g. through the suppression of respective 
chemokines such as eotaxins, and thereby prevent the onset of inflammaton. With respect to 
continuing studies, it might be interesting to address whether transfer of AvCystatin-MФ is 
still protective after intranasal challenge.  
Allergic asthma is correlated with elevated levels of antigen-specific IgE (Holgate, 2008) that 
becomes attached to Fcε receptors on mast cells, basophils and eosinophils through a 
specific domain of the IgE constant region (Presta et al., 1994; Platts-Mills, 2001 b). The 
involvement of IgE in the development of asthma has been demonstrated by showing that 
passive transfer of antigen-specific IgE antibodies is sufficient to induce cutaneous 
hypersensitivity and increased airway responsiveness in unsensitized recipient mice (Oshiba 
et al., 1996). Moreover, injection of plasma from atopic individuals caused positive allergen 
skin test reactions in nonatopic individuals (reviewed in Platts-Mills, 2001 b). IgE itself is 
supposed to promote the up-regulation of high-affinity Fcε receptors on effector cells which 
could explain its high biological activity even when present in low concentrations (Yamaguchi 
et al., 1997). Crosslinking of two adjacent IgE molecules by antigen leads to the release of 
histamine, leukotrienes, prostaglandins, cytokines and chemokines (reviewed in Barrett and 
Austen, 2009). These mediators are responsible for immediate and late allergic reactions as 
they increase vascular permeability and promote the up-regulation of adhesion molecules for 
lymphocytes and other effector cells (reviewed in Platts-Mills, 2001 b). In the present study, 
transfer of AvCystatin-MФ suppressed total- and antigen-specific IgE levels in recipient mice. 
IL-4 and IL-13 are crucial for both isotype switching by B cells and the secretion of allergen-
specific IgE by plasma cells. Since AvCystatin-MФ were transferred into already sensitized 
mice, it is unlikely that the macrophages prevent isotype switching to IgE, however through 
modulation of T cell responses and the resulting suppression of IL-4 and IL-13 they may 
have dampened the release of IgE by plasma cells in response to intranasal provocation 
which, in turn, limits effector cell activation and degranulation. The latter scenario has 
experimentally been demonstrated in previous studies by showing that the sensitization of 
basophils with sera of ovalbumin/AvCystatin-treated mice induced less degranulation 
compared to basophil sensitization with sera of control animals (Schnoeller et al., 2008). 
In addition, transfer of AvCystatin-MФ significantly reduced airway eosinophilia as detected 
by cell counts for eosinophils in the BAL-fluid. Eosinophils are major players in asthma. They 
produce Th1 (IFN-γ, IL-2) and Th2 (IL-4, IL-5, IL-13) cytokines, act as APCs and modulate 
other cells, e.g. dendritic cells, CD4+ T cells, B cells, mast cells, basophils and neutrophils 
(reviewed in Akuthota et al., 2008). IL-10 was reported to interfere with LPS-induced 




1994) suggesting that the AvCystatin-MФ-induced IL-10 production by T cells might hamper 
eosinophil activity. Another possibility is that AvCystatin-MФ interfere with eosinophil 
recruitment. In the present study, it was found that reduced eosinophil numbers in the BAL-
fluid were associated with suppressed expression of eotaxin-1 (CCL11), eotaxin-2 (CCL24), 
CCR3 and MCP-5 (CCL12) in lung homogenates. In the lung, eotaxin-1, eotaxin-2 and MCP-
5 are commonly produced by lung fibroblasts and epithelial cells. AvCystatin-MФ could not 
be detected in the lungs of recipient mice. Thus, it seems unlikely that the suppression of 
eotaxin production is mediated through cell-cell interaction. However, AvCystatin-MФ were 
tracked in the peribronchial lymph nodes and could probably secrete mediators which are 
transported to the lungs and either silence eotaxin expression by the respective cells or 
actively cleave eotaxins. The latter mechanism has been described for hookworm 
metalloproteases in vivo and in vitro (Culley et al., 2000). Although the inhibition of eotaxin 
activity through macrophage-secreted metalloproteases could explain the reduced eosinophil 
numbers in the BAL-fluid after transfer of AvCystatin-MФ, it does not explain the observed 
suppression of eotaxin transcript levels in lung homogenates. Thus, it is yet unclear whether 
metalloproteases are involved in AvCystatin-MФ-mediated suppression of eotaxins. 
Alternatively, AvCystatin-MФ might modulate CD4+ T cells in the spleen or PBLNs which 
migrate to the lungs in response to allergen-exposure and suppress eotaxin production by 
local fibroblasts or epithelial cells. Eotaxin activity is mediated through the eotaxin receptor 
CCR3 which is primarily expressed on eosinophils (Lukacs et al., 2003; Pope et al., 2005). 
The detection of lowered CCR3 transcript levels in homogenized lung tissue after treatment 
with AvCystatin-MФ nicely reflects the reduced eosinophil number in the BAL-fluid. MCP-5 is 
important for the early phase of airway inflammation. It is chemotactic for eosinophils and 
other leukocytes and promotes their migration through the lung interstitium (Gonzalo et al., 
1998; Jia et al., 1996). Thus, AvCystatin-MФ might not only suppress chemoattraction of 
eosinophils but may also inhibit eosinophil migration through suppression of MCP-5.  
Hypersecretion of mucus contributes to airway obstruction and hyperresponsiveness. Under 
healthy conditions, mucociliary clearance protects the airways against infections and enables 
normal lung functions. Inhaled pollutants and particles are trapped in a thin liquid layer, 
transported to the tip of the cilia and removed by cilia beating. In chronic asthma, increased 
mucus production leads to plugging of the airways, impaired airflow, induces cough and 
affects ciliary clearance functions (reviewied in Rogers, 2004). IL-13 was shown to mediate 
goblet cell hyperplasia and to hold important functions for the induction of mucus in the 
airways (Kuperman et al., 2002; Whittaker et al., 2002; Izuhara et al., 2009). The 
suppression of IL-13 in CD4+ T cells after contact with AvCystatin-MФ-secreted factors 




al. (2003 b), IL-5 and eotaxin-2 were shown to cooperatively promote the production of IL-13 
through recruitment of eosinophils to the lung of mice in an experimental model of eotaxin-2-
induced airway eosinophilia. Different cell populations of the BAL-fluid were examined for 
their capacity to produce IL-13. Thereby, eosinophils but not lymphocytes were determined 
as the primary source of IL-13. In the present study, suppression of IL-13 and mucus 
production could thus also depict a consequence of the AvCystatin-MФ-mediated 
suppression of IL-5 and/or eotaxins.    
To evaluate whether the immunosuppression by AvCystatin-MФ is cell-mediated and not a 
“carry-over” effect of AvCystatin, splenocytes of recipient mice treated with either AvCystatin- 
or control-stimulated macrophages were in vitro restimulated with 10 µg/ml AvCystatin for 96 
hours. Analyses of culture supernatants via ELISA revealed no AvCystatin-specific cytokine 
response (data not shown). In parallel, the fate of iodinated AvCystatin was determined by 
cooperation partners after intravenous and intraperitoneal application into mice. Thereby, 
rapid urinary excretion of the protein for both application modes was detected after 18-20 
hours (data not shown). This shows that AvCystatin modulates macrophages during a short 
time frame and that the induced macrophage population is capable of efficiently ameliorating 
ovalbumin-induced airway hyperreactivity independent of the immunomodulator`s presence.  
5.2.2 Macrophage tracking 
To unravel the immunosuppressive properties of AvCystatin-MФ in ovalbumin-induced 
airway inflammation, the localization of transferred macrophages was examined in different 
tissues of the recipient mice. CFSE-labelled macrophages were detected in the spleen 
(AvCystatin-MФ: 194491 ± 27549 cells; control-treated MФ: 94680 ± 10013 cells; mean ± 
SEM) and to a lower amount in the PBLNs (AvCystatin-MФ: 3985 ± 2870; control-treated 
MФ: 1824 ± 202; mean ± SEM) but not in the lungs or the BAL-fluid seven days after 
intravenous administration into recipient animals. Several studies support the idea that 
macrophages are long-lived cells. The half-life of murine alveolar macrophages supposedly 
ranges from 30 days to 2 years (Murphy et al., 2008; Tetley, 2002). In vivo tracking of IFN-γ-
treated macrophages in a murine model of colitis showed that intravenously injected 
macrophages (2.5x106 cells/mouse) migrated to diverse organs and tissues such as the 
spleen, Peyer`s patches, mesenteric lymph nodes, colonic mucosa, lung, liver, bone marrow 
and cervical lymph nodes and were still detectable seven days after administration (Brem-
Exner et al., 2008). In a murine model of adriamycin-induced nephropathy (AN), 1x106 
fluorescently labelled M2c-polarized or untreated splenic control macrophages (M0) were 




macrophages were still detectable on day 28 in the kidneys and renal draining lymph nodes 
(RDLN) of recipient mice. Fewer macrophages were observed in animals treated with M0 
macrophages (Cao et al., 2010). In a similar disease model, splenic macrophages were 
intravenously injected into severe combined immunodeficient (SCID) mice suffering from 
adriamycin-induced nephropathy after in vitro differentiation into M1 (LPS) or M2a (IL-4/IL-
13) macrophages. In addition, untreated M0 macrophages were transferred. After injection,
M0, M1 and M2a macrophages were similarly distributed in the kidneys, spleen and liver of 
recipient mice and maintained their phenotype for up to 4 weeks (Wang et al., 2007). By 
investigating trafficking patterns of C2D cell line macrophages (immature macrophages that 
show a MHC-II-/- and TLR-4Lps-n genotype), Potts et al. (2008) showed that intraperitoneally 
injected C2D macrophages were detectable as long as 2 months in the recipient mice. 
Together, these results suggest long-term survival of distinct macrophage populations and 
their suppressive properties. AvCystatin-MФ were not detected in the lung or BAL-fluid but in 
PBLNs and the spleen. It is known that macrophages migrate to draining lymph nodes to 
prime T cell responses (Muller and Randolph, 1999; Randolph et al., 1999; Atochina et al., 
2008). Therefore, AvCystatin-MФ might exert an indirect suppression on airway inflammation 
through the modulation of T cell functions in the PBLNs or the spleen. Thus, further in vivo 
tracking studies are required to determine the stability and migration pattern of AvCystatin-
MФ in more detail and to examine specific compartments in which an interaction between 
AvCystatin-MФ and T cells takes place such as the marginal zone of the spleen for example.  
5.2.3 Relevance of other cell types in transferring AvCystatin effects 
A number of studies show that specific B cell populations can mediate protection against 
allergic airway inflammation and EAE. In a study by Mangan et al. (2004), intraperitoneal 
injection of 0.5-1.0x107 splenic B cells of Schistosoma mansoni-infected mice protected 
recipient animals against systemic anaphylaxis through the secretion of IL-10. Wilson et al. 
(2010) isolated a population of CD19+CD23high B cells from the mesenteric lymph nodes of 
Heligmosomoides polygyrus-infected mice and showed that intravenous transfer of 4x106 B 
cells profoundly protects against Der p1-induced allergic inflammation and myelin 
oligodendrocyte glycoprotein peptide fragment 35-55 (MOG35-55 peptide)-induced EAE 
through an IL-10-independent mechanism. In another investigation, intraperitoneal transfer of 
2x106 IL-10+CD1dhigh splenic B cells purified from Schistosoma mansoni-infected mice 
successfully prevented ovalbumin-induced airway inflammation through IL-10-dependent 
induction of pulmonary CD4+CD25+Foxp3+ T cells (Amu et al., 2010). These studies clearly 
demonstrate the importance of B cells as target cells for helminth parasites. In the present 




B cells account for approximately 30-40% of the whole peritoneal exudate cell population 
after injection of AvCystatin (data not shown). However, whereas AvCystatin was actively 
taken up by peritoneal macrophages, CD19+ B cells were not targeted by the 
immunomodulator. Moreover, intravenous transfer of 2x106 CD19+ B cells from AvCystatin- 
or control-treated animals into ovalbumin-sensitized recipient mice did not protect against 
ovalbumin-induced airway hyperreactivity questioning B cells to transfer AvCystatin 
immunosuppressive effects.  
Recent publications highlight a crucial role of dendritic cells in immunomodulation by 
parasitic worms. Heligmosomoides polygyrus infection, for example, was shown to alter 
phenotypic dendritic cell function in the mucosa thereby protecting mice against colitis (Hang 
et al., 2010). The depletion of dendritic cells in Schistosoma mansoni infection impaired Th2 
cytokine production by CD4+ T cells and shifted the host immune response towards IFN-γ 
production (Phythian-Adams et al., 2010). The present study demonstrated an active 
endocytotic uptake of AvCystatin by peritoneal macrophages. However, AvCystatin also 
interacted with CD11c+F4/80- cells suggesting that dendritic cells could be altered by 
AvCystatin. Preliminary data indeed show that treatment with AvCystatin induces a dendritic 
cell phenotype with intermediate expression of CD80 and CD86 but low expression of MHC-
II and CD40 (unpublished data). Such “immature” dendritic cells are ineffective in driving T 
cell responses and might be important for the induction of tolerance (Lutz and Schuler, 
2002). In the present study, co-culture experiments showed that dendritic cells are necessary 
for the activation of CD4+ T cells since ovalbumin-peptide-treated AvCystatin-MФ were not 
sufficent to activate CD4+ T cells (further discussed in chapter 5.2.5.3). In order to 
investigate whether AvCystatin-MФ modulate dendritic cells to instruct IL-10-producing CD4+ 
T cells, dendritic cells were pre-cultured with AvCystatin-MФ in a transwell approach 
separating the cell populations from each other. Afterwards, dendritic cells were washed and 
subsequently co-cultured with CD4+ T cells in the absence of macrophages. However, 
macrophage pre-incubated dendritic cells were not able to induce IL-10 production in CD4+ T 
cells (data not shown). This shows that dendritic cells are important for CD4+ T cell activation 
but do not transfer suppressive macrophage effects on CD4+ T cells.  
5.2.4 Effects of AvCystatin-MФ in DSS-induced colitis 
To date, millions of people suffer from massive inflammation of the colon accompanied by 
weight loss, diarrhea, bloody feces, shortening of the colon and mucosal ulceration (Elson et 
al., 1995; Okayasu et al., 1990). Crohn`s disease (CD) and ulcerative colitis (UC) are 




Neurath, 2012). Although the etiology has not been fully elucidated, genetic susceptibility, 
different environmental factors (e.g. smoking or imbalances of the intestinal microbial flora) 
and immunologic causes (local inflammatory responses of T cells, NK cells or resident 
macrophages) are speculated to be involved in the development of IBD (reviewed in 
Hanauer, 2004). To investigate whether AvCystatin-MФ transfer protection against intestinal 
inflammation, female C57BL/6 mice were treated with DSS which exerts toxic effects on gut 
epithelial cells and mimicks human UC in mice (Okayasu et al., 1990). Single transfer of 
AvCystatin-MФ prevented body weight loss and shortening of the colon. Histological analysis 
of distal colon sections further revealed less epithelial/mucosal damage after administration 
of AvCystatin- but not control-treated macrophages. Moreover, animals treated with 
AvCystatin-MФ showed reduced recruitment of neutrophils and eosinophils to the lamina 
propria. Both cell types are supposed to play a crucial role in the immunopathogenesis of 
colitis. Eosinophils contribute to tissue destruction through the release of proinflammatory 
mediators, e.g. major basic protein (MBP), eosinophil cationic protein (ECP) or eosinophil 
peroxidase (EPO). In a study by Forbes et al (2004), eosinophil-secreted EPO was shown to 
be critically involved in the development of intestinal inflammation since symptoms of DSS-
induced colitis were markedly suppressed in EPO-deficient but not in wildtype mice. 
Neutrophils accumulate in the colon mucosa during treatment with DSS and secrete 
cathepsin G, elastase, myeloperoxidase (MPO), lysozyme, lactoferrin and collagenase, 
factors which have been shown to exert harmful effects on gut tissue (reviewed in Naito et 
al., 2007). Depletion of neutrophils with specific antibodies or inhibition of neutrophil-secreted 
products such as elastase was demonstrated to successfully reduce clinical symptoms of 
colitis in mice (Natsui et al., 1997; Morohoshi et al., 2006). 
The amelioration of colitis through transfer of macrophages was reported in a study by 
Hunter et al. (2010). The investigators stimulated murine peritoneal macrophages in vitro 
with IL-4/IL-13, adoptively transferred these M2a-polarized macrophages intraperitoneally 
and intravenously into BALB/c mice 48 hours prior to treatment with dinitrobenzene sulfonic 
acid (DNBS, another chemical shown to induce colitis in mice) and thereby suppressed 
symptoms of intestinal inflammation. ConA-stimulated splenocytes of mice treated with M2a 
macrophages produced higher levels of IL-10 compared to control treatment with IFN-γ-
stimulated macrophages suggesting a modulatory effect of M2a macrophages on T cells. 
Neutralization of IL-10 impaired the amelioration of colitis. However, staining of Foxp3+ 
regulatory T cells determined no significant differences between experimental groups. The 
investigators thus speculate that the protective effects could also be mediated by IL-10-
secreting macrophages or B cells induced by the transferred M2a macrophages. In contrast 




macrophages (IFN-γ-MdC) are profoundly capable of abrogating colitis in mice after tail-vein 
injection. IFN-γ-MdC deleted intestinal lymphocytes in an in vitro co-culture assay and 
enriched the surviving lymphocytes for CD4+CD25+Foxp3+ T cells (Brem-Exner et al., 2008). 
Compared to the DNBS-colitis model used by Hunter and colleagues, Brem-Exner et al. 
(2008) induced colitis through transfer of CD4+CD62L+ T cells into SCID mice. The 
investigators of the latter study further used bone marrow-derived macrophages instead of 
peritoneal macrophages for in vitro stimulation with IFN-γ. These differences indicate that 
macrophage functions in murine models of colitis depend on diverse factors such as the 
mouse strain, the mode of inducing colitis and the cells which are used for macrophage 
differentiation.  
To date, it is not clear whether AvCystatin-MФ interfere with intestinal inflammation or rather 
prevent the onset of inflammatory responses by tranquilizing disease-driving cells such as 
macrophages and thereby suppress granulocyte recruitment. Such a scenario is conceivable 
since preliminary tracking experiments showed AvCystatin-MФ not only to migrate to the 
mesenteric lymph nodes and to the colon but also to locally proliferate in these 
compartments (data not shown). Adoptive transfer of AvCystatin-MФ one day after access to 
DSS did not induce Foxp3-expressing regulatory T cells (data not shown). Moreover, ConA-
stimulation of splenocytes, lamina propria cells or mesenteric lymph node cells of mice 
treated with AvCystatin-MФ did not induce an IL-10 response by the respective cells (data 
not shown). This is not surprising as DSS-induced colitis reflects the pathology of acute 
colitis which is driven by macrophages and granulocytes rather than by CD4+ T cells. 
Strikingly, these findings show that AvCystatin-MФ in DSS-induced colitis act via a 
mechanism which is different from the mechanism determined for ovalbumin-induced airway 
hyperreactivity. The inhibition of colonic epithelial cell-derived chemokines by AvCystatin-MФ 
might constitute an alternative mode of suppression. IL-8, for example, represents an 
important neutrophil chemoattractant which is increased in the mucosa of human patients 
with UC (Isaacs et al., 1992; reviewed in Naito et al., 2007). In the murine system no IL-8 
homologue has been identified but macrophage inflammatory protein 2 (MIP-2), keratinocyte 
chemoattractant (KC or CXCL1) or lipopolysaccharide-induced CXC chemokine (LIX) are 
important neutrophil chemoattractants in mice (Rovai et al., 1998; Song et al., 1999). 
Eotaxins produced by macrophages or intestinal epithelial cells are essential for eosinophil 
recruitment to the colon (Ahrens et al., 2008). By analysing colon homogenates in the 
present study, no significant differences in eotaxin expression between experimental groups 
were detected (data not shown). Another mechanism by which AvCystatin-MФ might execute 
effects on the development of colitis is to influence tight or gap junction functions. Cytokines 




structure and function of tight junctions in vitro and in vivo thereby affecting paracellular 
permeability (reviewed in Walsh et al., 2000). Moreover, LPS/IFN-γ-activated macrophages 
were shown to inhibit enterocyte gap junctions by suppressing the phosphorylation of 
connexin 43 (Cx43) in an NO-dependent manner. NO production by the M1-polarized 
macrophages led to an internalization of Cx43 in adjacent enterocytes and efficiently 
inhibited enterocyte migration (Anand et al., 2008). Thus, it is possible that AvCystatin-MФ 
either directly secrete specific mediators which regulate barrier functions in the colon or, 
indirectly, influence intestinal epithelial cells to produce such factors.  
5.2.5 Macrophage profiling 
To gain insights into the macrophage-mediated immunosuppression, transcriptional profiling 
of AvCystatin-MФ was performed. In vitro and in vivo stimulation with AvCystatin initially up-
regulated pro- and anti-inflammatory marker genes such as iNOS, IL-12/23p40, TNFα, IL-6 
and IL-10 in peritoneal macrophages. However, at a later timepoint, the macrophage 
signature changed to an M2a/M2b hybrid phenotype which was characterized through the 
expression of SPHK-1, LIGHT and ARG-1.  
5.2.5.1 Phenotypic plasticity of AvCystatin-MФ 
It has been reported that nematode-secreted molecules often generate pro-inflammatory 
activity before gradually changing to an anti-inflammatory response (Goodridge et al., 2005 
a). Since macrophages show high phenotypic and functional plasticity, the initial expression 
of pro-inflammatory markers by AvCystatin-MФ before switching to a suppressive phenotype 
is not unusual. Although it is not completely clear whether phenotypical changes are a result 
of cell differentiation into another activation state or whether new macrophage populations 
are recruited to the tissue and replace the original cells (Mosser and Edwards, 2008), a rising 
number of publications substantiate that macrophages adapt their phenotypic properties to 
environmental changes. Phenotypical conversion was reported for macrophages in cancer 
which shift from classical activation to an alternative regulatory status and for macrophages 
in obesity that switch from wound-healing activity to classical macrophage activation 
(reviewed in Mosser and Edwards, 2008). In a study using the C2D macrophage cell line, 
Potts et al. (2008) found that macrophages respond to in vivo signals that are absent in vitro. 
After intraperitoneal injection of untreated C2D macrophages, cells differentiated from an 
immature phenotype to a mature activation stage which expressed increased levels of c-fms, 
F4/80 and CD11b thereby substantiating that the in vivo environment affects phenotypic 
characteristics of macrophages. Treatment of M2b macrophages with serum amyloid P 




towards an M2a phenotype through the activation of PI3K/AKT-ERK (Zhang et al., 2011). 
Similarly, PPARγ ligands were shown to induce a phenotypic conversion of macrophages 
from M2b towards M2a activation thereby promoting mucosal defense against 
gastrointestinal candidiasis (Lefèvre et al., 2010). Stout et al. (2005) found that changes of 
microenvironmental conditions affect and alter the functional phenotype of macrophages. 
Moreover, Mylonas et al. (2009) reported on helminth-derived macrophages that could be 
reprogrammed to perform microbial killing. In the present investigation in vivo- and in vitro-
generated AvCystatin-MФ showed similar gene expression. Since the recruitment of 
additional macrophage populations is not possible in vitro, AvCystatin-MФ seem to shift their 
phenotype from an early M1-like to a suppressive profile. This excludes the possibility that 
the determined phenotype is an agglomeration of different macrophage subpopulations that 
have been recruited to the peritoneum after treatment with AvCystatin. A stable expression of 
SPHK-1, LIGHT and ARG-1 for at least seven days was determined for in vitro-stimulated 
AvCystatin-MФ (data not shown). However, whether AvCystatin-MФ maintain their 
transcriptional signature after being transferred into disease models or rather adapt their 
phenotype to the prevailing microenvironmental conditions is not yet known.  
The expression of “early” and “late” marker genes in AvCystatin-MФ was identical (except for 
the expression of IL-10) in macrophages from wildtype and IL-10-deficient mice suggesting 
that the phenotypic conversion of AvCystatin-MФ is IL-10 independent. By characterizing 
gene expression in LPS-tolerogenic macrophages, Porta et al., (2009) found NF-kappaB 
subunit p50 to limit the recruitment of polymerase II on M1 promoter genes which led to a 
suppression of STAT1 activation, the inhibition of IFN-β production and M1-polarization of 
murine peritoneal macrophages. Contrariwise, NF-kappaB p50 supported the recruitment of 
polymerase II on M2 promoter genes thereby driving M2 macrophage polarization through 
up-regulation of M2-related genes such as IL-10, TGF-β, ARG-1, CCL2, CCL17 and CCL22. 
Thus, NF-kappaB p50 may constitute a potent negative regulator of M1 gene expression but 
an important inducer of M2 macrophage polarization (Porta et al., 2009). Preliminary 
experiments show that NF-kappaB p50 activity might also be important for phenotypic 
changes in AvCystatin-MФ. As reported earlier, AvCystatin induced expression of SPHK-1, 
LIGHT and ARG-1 in peritoneal macrophages. The induction of these markers, however, 
was reduced in macrophages of p50-deficient mice (data not shown). In summary, 
phenotypical changes of macrophages are an important and defining feature of macrophage 
plasticity. Such flexibility also applies for AvCystatin-MФ which convert their phenotype from 
M1 to M2a/M2b activation independent of IL-10 but possibly through the activity of the NF-




5.2.5.2 AvCystatin-MФ hybrid phenotype 
The identification and characterization of macrophage subpopulations is highly relevant to 
the understanding of disease pathogenesis but also for diagnostic or therapeutic intervention. 
The currently used concept of murine macrophage classification distinguishes M1 and M2 
(M2a, M2b and M2c) polarization. Since macrophage activation is not static, this 
classification might be oversimplified. Three main aspects have been proposed to influence 
the diversity of macrophage activation. First the complexity of the environmental milieu, 
second the sequence of exposure to the stimuli and finally the status of macrophage 
differentiation at the time of its exposure (Stempin et al., 2009). Therefore, Mosser and 
Edwards (2008) proposed a classification system that reflects macrophage diversity more 
adequately by including macrophages with overlapping expression profiles and functions. 
The respective authors also suggested the existence of hybrid macrophage populations by 
stimulating murine macrophages with a combination of IL-4 and LPS in the presence of 
immune complexes. The resulting macrophage population expressed RELM-α and showed 
hypersecretion of IL-10 thus sharing characteristics of M2a and M2b macrophages (Mosser 
and Edwards, 2008). In the present study, AvCystatin-MФ were found to show characteristics 
of M2b macrophages by expressing SPHK-1, LIGHT and features of M2a activation by 
expressing ARG-1 further supporting the idea of macrophage subsets with overlapping 
phenotypes. 
5.2.5.3 Biological functions of specific AvCystatin-MФ markers 
SPHK-1 is a lipid kinase which phosphorylates sphingosine to sphingosine-1-phosphate 
(S1P), a lysosphingophospholipid, which either acts as a second messenger within cells or 
extracellularly binds to a specific group of G-protein-coupled receptors (S1PR1-S1PR5). In 
mammals, S1P predominantly occurs in the blood or lymph (Hla et al., 2008) and, depending 
on which cell type and receptor is addressed, exerts diverse biological functions. S1P was 
shown to suppress CD4+ T cell proliferation (Jin et al., 2003), to promote cell migration and 
proliferation and to regulate calcium mobilization and apoptosis (Spiegel and Milstien, 2003). 
In a study by Wang et al. (2005), S1P was found to mediate immunosuppressive effects on T 
cells through the S1P-S1PR4 axis. Stimulation of the mouse CD4+ T cell lines D10G4.1 and 
EL4.IL-2 with S1P in a dose-depedent manner after activation with anti-CD3/anti-CD28 
suppressed CD4+ T cell proliferation, inhibited the production of IL-2, IL-4 and IFN-γ but 
increased the secretion of IL-10. These findings closely reflect the effects of AvCystatin-MФ 
on ovalbumin-specific CD4+ T cells. Moreover, it has been shown that SPHK-1 is activated 
by ERK-mediated phosphorylation at position Ser225 (Pitson et al., 2003). It is therefore 




the activation of SPHK-1. However, by using a S1PR antagonist and supplementing cultures 
of dendritic cells and CD4+ T cells with S1P, no evidence was found for a S1P-mediated 
induction of CD4+IL-10+ T cells. S1P was also elucidated to exert functions on macrophage 
biology. Thus, it is possible that S1P acts back on AvCystatin-MФ and thereby equips the 
suppressive macrophage population with additional functions. Different studies show that 
S1P is critical for macrophage trafficking (Gude et al., 2008), protects macrophages against 
apoptosis (Weigert et al., 2007), mediates phagosome maturation by modulating actin 
assembly (Anes et al., 2003) and drives anti-inflammatory activation of macrophages 
(Hughes et al., 2008). In a recent investigation, S1P further increased antibody-mediated 
phagocytic activity of alveolar macrophages through the interaction with S1PR2 and 
regulation of Fcγ receptor expression (McQuiston et al., 2011). These findings favour the 
idea that S1P could also influence Fcγ receptor expression in AvCystatin-MФ. Surface 
marker analysis revealed an up-regulation of CD16/32 on AvCystatin-MФ which was 
reflected by real-time PCR analysis of CD32 (Fcγ receptor II) RNA expression. RNA levels of 
CD64 (Fcγ receptor I) and CD16 (Fcγ receptor III), however, were decreased (data not 
shown). Murine macrophages express two S1P receptors, namely S1PR1 and S1PR2 
(Duong et al., 2004; Hughes et al., 2008). In order to analyse effects of S1P on AvCystatin-
MФ functions, S1P receptors on macrophages could be blocked by the specific antagonists 
VPC23019 (S1PR1) and JTE013 (S1PR2) and the macrophages evaluated for suppressive 
activity or additional functions such as trafficking properties or protection against apoptosis. 
LIGHT is a member of the tumor necrosis family and has also been desinated as TNF 
superfamily member 14 (TNFSF14) or CD258. It is expressed by activated immune cells 
such as T cells, macrophages, monocytes, granulocytes and dendritic cells (Mauri et al., 
1998; Tamada et al., 2000) and constitutes a 29 kDa type II homotrimer transmembrane 
protein. However, LIGHT can also be cleaved from the cell surface (Mauri et al., 1998, 
Edwards et al., 2006). It binds two receptors, the herpesvirus entry mediator (HVEM) and the 
lymphotoxin β receptor (LTβR) and was shown to transduce co-stimulatory signals into CD4+ 
T cells through HVEM (Wan et al., 2002; Shi et al., 2002; Tamada et al., 2000). Since the 
interaction between LIGHT and T cells has been reported, soluble LIGHT (sLIGHT) 
theoretically represents a candidate for the induction of IL-10 in CD4+ T cells after treatment 
with AvCystatin-MФ. On the other side, there are no studies which provide evidence for an 
IL-10-inducing function of LIGHT. Moreover, M2b macrophages which express and secrete 
LIGHT (Edwards et al., 2006) did not induce CD4+IL-10+ T cells in the established co-culture 
assay. Therefore, it is questionable whether AvCystatin-MФ-derived LIGHT mediates IL-10 
induction in CD4+ T cells. LIGHT has been addressed as a candidate for cancer treatment as 




2000). AvCystatin-MФ were found to up-regulate ICAM-1. Hence, it will be interesting to 
address whether (a) the expression of LIGHT in AvCystatin-MФ is required to induce ICAM-1 
and (b) ICAM-1 on AvCystatin-MФ can induce apoptosis in tumor cells. Doherty et al. (2011) 
showed that LIGHT is important for airway remodelling in mouse models of chronic asthma. 
Inhibition of LIGHT in the respective study impaired fibrosis, smooth muscle accumulation 
and suppressed the expression of lung TGF-β. This hints towards a possible function of 
AvCystatin-MФ-derived LIGHT for lung regenerative functions during airway inflammation. 
Tracking of AvCystatin-MФ showed that the macrophages reside in the spleen and PBLNs. 
By reason that AvCystatin-MФ were not directly tracked in the lungs, it is likely that they 
mediate suppression on lung inflammation by inducing IL-10-producing lymphocytes rather 
than mediating local regenerative effects on lung tissue as described by Doherty et al. 
(2011). By investigating the influence on macrophage functions, LIGHT was found to act as a 
mediator for macrophage migration associated with the activation of signalling kinases such 
as MAPK, PI3K/AKT, NF-kappaB, Src members, and FAK (Wei et al., 2006). MAPK p38 and 
ERK were phosphorylated in macrophages after treatment with AvCystatin. Preliminary data 
further indicate that induction of LIGHT in AvCystatin-MФ is associated with the NF-kappaB 
subunit p50. Whether expression of LIGHT in AvCystatin-MФ is correlated with macrophage 
migration as shown in Wei et al. (2006) is not yet known.  
ARG-1 is a typical M2a activation marker of murine macrophages and commonly expressed 
after exposure to IL-4 and IL-13. ARG-1 is localized in the cytoplasm of liver cells but can 
also be expressed in other cell types after appropriate stimuli (Morris, 2000). In mice, ARG-1 
is mainly induced in macrophages. In the human system, it is constitutively expressed in 
granulocytes (reviewed in Stempin et al., 2009). ARG-1 has been shown to act in a context-
dependent manner. It either protects the host against parasite (re)infection or negatively 
regulates Th2 responses by suppressing T cell activity through L-arginine depletion that 
leads to CD3 instability (Modolell et al., 2009). AvCystatin-MФ modulated CD4+ T cell 
responses suggesting that ARG-1 could be involved in this effect. Inhibition of ARG-1 
through the inhibitor BEC, however, did not reverse this effect indicating that T cell 
modulation by AvCystatin-MФ is ARG-1-independent. Another feature of ARG-1 is the ability 
to mediate tissue recovery through production of polyamines and collagen. 
Acanthocheilonema viteae is a nematode that migrates through the host`s body and thereby 
causes tissue injury. The induction of ARG-1-expressing macrophages by AvCystatin seems 
to be beneficial for the parasite to mediate tissue remodelling and prevent inflammatory host 
responses induced through tissue damage. Whereas helminth-induced ARG-1 expression in 
macrophages mainly depends on IL-4/IL-13-mediated activation of STAT6, intracellular 




independent of STAT6 activation via the TLR pathway (El Kasmi et al., 2008). AvCystatin 
was actively taken up by peritoneal macrophages and in vivo as well as in vitro induced a 
specific macrophage phenotype. The absence of Th2 cells in the in vitro macrophage culture 
(purity ≥ 95%) denotes that the induction of ARG-1 in AvCystatin-MФ does not depend on 
Th2 cytokines but is rather directly mediated by the immunomodulator. AvCystatin induces 
MAPK-mediated activation of STAT-3 and CREB in macrophages (Klotz et al., 2011 b). 
Whether AvCystatin in addition addresses the STAT-6 pathway or an alternative pathway to 
induce ARG-1 in macrophages is unclear.    
Besides transcriptional analysis, the in vivo effect of AvCystatin on macrophage surface 
marker expression was determined by flow cytometry analysis. AvCystatin induced up-
regulation of MHC-II, costimulatory molecules (CD40, CD80, CD86), ICAM-1, Fcγ receptors 
(CD16/32), PD-L1 and PD-L2 18-20 hours after intraperitoneal application into mice. 
Whereas M1-polarized macrophages are known to exhibit enhanced antigen-presenting and 
anti-microbial activity, M2 macrophages are described to be less efficient APCs. Schebesch 
et al. (1997) however, showed that this does not necessarily depend on decreased 
expression of MHC-II or costimulatory markers since CD11a, CD40, CD54, CD58, CD80 and 
CD86 were similarly expressed in M1 and M2 macrophages. Thus, M2 macrophages in 
principle exhibit all requirements to drive immune responses (Noel et al., 2004). IL-10-
hypersecreting M2b macrophages, for example, express high amounts of MHC-II, CD86 and 
beyond that can efficiently activate CD4+ T cells through antigen-presentation (Edwards et 
al., 2006). AvCystatin-MФ show similarities with M2b macrophages. However, in the absence 
of dendritic cells they are insufficient to drive T cell responses. The inability of AvCystatin-MФ 
to activate CD4+ T cells was observed when ovalbumin-peptide-treated AvCystatin-MФ were 
in vitro incubated with ovalbumin-specific CD4+ T cells and failed to induce antigen-specific 
cytokine responses in CD4+ T cells (data not shown). It is likely that this discrepancy between 
M2b macrophages and AvCystatin-MФ results from metabolic differences. After being 
activated, murine macrophages metabolize the amino acid L-arginine in two competitive 
pathways. In the presence of Th1 stimuli, macrophages convert L-arginine into NO through 
iNOS. This pathway represents a key element to control and eliminate intracellular 
pathogens by increased cytotoxic and antimicrobial activity. Under Th2 conditions, ARG-1 is 
expressed which catalyzes the conversion of L-arginine into proline, L-orthinine and 
polyamines which are important factors for cell growth, collagen formation, and tissue repair 
(Hesse et al., 2001). This alternative pathway induces macrophages which exhibit regulatory 
and recovery functions rather than effector functions that lead to pathogen killing (Mosser, 
2003). The competitive nature of the two metabolic pathways was nicely reflected by the 




AvCystatin led to an early expression of iNOS in macrophages, ARG-1 was induced after the 
observed conversion to a suppressive phenotype. M2b macrophages are described to exhibit 
similarities with M1 macrophages since they also produce low amounts of pro-inflammatory 
marker genes, e.g. iNOS and do not exert ARG-1 activity (Mosser, 2003). AvCystatin-MФ, in 
contrast, did not show expression of pro-inflammatory markers 18-20 hours after treatment 
with AvCystatin but expressed ARG-1 in addition to the M2b activation markers SPHK-1 and 
LIGHT. Hence, although M2b and AvCystatin-MФ share characteristics, M2b macrophages 
might be more orientated towards the classical metabolic pathway whereas AvCystatin-MФ 
show higer affinity to the alternative pathway. This could explain why AvCystatin-MФ in 
comparison to M2 macrophages fail to activate T cells.   
Similar to the expression of ICAM-1 in AvCystatin-MФ, murine alveolar macrophages were 
shown to up-regulate ICAM-1 during infection with Nippostrongylus brasiliensis (Siracusa et 
al., 2008). The functional role of ICAM-1 in helminth-derived or AvCystatin-induced 
macrophages remains speculative. Studies on ICAM-1 functions in rats and mice showed 
that expression of ICAM-1 on alveolar epithelial cells increases the adhesiveness of alveolar 
macrophages (Ward, 2003). ICAM-1 on alveolar macrophages was found to be associated 
with the actin cytoskeleton (Barton et al., 1996) thereby promoting macrophage mobility in 
the alveolus and in addition to facilitate phagocytosis of particulates by alveolar 
macrophages (Paine et al., 2002). ICAM-1 binds to integrins on endothelial cells and 
mediates transmigration of leucocytes or macrophages into tissues. In context of the present 
study, this could suggest that ICAM-1 supports the migration of AvCystatin-MФ into lung 
tissue. Since AvCystatin-MФ were not detected in the lung, it is possible that they initially 
migrate to the lung, interact with local cells (e.g. epithelial cells) before migrating to 
secondary lymphoid organs such as the spleen or the PBLNs. To determine a precise 
migration pattern of AvCystatin-MФ, continuative in vivo tracking is necessary which includes 
the analysis of additional timepoints and tissues. As mentioned above, ICAM-1 was shown to 
induce apoptosis in tumor cells (Zhai et al., 1998; Rooney et al., 2000). Thus, it is feasible 
that AvCystatin-MФ could also exert tumoricidal effects through ICAM-1.   
After treatment with AvCystatin, macrophages up-regulated Fcγ receptors which constitute a 
family of receptors that is important for the recognition of IgG Fc fragments. Interestingly, 
crosslinking of Fcγ receptors by immune complexes in the presence of TLR ligands induce 
IL-10-hypersecreting type 2 (M2b) macrophages. To date, one inhibitory Fcγ receptor (Fcγ 
receptor II) and three activating Fcγ receptors (Fcγ receptor I, III and IV) are described for 
mice. Whereas Fcγ receptor I (CD64) is permanently saturated with monomeric IgG, Fcγ 




instead are efficient in binding IgG-IC (Nimmerjahn and Ravetch, 2006). As discussed 
earlier, it is possible that AvCystatin addresses Fcγ receptors to modulate macrophage 
functions. However, in that case AvCystatin would have had to directly bind Fcγ receptors as 
the in vivo generation of AvCystatin immune complexes (AvCystatin-IC) within a time frame 
of 18-20 hours is rather unlikely. Apart from that, initial in vitro experiments showed that 
treatment of macrophages with AvCystatin-IC in combination with LPS induced lower 
expression of iNOS and IL-12/23p40 but increased transcript levels of IL-10 and SPHK-1 
whereas LIGHT and ARG-1 expression was almost equal when compared to AvCystatin 
treatment (data not shown). These preliminary findings suggest that using AvCystatin-IC 
instead of AvCystatin could be a powerful tool to induce a macrophage population with 
enhanced immunosuppressive properties.  
PD-L2 is commonly expressed on M2 macrophages and negatively regulates CD4+ T cell 
activation, suppresses T cell proliferation and dampens Th2-allergic inflammation (Zhang et 
al., 2006; Huber et al., 2010). Nippostrongylus brasiliensis was determined to induce PD-L2 
on murine macrophages in an IL-4/IL-13 and STAT6-dependent manner. In vivo blockade of 
PD-L2 in the respective study increased Th2 responses in the lung of infected mice 
suggesting a Th2-silencing function of PD-L2 (Huber et al., 2010). In a murine model of 
asthma, PD-L2-deficient mice showed exacerbated airway inflammation whereas opposing 
effects were demonstrated for PD-L1-deficient mice (Akbari et al., 2010). PD-L1 expression 
has originally been attributed to classical macrophage activation. However, studies using 
different murine helminth infection models show that PD-L1 can also be up-regulated on M2 
macrophages and successfully inhibit CD4+ T cell responses. Blockade of PD-L1 and PD-L2 
on Taenia crassiceps-induced macrophages, for example, reversed CD4+ T cell proliferation 
in response to parasite antigens (Terrazas et al., 2005). Moreover, in a murine model of 
Schistosoma mansoni infection, PD-L1 was selectively up-regulated on splenic macrophages 
and shown to induce CD4+ T cell anergy (Smith et al., 2004). A new function of PD-L1 was 
demonstrated by its ability to promote the induction and maintenance of Foxp3-expressing 
regulatory CD4+ T cells (Francisco et al., 2009). The investigators generated Foxp3+ 
regulatory T cells in vitro by using PD-L1-coated beads and found PD-L1 to induce 
conversion of naive CD4+ T cells into regulatory CD4+ T cells through inhibition of phospho-
AKT, mammalian target of rapamycin (mTOR), S6 ribosomal protein, ERK2 but up-regulation 
of the phosphatase and tensin homolog (PTEN). PD-L1 further maintained the expression of 
Foxp3 on the induced regulatory T cells. Thus, both PD-L1 and PD-L2 are important 
molecules for cell contact-dependent inhibition of CD4+ T cell functions. AvCystatin-MФ 
showed up-regulation of both molecules 18-20 hours after treatment with the 




contact-independent. In order to definately exlude a role of programmed death ligands or a 
possible additive effect on the IL-10 induction in CD4+ T cells, both molecules were blocked 
by using anti-PD-L1 and anti-PD-L2 antibodies described in Terrazas et al. (2005). Blockade 
of PD-L1 and PD-L2, however, had no effects on the AvCystatin-MФ-mediated IL-10 
induction in CD4+ T cells.  
In summary, treatment with AvCystatin induced the expression of macrophage markers 
which exert important immunoregulatory functions and thus constitute important candidates 
for the AvCystatin-MФ-mediated immunosuppression.   
5.2.6 Mechanistical analyses of IL-10 induction by AvCystatin-MФ 
5.2.6.1 IL-10 induction in CD4+ T cells by different macrophage populations 
Transcriptional profiling of AvCystatin-MФ determined similarities to M1 macrophages initially 
after stimulation and characteristics of M2a and M2b macrophage activation at a later 
timepoint. Specific properties of AvCystatin-MФ with respect to the induction of IL-10 in T 
cells were determined by in vitro experiments incubating M1, M2a and M2b macrophages 
with ovalbumin-peptide-treated dendritic cells and ovalbumin-specific CD4+ T cells. M1 and 
M2a macrophages showed no self-production of IL-10 after stimulation with the respective 
stimuli whereas higher levels of IL-10 were secreted by M2b macrophages. This is in line 
with reports that describe M2b macrophages as IL-10-hypersecreting cells. IL-10 production 
by M2a macrophages was reported in a study by Zhang et al. (2011). Other studies, 
however, describe M2a macrophages as an inefficient source for IL-10 (Edwards et al., 
2006). In the present investigation, a significant increase of IL-10 was only detected in 
culture supernatants of dendritic cells and CD4+ T cells in the presence of in vivo-generated 
AvCystatin-MФ but not after incubation with M1, M2a or M2b macrophages. Since in vitro-
treated macrophages were less effective inducers of IL-10 production in CD4+ T cells, it can 
be assumed that specific environmental conditions within the peritoneal cavity are necessary 
to equip AvCystatin-MФ with IL-10-inducing properties. Analysis of the cell composition in the 
peritoneal cavity of AvCystatin-treated mice revealed an influx of Ly6C+ monocytes which 
was not detectable in control-treated animals. These cells, however, were completely 
depleted through biotinylated anti-Gr1 antibodies during macrophage purification and thus do 
not directly contribute to the protective macrophage effects in ovalbumin-induced airway 
hyperreactivity (data not shown). However, it is possible that recruited monocytes interact 
with resident peritoneal macrophages during a short time frame and thereby mediate IL-10-




similarities with M1, M2a and M2b macrophages on a transcriptional basis but, in addition, 
exhibit regulatory properties which are distinct from these macrophage populations.  
5.2.6.2 Evaluation of specific markers for the IL-10 induction in CD4+ T cells 
SPHK-1, ARG-1 and programmed death-ligands have been described to exert regulatory 
effects on CD4+ T cells (Wang et al., 2005; Pesce et al., 2009 b; Francisco et al., 2009). 
SPHK-1 phosphorylates sphingosine to S1P which binds to S1P receptors (S1PR) and 
thereby can affect CD4+ T cell responses. In order to prevent binding of S1P to S1PR1, 
ovalbumin-specific CD4+ T cells were pre-treated with different concentrations of the S1PR1 
antagonist VPC23019 and thereafter incubated with ovalbumin-peptide-treated dendritic cells 
and macrophages. The efficiency of VPC23019 antagonism has formerly been described by 
Osada et al. (2002) and Davis et al. (2005). Blockade of S1PR1 by VPC23019 did not 
influence the AvCystatin-MФ-induced IL-10 production by ovalbumin-specific CD4+ T cells in 
the established co-culture system. However, this finding has to be handled with care. 
Besides S1PR1, another S1PR, namely S1PR4, is expressed on murine CD4+ T cells. To 
date, no antagonists are available for S1PR4. Thus, despite blocking the S1P-S1PR1 axis 
through VPC23019, S1P could still have induced IL-10 through S1PR4. In order to prove this 
possibilitiy, CD4+ T cell and dendritic cell co-cultures were supplemented with S1P in a dose-
dependent manner. Supplementation with S1P, however, did not induce IL-10 secretion by 
CD4+ T cells. The induction of IL-10 through S1P has been demonstrated in a publication by 
Wang et al. (2005). The authors showed that the mouse Th2 T cell line D10G4.1 secreted 
increased amounts of IL-10 after activation with anti-CD3/anti-CD28 and treatment with S1P 
via the S1P-S1PR4 axis. In the present investigation, S1P-mediated IL-10 induction could 
not be verified in ovalbumin-specific CD4+ T cells of DO11.10 mice suggesting that this could 
be a specific effect of D10G4.1 cells. In order to study the functions of S1PR4 in T cells, 
Wang and colleagues experimentally modified D10G4.1 cells through the transfection of an 
insert encoding for the mouse S1PR4 gene and further treated the cells with FTY720, a 
derivative of myriocin (ISP-1) from the fungus Iscaria sinclarii, to down-regulate S1PR1 prior 
to treatment with S1P (Wang et al., 2005). The results of the present study, however, hint 
towards an irrelevant function of SPHK-1/S1P for the observed IL-10 induction in CD4+ T 
cells. This is substantiated by the finding that M2b macrophages, which have been well 
characterized for high expression of SPHK-1 (Anderson and Mosser, 2002; Edwards et al., 
2006), did not induce IL-10 in CD4+ T cells in the established in vitro co-culture system. 
Further experiments either using the ARG-1 inhibitor BEC or programmed death ligand 
neutralizing antibodies anti-PD-L1 and anti-PD-L2 did not reveal a suppression of IL-10 




measuring urea in the supernatant of in vitro-generated M2a macrophages either cultured 
alone or in the presence of different BEC concentrations. Moreover, both anti-PD-L1 and 
anti-PD-L2 antibodies have formerly been demonstrated to efficiently inhibit effects of 
macrophage-expressed PD-L1 and PD-L2 on CD4+ T cell responses (Terrazas et al., 2005). 
Collectively, these findings exclude the induction of IL-10-producing CD4+ T cells by the 
AvCystatin-MФ markers SPHK-1, ARG-1, PDL-1 and PD-L2. These markers might be 
descriptive for the macrophage phenotype or important for other macrophage functions but 
dispensible for the induction of CD4+IL-10+ T cells.   
5.2.6.3 Factors which are described to induce IL-10 in T cells 
A couple of soluble factors have been described as inducers of IL-10 in CD4+ T cells. Pro-
inflammatory cytokines, for example, induce IL-10 to regulate immune responses and to 
prevent overshooting reactions (reviewed in Couper et al., 2008). IL-12 in combination with 
high antigen doses was reported to induce IL-10-producing CD4+ Th1 T cells via 
phosphorylation of ERK and activation of STAT4 (Saraiva et al., 2009). IL-27 has been 
shown to differentiate naïve CD4+ T cells into IL-10-producing cells and, in combination with 
TGF-β, enhance Tr1 development (Awasthi et al., 2007). Stumhofer et al. (2007) 
demonstrated that IL-27 and IL-6 can independently induce IL-10-producing CD4+ T cells 
under different microenvironmental conditions. This effect was dependent on STAT1 and 
STAT3 activation for IL-27 and STAT3 signalling for IL-6. NO induced the development of 
CD4+CD25+Foxp3- regulatory T cells (NO-Tregs) which attenuated colitis and collagen-
induced arthritis in an IL-10-dependent manner after intraperitoneal injection into mice 
(Niedbala et al., 2007). In the present investigation, macrophage expression of IL-12p40, IL-6 
and iNOS peaked between 1 and 5 hours after contact with AvCystatin and declined 
afterwards. Successional experiments verified a similar expression of IL-27 in AvCystatin-MФ 
(data not shown). For in vitro incubation with dendritic cells and CD4+ T cells, macrophages 
were isolated from mice 18-20 hours after intraperitoneal administration of AvCystatin. To 
this timepoint, AvCystatin-MФ had already changed from M1 activation to a suppressive 
M2a/M2b hybrid phenotype which did not express pro-inflammatory gene transcripts or 
secrete the respective cytokines. Moreover, no IL-10 induction in T cells was determined 
through the secretion of pro-inflammatory cytokines by M1 macrophages in the established 
co-culture assay. Together, these findings challenge IL-12, IL-6, NO and IL-27 to be 
mediators for the observed IL-10 induction in ovalbumin-specific CD4+ T cells. Nevertheless, 
it will be useful to block receptors on and pathways in CD4+ T cells addressed by these 
cytokines and to evaluate IL-10 production by T cells in co-culture assays with AvCystatin-




as an important inducer of IL-10 in naïve CD4+ T cells, Th1 CD4+ T cells or Tc1 T cells which 
constitute a subpopulation of CD8+ cytotoxic T cells (Spolski et al., 2009). IL-21 is produced 
by different subpopulations of CD4+ T cells and by NK T cells (Spolski et al., 2008) 
questioning macrophages as a cellular source for this cytokine. One can speculate that 
AvCystatin-MФ induce IL-21 secretion by activated CD4+ T cells which finally acts back on T 
cells thereby inducing IL-10 production. This scenario, however, is rather unlikely since CD4+ 
T cells produced IL-10 already 48 hours after contact with AvCystatin-MФ. Such early 
production of IL-10 by naïve T cells is surprising and presumably not induced by an autocrine 
IL-21 feedback mechanism. Induction of IL-10 in IFN-γ-secreting CD4+ Th1 cells has been 
determined for notch ligands of the delta-like family (DII-1 and DII-4) in combination with 
costimulation by IL-12 or IL-27 in a STAT4-dependent manner (Rutz et al., 2008). Expression 
of notch ligands by macrophages was reported for the treatment of macrophages with 
schistosomal egg antigen (Goh et al., 2008) and during influenza H1N1 virus infection (Ito et 
al., 2011). Whether notch ligands are induced in AvCystatin-MФ has to be determined. At 
present, the secretion of notch ligands by AvCystatin-MФ is theoretically possible and thus 
represents a feasible mechanism for the induction of IL-10 in CD4+ T cells. Preliminary data 
further indicate that Fas ligand (FasL), a type-II transmembrane protein of the tumor necrosis 
factor family, is up-regulated in AvCystatin-MФ. Yang et al. (2003 a) showed that the 
inhibition of Fas/Fas ligand interaction by antagonistic antibodies prevents IL-10 induction in 
human Jurcat cells, an immortalized T lymphocyte cell line that is preliminary used to study 
issues in cancer and T cell signalling. In another study, soluble FasL (sFasL) has been 
reported to modulate IL-10 transcription and secretion in human CD8+ lymphocytes and 
neutrophils since depletion of sFasL suppressed IL-10 modulation in the respective cells 
(Giho et al., 2010). Thus, Fas ligand constitutes another possible candidate for the induction 
of CD4+IL-10+ T cells by AvCystatin-MФ. Additional investigations showed that AvCystatin-
MФ-secreted components only induced IL-10-producing T cells if they were freshly added to 
activated CD4+ T cells. Frozen and thawed macrophage supernatants, however, failed to 
induce IL-10 in CD4+ T cells (data not shown). Moreover, supernatants from AvCystatin-MФ 
cultured in FCS-free medium were not capable in inducing CD4+IL-10+ T cells (data not 
shown). These results hint towards a mediator that is rather unstable and probably gets 
stabilized through FCS after being secreted by the macrophages. Thus, it is important to 
identify single candidates by the analysis of AvCystatin-MФ supernatants and to evaluate 




5.2.7 Clinical impact of regulatory macrophages 
At present, glucocorticoids and antihistamines are most commonly used to treat allergy-
related disorders. The disadvantages are side effects like osteoporosis, the need to take 
drugs life-long and an unsatisfactory disease control in 30% of allergic patients (Hawrylowicz 
and O`Garra, 2005). Autoimmune diseases are commonly treated with immunosuppressant 
drugs, e.g. corticosteroids which, in the long run, can lead to diabetes, eye disease 
(glaucoma or cataract), stomach ulcers, high blood pressure and depression. Treatment with 
living parasites to allay or cure inflammatory bowel disease in human patients has 
successfully been demonstrated (Summers et al. 2005; Croese et al., 2006). However, 
although the concept of worm therapy has been described as safe and effective, the 
application of living parasites always bear the risk of unwanted side effects. Therapeutic 
intervention by applying helminth-secreted immunomodulators is another strategy to treat 
inflammatory responses. Such products, however, often exert immunogenic activity. Thus it 
might be critical to use helminth-derived molecules as pharmaceuticals. Cell-based therapies 
constitute a novel approach in which cells are differentiated into a specific activation stage 
and finally administered into patients in order to transfer immunosuppressive properties. 
Macrophages represent good candidates for cell-based therapeutic intervention not only for 
atopic and autoimmune diseases but also for the treatment of kidney diseases or to promote 
tolerance to transplanted organs (Table 5-1).  
A case report by Hutchinson and colleagues described the successful treatment of a human 
kidney transplant recipient with central venous infusion of IFN-γ-treated transplant 
acceptance-inducing cells (TAICs) which show similarities to unactivated, tissue-resident 
macrophages and possess CD4+ T cell suppressive functions (Hutchinson et al., 2008 and 
2009). The mouse equivalent of human TAICs is a macrophage derivative which has been 
designated as IFN-γ-stimulated monocyte-derived cells (IFN-γ-MdCs). IFN-γ-MdCs were 
differentiated from bone marrow-derived macrophages (BMMФ) through IFN-γ treatment. 
Intravenous transfer of 5x106 IFN-γ-MdCs into SCID mice successfully mitigated 
CD4+CD62L+ T cell-induced colitis. The protective effects of IFN-γ-MdCs on intestinal 
inflammation in vivo were speculated to depend on T cell-suppression since IFN-γ-MdCs in 
vitro deleted lymphocytes that had been isolated from mesenteric lymph nodes of colitic mice 
and enriched surviving lymphocytes for CD4+CD25+Foxp3+ regulatory T cells (Brem-Exner et 
al., 2008). In another study, intravenous (1x106) as well as intraperitoneal (0.75x106) injection 
of peritoneal macrophages after in vitro treatment with IL-4/IL-13 (M2a activation) reduced 
intestinal inflammation in a murine model of DNBS-induced colitis in an IL-10-dependent 




murine BMMФ with LPS and immune complexes induces M2b macrophages which are able 
to prevent the development of EAE. In the respective study, 2x106 M2b macrophages were 
intraperitoneally transferred into mice prior to induction of EAE with the MOG35-55 peptide. 
Compared to control groups, ConA-stimulated splenocytes of M2b macrophage-treated 
animals showed higher production of IL-10 suggesting that the suppressive effects on EAE 
were mediated through the induction of IL-10-producing T cells (Tierney et al. 2009). 
Different studies found macrophages to exert suppressive and regenerative functions also in 
acute and chronic kidney diseases. Zhang et al. (2011) showed that binding of serum 
amyloid P component to activated lymphocyte-derived DNA (ALD-DNA) forms complexes 
which in vitro induces M2a activation of murine BMMФ. Intravenous transfer of 2.5x106 
SAP/ALD-DNA-induced M2a macrophages for a total of three times successfully extenuated 
murine lupus nephritis through the production of IL-10 (Zhang et al., 2011). In another study, 
intravenous injection of 1x107 untreated BMMФ into mice ameliorated renal fibrosis in a 
model of late stage unilateral ureteral obstruction (UUO) that reflects progressive renal 
interstitial fibrosis. Three-time repeated transfer of BMMФ was associated with an increased 
infiltration of interstitial macrophages which were suggested by the investigators to facilitate 
tissue repair and thereby attenuate renal fibrosis (Nishida et al., 2005). In a study by Cao et 
al. (2010), murine splenic macrophages were stimulated in vitro with IL-10 and TGF-β to 
induce M2c macrophage activation. Intravenous transfusion of 1x106 IL-10/TGF-β-modified 
M2c macrophages was sufficient to mediate protection against renal injury in a murine model 
of adriamycin-induced nephropathy (AN). This protection was associated with an increase of 
Foxp3+ regulatory T cells in renal draining lymph nodes. In a similar study, splenic 
macrophages were stimulated in vitro with IL-4/IL-13 and transferred into SCID mice. 
Transfer of these M2a-polarized macrophages reduced inflammatory renal disease possibly 
by affecting chemokine and cytokine expression (decrease of CCL2 and TNF-α and increase 
of CCL17) of infiltrating host macrophages (Wang et al., 2007). In a recent study by Jung et 
al. (2012), intravenous transfer of IL-10-overexpressing rat BMMФ protected recipient rats 
against renal ischemia/reperfusion injury (IRI). After infusion of 1x106 cells, macrophages 
migrated to the injured kidney tissue, increased regenerative markers such as stathmin, a 
protein that regulates the microtubule cytoskeleton (Rubin and Atweh, 2004), and 
proliferation cellular nuclear antigen (PCNA), a nuclear protein which is associated with the S 
phase of proliferation (Theocharis et al., 1994), and reduced blood urea nitrogen and 
creatinine. The macrophage-mediated protection was mediated via IL-10 and dependent on 
intracellular iron and lipocalin-2 as binding of iron through a chelating agent or the blockade 




Transfer of macrophages can also protect against bacterial pneumonia. This was 
demonstrated in a study by Hart et al. (2003). The investigators intravenously and 
intraperitoneally transferred 2x107 C2D macrophages into immunocompromised mice 
thereby protecting the animals against pneumonia after challenge with Pasteurella 
pneumotropica. The results of the present thesis further provide evidence that treatment with 
helminth immunomodulators can induce macrophages capable of mediating 
immunosuppressive effects in different disease contexts. Collectively, these results show that 
the option to modify macrophages towards a suppressive phenotype or to use specific 
macrophage cell lines for the treatment of diverse diseases constitutes a promising 
alternative to currently used forms of therapy. 







disease model reference 
human splenic TAICs IFN-γ (IFN-γ-TAICs) i.v. 
1.07x106 / kg 
body weight 
kidney 
transplantation Hutchinson et al. (2009) 





Brem-Exner et al. (2008) 




1x106 (i.v.) DNBS-colitis Hunter et al. (2010) 
murine BMMФ IFN-γ + LPS + IC (M2b) i.p. 2x10
6 EAE Tierney et al. (2009) 
murine BMMФ SAP/ALD-DNA (M2a) 3 x i.v. 2.5x10
6 lupus nephritis Zhang et al. (2011) 
murine BMMФ no stimulation 3 x i.v. 1x107 UUO Nishida et al. (2005) 
murine splenic MФ IL-10 and TGF-β (M2c) i.v. 1x10
6 AN Cao et al. (2010) 
murine splenic MФ IL-4 and IL-13 for (M2a) i.v. not stated AN Wang et al. (2007) 
IL-10-overexpressing  
rat BMMФ no stimulation i.v. 1x10
6 IRI Jung et al. (2012) 
murine C2D cell line no stimulation i.v. and i.p. 2x10
7 bacterial 
pneumonia Hart et al. (2003) 
Table 5-1: MФ-based therapy in different disease settings. TAICs: transplant acceptance-inducing 
cells; MФ: macrophage; BMMФ: bone marrow-derived MФ; IFN-γ MdCs: IFN-γ-stimulated monocyte-
derived cells; SAP: serum amyloid P component; ALD-DNA: activated lymphocyte-derived DNA; i.p.: 
intraperitoneal; i.v.: intravenous; DNBS: dinitrobenzene sulfonic acid; EAE: experimental autoimmune 






Since the inhibition of distinct macrophage markers (SPHK-1, ARG-1, PD-L1 and PD-L2) did 
not affect IL-10-induction in CD4+ T cells, it is necessary to identify additional products 
(proteins, lipids, enzymes etc.) secreted by AvCystatin-MФ which may be responsible for this 
effect. This might include a combination of different techniques such as microarray analysis 
for a broader screen of AvCystatin-induced gene expression in macrophages, two-
dimensional polyacrylamide gel electrophoresis (2-D PAGE) and mass spectrometry 
techniques. Studies on the stability of identified factors will show whether they can be 
synthesized on a large scale and used to generate immunosuppressive CD4+ T cells. In 
parallel, it is important to unravel the receptors on and signalling pathways in CD4+ T cells 
addressed by the macrophage-secreted mediator(s). This could either be realized through 
the inhibition of specific receptors and signalling pathways that lead to IL-10 induction in 
CD4+ T cells or alternatively by subtractive gene expression analysis of CD4+ T cells treated 
with supernatants from AvCystatin- or control-stimulated macrophages.       
Another interesting question will be whether the IL-10-inducing capacity of AvCystatin-MФ 
depends on the macrophage phenotype. Although single marker genes were determined not 
to be directly involved in inducing this effect, a combination of these or other as yet undefined 
markers may be necessary for equipping macrophages with important immunosuppressive 
functions. Thus, it is advisable to examine the stability of the macrophage phenotype in more 
detail and to investigate whether the ability of macrophages to induce IL-10-producing CD4+ 
T cells is affected by modified environmental conditions. Concerning the therapeutic usability 
of AvCystatin-MФ, it would be of great advantage if (a) the macrophages perpetuate their 
phenotype and/or suppressive functions after having been frozen and (b) the macrophages 
could be increased in numbers through in vitro treatment with growth factors. The latter 
scenario seems to be realistic since the ability of macrophages to proliferate has recently 
been reported (Jenkins et al., 2011).  
In regard to the model of ovalbumin-induced airway hyerreactivity it will be worth to study 
whether AvCystatin-MФ are still protective if mice are challenged at a later timepoint after 
transfer of macrophages or alternatively if a time-delayed second challenge is given. This 
would reflect the situation of allergic patients who are seasonally exposed to allergens. In the 
present study, AvCystatin-MФ were transferred after in vivo stimulation for 18-20 hours. To 
examine whether AvCystatin-MФ exert prolonged suppressive activity, experiments have to 
be performed in which AvCystatin-MФ are transferred into mice at later timepoints (e.g. 48 




The mechanism of the AvCystatin-MФ-mediated immunosuppression in DSS-induced colitis 
remains elusive. Compared to the ovalbumin-induced model of airway hyperreactivity, no 
induction of IL-10-producing T cells was determined in recipient mice after administration of 
AvCystatin-MФ. Hence, an important aspect of continuing investigations is to elucidate 
functional differences of AvCystatin-MФ in the respective disease models. It seems to be 
cogitable that AvCystatin-MФ either directly modulate the cytokine and chemokine response 
of resident host macrophages or mediate protection against intestinal inflammation by 
affecting the chemokine expression of epithelial cells or tight junction functions.  
Another feature for ongoing projects is the idea to test AvCystatin-MФ in a model of helminth 
infection thereby evaluating if the macrophages suppress Th2 immune responses and 
mediate parasite survival or rather promote host protection and worm expulsion. Since 
AvCystatin-MФ also express markers which have been shown to exert important functions in 
other disease settings, it might be worth testing AvCystatin-MФ in corresponding contexts. 
ICAM-1, for example, was found to induce apoptosis in tumor cells (Zhai et al., 1998; Rooney 
et al., 2000). Thus, the effects of AvCystatin-MФ on cancer cells could be tested by using a 
murine or human tumor cell line. Preliminary data further show AvCystatin-MФ to up-regulate 
lipocalin-2, a 25 kDa protein that has been reported to mediate protection against 
ischemia/reperfusion injury (Jung et al., 2012). If lipocalin-2 expression in AvCystatin-MФ is 
repeatable, it will also be useful to evaluate AvCystatin-MФ functions in a disease model of 
kidney disease. 
To unlock clinical benefits of macrophages, it is essential to translate experimental findings 
from mouse studies to the human situation. Thus, studying the key molecular events for the 
induction of suppressive human macrophages by AvCystatin is a major concern for future 
projects. However, while several activation markers have been described for murine 
macrophages, there is still an obvious lack of reliable human markers. ARG-1 or Ym1, for 
example, are restricted to murine M2 macrophages and thus constitute improper markers for 
human alternatively activated myeloid cells (Raes et al., 2005). One general problem in 
translating data from mouse macrophages to human cells arises due to the fact that human 
macrophages respond differently to Th2 cytokines (Scotton et al., 2005). Another difficulty for 
translational research is that relevant human tissues are not as easily accessible for 
experimental investigation as they are for mice (Jenkins and Allen, 2010). To study whether 
human monocyte-derived macrophages show phenotypic properties or regulatory functions 
similar to AvCystatin-MФ, constitutes an important step towards the clinics and will show 
whether findings from the present investigation can be translated into the human system. 
MATERIAL AND METHODS 
_____________________________________________________________________________ 
85 
7 MATERIAL AND METHODS 
7.1 Material 
7.1.1 Laboratory equipment 
accu-jet pro pipette  Amersham Pharmacia, Freiburg, Germany 
autoMACS cell sorter  Miltenyi Biotec, Bergisch Gladbach, Germany 
Casy cell counter Innovatis, Reutlingen, Germany 
cell incubator  Heraeus, Hanau, Germany 
centrifuge 5804 R  Eppendorf, Hamburg, Germany 
cytospin centrifuge   Cellspin I, Tharmac, Waldsolms, Germany 
DFC480 camera Leica, Solms, Germany 
electrophoresis power supply Amersham Pharmacia, Freiburg, Germany  
ELISA reader  Dynatech, Denkendorf, Germany 
ELx405 select ELISA washer BioTek, Bad Friedrichshall, Germany       
FastPrep-24 homogenizer  MP Biomedicals, Heidelberg, Germany 
FPLC ÄKTA  Amersham Pharmacia, Freiburg, Germany 
Hera Safe sterile work bench Heraeus Instruments, Osterode, Germany 
Leica DFC480 camera Leica, Solms, Germany 
Leica DM500 microscope  Leica, Solms, Germany 
Leica TCS SP2 confocal microscope Leica, Solms, Germany 
LSRII Fortessa flow cytometer BD Biosystems, Heidelberg, Germany 
magnetic stirrer (RCT Basic)  IKA, Staufen, Germany 
NanoDrop ND-1000  Peqlab Biotechnologie, Erlangen, Germany 
real-time PCR system 7300   Applied Biosystems, Darmstadt, Germany 
semi-dry electroblotting system Peqlab Biotechnologie, Erlangen, Germany 
thermocycler (FlexCycler)   Analytikjena, Jena, Germany 
thermomixer comfort thermoblock  Eppendorf, Hamburg, Germany 
waterbath DC3 Haake, Karlsruhe, Germany 




1 ml tuberculin single use syringe  Braun, Melsungen, Germany 
1 ml U-40 single use insulin syringe Terumo, Eschborn, Germany 
1.0 µm thin certs 24 well greiner bio-one, Frickenhausen, Germany 
24 well culture cluster Corning Costar, Bodenheim, Germany 
48 well culture cluster Corning Costar, Bodenheim, Germany 
96 well culture cluster Corning Costar, Bodenheim, Germany 
96 well flat bottom ELISA plate ThermoFisher Scientific, Schwerte, Germany 
96 well multiply-PCR plate  Sarstedt, Nümbrecht, Germany 
biosphere filter tips (200 µl)  Sarstedt, Nümbrecht, Germany 
C-Chip disposable hemocytometer Digital Bio, Seoul, Korea 
cell strainer (70 µm Nylon)  BD Biosciences, Heidelberg, Germany 
cryo tubes (CRYO.S)  greiner bio-one, Frickenhausen, Germany 
EndoTrap red columns Profos, Regensburg, Germany 
eppendorf tubes (1.5 and 2 ml)  Eppendorf, Hamburg, Germany  
falcon cellstar tubes (15 and 50 ml) greiner bio-one, Frickenhausen, Germany  
FastPrep-24 lysing matrix tubes D MP Biomedicals, Heidelberg, Germany 
gauze swabs  Paul Hartmann, Heidenheim, Germany 
hypodermic needle (0.4x20 mm) Braun, Melsungen, Germany 
MACS pre-separation filter (30 µm) Miltenyi Biotec, Bergisch Gladbach, Germany 
MACS separation columns  Miltenyi Biotec, Bergisch Gladbach, Germany 
microscope slides (76x26 mm) ThermoFisher Scientific, Schwerte, Germany 
microtainer brand tubes BD Biosciences, Heidelberg, Germany 
PCR soft tubes (0.2 ml) Biozym, Hessisch Oldendorf, Germany 
petri dishes (21x16 mm) Sarstedt, Nümbrecht, Germany 
safe seal-tips (10 µl und 1000 µl) Biozym, Hessisch Oldendorf, Germany 
sealing tape for 96 well PCR plate  Sarstedt, Nümbrecht, Germany 
single use filter (0.20 and 0.45 µm)  Sartorius Stedim Biotech, Goettingen, Germany 
single use syringe (5 and 10 ml) Braun, Melsungen, Germany 
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stripette (10, 25 and 50 ml)  Corning Costar, Bodenheim, Germany 
titertube micro tubes  BIO-RAD, München, Germany 
tracheal drain tubes (0.7x19 mm) BD Biosciences, Heidelberg, Germany 
transfer pipettes (3.5 ml) Sarstedt, Nümbrecht, Germany  
U96 maxisorp NUNC-immuno plate Nunc, Wiesbaden, Germany 
Whatman blotting papers  Schleicher & Schuell, Dassel, Germany  
MATERIAL AND METHODS 
_____________________________________________________________________________ 
88 
7.1.3 Buffer, media and staining solutions 
Cell culture and cell preparation 
DMEM complete (cDMEM) DMEM high glucose (PAA, Cölbe, Germany) 
10% (v/v) fetal bovine serum 
1 mM L-glutamine 
100 U/ml penicillin G 
100 mg/ml streptomycin 
RPMI complete (cRPMI) RPMI (PAA, Cölbe, Germany) 
10% (v/v) fetal bovine serum 
1 mM L-glutamine 
100 U/ml penicillin G 
100 mg/ml streptomycin 
phosphate buffered saline (PBS) 140 mM NaCl  
3.4 mM KCl  
1.8 mM KH2PO4  
10 mM Na2HPO4 
erythrocyte lysis buffer (pH 7.5) 0.02 M KHCO3 
0.155 M NH4Cl 
0.1 mM EDTA 
intestinal wash buffer Hank`s BBS (PAA, Cölbe, Germany) 
0.1% (v/v) bovine serum albumin (BSA) 
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Cell sorting and flow cytometry 
FACS buffer  PBS, 0.2% (v/v) BSA, 2 mM EDTA 
running buffer (MACS) PBS, 0.2% (v/v) BSA, 2 mM EDTA 
rinsing buffer (MACS) PBS, 2 mM EDTA 
Protein purification (AvCystatin and SNAP-tag) 
LB medium 10 g Tryptone 
10 g NaCl 
5 g yeast extract 
ad. 1 liter H2O dest. 
lysis buffer A1  PBS, 0.1% (v/v) Triton X-100, pH 8 
wash buffer 1  PBS, 10% (v/v) glycerin, pH 6 
wash buffer 2  PBS, 10% (v/v) glycerin, pH 5 
elution buffer  PBS, 10% (v/v) glycerin, pH 3 
neutralization buffer PBS, pH 10 
dialysis buffer  PBS, pH 7.4 
Activity test 
papain reaction buffer 0.2 M K2HPO4 
0.2 M KH2PO4 
0.004 M DTT 
0.004 M EDTA 
0.01% (v/v) Brij 35 




2x loading buffer 10% (v/v) glycerol  
5% (v/v) beta-mercaptoethanol 
3% (v/v) SDS  
100 mM Tris-HCl   
buffer L (pH 8.4)  1.5 Tris-HCl, 0.4% (v/v) SDS 
buffer M (pH 6.8) 0.5 M Tris HCl, 0.4% (v/v) SDS 
stacking gel (6%) 0.75 ml acrylamide (rotiphorese gel 30) 
1.25 ml buffer M  
5 μl TEMED  
3 ml H2O bidest.  
50 μl APS (10%)  
separation gel (14%) 4.7 ml acrylamide (rotiphorese gel 30) 
2.5 ml buffer L  
10 μl TEMED  
2.8 ml H2O bidest.  
100 μl APS (10%) 
SDS running buffer 250 mM Tris-HCl 
1.9 M glycine 
1% (v/v) SDS 
Coomassie staining 2 tablets PhastGel blue R 
20% (v/v) ethanol 
10% (v/v) acetic acid 
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destaining solution 20% (v/v) ethanol 
10% (v/v) acetic acid 
Western blot analysis 
cell lysis buffer 10 mM Tris-HCl, pH 7.2 
1% (v/v) DOC 
1% (v/v) Triton X-100 
1 mM PMSF 
150 mM NaCl 
50 µg/ml leupeptin 
1 mM Na-orthovanadate 
50 mM NaF 
transfer buffer 48 mM Tris-HCl 
39 mM glycine 
0.037% (v/v) SDS 
20% (v/v) methanol 
TBST 10 mM Tris pH 8.0 
150 mM NaCl 
0.1% (v/v) Tween 20 
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7.1.4 Chemicals and biological reagents 
7.1.4.1 Chemicals 
bovine serum albumin fraction V AppliChem, Darmstadt, Germany 
Bz-Arg-pNA (BAPNA) Bachem, Bubendorf, Germany 
dextran sodium sulfate MP Biomedicals, Heidelberg, Germany 
EDTA  AppliChem, Darmstadt, Germany 
ethanol (absolute)  AppliChem, Darmstadt, Germany 
fetal bovine serum  Biochrom, Berlin, Germany 
Imject Alum adjuvant  ThermoFischer Scientific, Schwerte, Germany 
LAL reagent water  Lonza, Cologne, Germany 
L-glutamine  PAA Laboratories, Cölbe, Germany 
lysozyme  Sigma-Aldrich, Steinheim, Germany 
nonfat dried milk powder AppliChem, Darmstadt, Germany 
ovalbumin from chicken egg  Sigma-Aldrich, Steinheim, Germany 
papain from Carica papaya  Sigma-Aldrich, Steinheim, Germany 
paraformaldehyde  Carl Roth, Karlsruhe, Germany 
penicillin/streptomycin PAA Laboratories, Cölbe, Germany 
Percoll  GE Healthcare, München, Germany 
PhastGel blue R tablets Amersham Pharmacia, Freiburg, Germany 
phosphate-citrate buffer tablets Sigma-Aldrich, Steinheim, Germany 
rotiphorese gel 30 (acrylamid) Carl Roth, Karlsruhe, Germany 
sphingosine-1-phosphate (S1P) Calbiochem/Merck, Darmstadt, Germany 
TMB tablets  Sigma-Aldrich, Steinheim, Germany 
water (molecular biology grade) AppliChem, Darmstadt, Germany 
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7.1.4.2 MicroBeads and antibodies 
MicroBeads, dyes and antibodies which were used for cell purification, flow cytometry, 
western blot analysis and subclass-specific ELISA are listed in the following table. 
antibody conjugate clone/source manufacturer 
anti-AKT - rabbit Cell Signalling 
anti-AvCystatin - rabbit Dianova 
anti-Biotin MicroBeads - - Miltenyi Biotec 
anti-DUSP-1 - rabbit Santa Cruz 
anti-IL-10 receptor - 1B1 DRFZ 
anti-mouse CD273 - TY25 eBioscience 
anti-mouse CD274 - MIH5 eBioscience 
anti-mouse CD4 PerCp-eF710 RM4-5 eBioscience 
anti-mouse Foxp3 PE FKJ-16s eBioscience 
anti-mouse IFN-γ Pacific Blue XMG1.2 eBioscience 
anti-mouse IgE - R35-72 BD Biosciences 
anti-mouse IgE HRP MCA419P AbD Serotec 
anti-mouse IgE, κ - C38-2 BD Biosciences 
anti-mouse IgG1 AP Polyclonal Rockland 
Immunochemicals 
anti-mouse IgG1, κ - MOPC-31C BD Biosciences 
anti-mouse IgG2a AP Polyclonal Rockland 
Immunochemicals 
anti-mouse IgG2a, κ - G155-178 BD Biosciences 
anti-mouse IL-10 PE JES5-16E3 BD Biosciences 
anti-mouse-CD11b FITC M1/70 BD Biosciences 
anti-mouse-CD11c Biotin N418 eBioscience 
anti-mouse-CD11c Pacific Blue N418 BD Biosciences 
anti-mouse-CD16/32 APC 2.4G2 DRFZ 
anti-mouse-CD19 Biotin eBio1D3 eBioscience 
anti-mouse-CD19 FITC 1D3 eBioscience 
anti-mouse-CD273 PE TY25 BD Biosciences 
anti-mouse-CD274 PE MIH5 BD Biosciences 
anti-mouse-CD3ε Biotin 145-2C11 Miltenyi Biotec 
anti-mouse-CD4 Pacific Blue RM4-5 BD Biosciences 
anti-mouse-CD40 PE 1C10 eBioscience 
anti-mouse-CD80 PE 16-10A1 eBioscience 
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anti-mouse-CD86 Biotin GL1 eBioscience 
anti-mouse-Dx5 Biotin Dx5 eBioscience 
anti-mouse-F4/80 APC BM8 eBioscience 
anti-mouse-FcγR - 2.4G2 DRFZ 
anti-mouse-Gr1 Biotin RB6-8C5 DRFZ 
anti-mouse-ICAM-1 APC KAT1 DRFZ 
anti-mouse-MHC-II FITC M5/114.15.2 eBioscience 
anti-ovalbumin IgG - rabbit Acris Antibodies 
anti-p38 MAPK - rabbit Cell Signalling 
anti-p44/42 MAPK - rabbit Cell Signalling 
anti-phospho-AKT (Ser473) - rabbit Cell Signalling 
anti-phospho-DUSP-1 
(Ser359) 
- rabbit Cell Signalling 
anti-phospho-p38 MAPK 
(Thr180/Tyr182) 
- rabbit Cell Signalling 
anti-phospho-p44/42 MAPK 
(Thr202/Tyr204) 
- rabbit Cell Signalling 
anti-β-actin - rabbit Cell Signalling 
armenian hamster IgE 
isotype control 
PECy7 HTK888 BioLegend 
CD19 MicroBeads - - Miltenyi Biotec 
CD25 APC PC61 BD Biosciences 
DyLight549 - - ThermoFisher Scientific 
fixable cell viability dye eF780 - eBioscience 
rat IgG1 isotype control PE eBRG1 eBioscience 
rat IgG1 isotype control APC eBRG1 eBioscience 
rat IgG1 isotype control FITC eBRG1 eBioscience 
rat IgG1 isotype control biotin eBRG1 eBioscience 
rat IgG2b κ isotype control PerCp-eF710 eB149/10H5 eBioscience 
streptavidin PECy7 Streptavidin BD Biosciences 




murine GM-CSF PreproTech, Hamburg, Germany 
murine IFN-γ  PreproTech, Hamburg, Germany 
murine IL-4   PreproTech, Hamburg, Germany 
murine IL-13  PreproTech, Hamburg, Germany 
murine IL-21  PreproTech, Hamburg, Germany 
7.1.4.4 Inhibitors and antagonists 
BEC (arginase-1-inhibitor)  Calbiochem/Merck, Darmstadt, Germany 
cytochalasin D Sigma-Aldrich, Steinheim, Germany 
genistein (tyrosine kinase-inhibitor)  Calbiochem/Merck, Darmstadt, Germany 
JNK inhibitor II (JNK-inhibitor) Calbiochem/Merck, Darmstadt, Germany 
Ly294002 (PI3K-inhibitor)  Calbiochem/Merck, Darmstadt, Germany 
proteinase inhibitor cocktail  Roche, Mannheim, Germany 
SB203580 (p38-inhibitor)  Calbiochem/Merck, Darmstadt, Germany 
U0126 (MEK1/2-inhibitor)  Calbiochem/Merck, Darmstadt, Germany 
VPC23019 (S1PR1 antagonist) Avanti Polar Lipids, Alabaster, USA  
7.1.4.5 Other reagents 
brefeldin A (BFA) Sigma-Aldrich, Steinheim, Germany 
CFSE  Sigma-Aldrich, Steinheim, Germany 
collagenase VIII Sigma-Aldrich, Steinheim, Germany 
concanavalin A GE Healthcare, München, Germany 
DNA-ExitusPlus AppliChem, Darmstadt, Germany 
ionomycin Sigma-Aldrich, Steinheim, Germany 
isoflurane Baxter, Munich, Germany 
lipopolysaccharide  Sigma-Aldrich, Steinheim, Germany 
Ni-NTA agarose Qiagen, Hilden, Germany 
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OVA-peptide 323-339 GenScript, Piscataway, USA  
phorbol-12-myristate-acetate (PMA)  Sigma-Aldrich, Steinheim, Germany 
RNA stabilization reagent (RNAlater) Qiagen, Hilden, Germany 
RNase-ExitusPlus  AppliChem, Darmstadt, Germany 
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7.1.5 Primer sequences 
Primer pairs for quantitative real-time PCR were synthesised by and purchased from either 
TIB-MOLBIOL (Berlin, Germany) [1] or RealTimePrimers.com (Pennsylvania, USA) [2]. 
gene accession number sequence (5´- 3´) 
Arginase-1 
[1] 








NM_009914 fw: TCAACTTGGCAATTTCTGACCT 
rv: CAGCATGGACGATAGCCAGG   
DUSP-1 
[1] 












































NM_010927 fw: CCCTTCCGAAGTTTCTGGCAGCAGC 
rv: GGCTGTCAGAGCCTCGTGGCTTTGG 









NM_011333 fw: TTAAAAACCTGGATCGGAACCAA  
rv: GCATTAGCTTCAGATTTACGGGT  
MCP-5 
[1] 




NM_008907 fw: GAGCTGTTTGCAGACAAAGTTC 
rv: CCCTGGCACATGAATCCTGG  
RANTES 
[1] 
NM_013653 fw: GCTGCTTTGCCTACCTCTCC 
rv: TCGAGTGACAAACACGACTGC  
RELM-α 
[1] 
























NM_007393 fw: GGCTGTATTCCCCTCCATCG 
rv: CCAGTTGGTAACAATGCCATGT  
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7.1.6 Commercial kits 
BCA protein assay kit  Pierce Biotechnology, Rockford, USA 
CD4+ T cell isolation kit, mouse Miltenyi Biotec, Bergisch Gladbach, Germay 
ECL plus detection system  Amersham Pharmacia, Freiburg, Germany 
EndoTrap red 10 Profos, Regensburg, Germany 
FastStart universal SYBR green  Roche, Mannheim, Germany 
Hemacolor staining set Merck, Darmstadt, Germany 
High Capacity RNA-to-cDNA kit Applied Biosystems, Darmstadt, Germany 
innuPREP RNA kit  Analytikjena, Jena, Germany 
Limulus amoebocyte lysate QCL 1000 Cambrex, Walkersville, USA 
mouse IFN-γ ELISA Ready-Set-Go  eBioscience, Frankfurt am Main, Germany 
mouse IL-10 OptEIA ELISA set BD Biosciences, Heidelberg, Germany 
mouse IL-12 (p40) OptEIA ELISA set BD Biosciences, Heidelberg, Germany 
mouse IL-13 ELISA Ready-Set-Go  eBioscience, Frankfurt am Main, Germany 
mouse IL-2 ELISA Ready-Set-Go  eBioscience, Frankfurt am Main, Germany 
mouse IL-4 ELISA Ready-Set-Go  eBioscience, Frankfurt am Main, Germany 
mouse IL-5 ELISA Ready-Set-go   eBioscience, Frankfurt am Main, Germany 
QuantiChrom urea assay kit  BioAssay Systems, Hayward, USA 
7.1.7 Software 
EndNote (v. X4.0)  Thomson Reuters, Carlsbad, USA 
Adobe Photoshop CS3 (v. 10.0) Adobe Systems Incorporated, San Jose, USA 
Application Suite Software (v. 2.8.1) Leica, Solms, Germany 
FlowJo Software (v. 8.8.7)  Tree Star, Ashland, USA 
GraphPad Prism Software (v. 5.02) GraphPad Software, San Diego, USA 




7.2.1 Animals and ethics statement 
If not otherwise stated animals were purchased from Charles River, Sulzfeld, Germany or the 
Federal Institute for Risk Assessement (BfR) in Berlin, Germany. DUSP-1-deficient mice and 
control littermates were a kind gift from Roland Lang, Friedrich-Alexander Universität, 
Erlangen-Nürnberg, Germany. IL-10-deficient mice were provided by Ute Hoffmann and Alf 
Hamann, German Rheumatism Research Centre (DRFZ), Charité Hospital, Berlin, Germany. 
All experiments were approved by the animal ethics committee of the local government 
(State Office of Health and Social Affairs Berlin, Germany) and performed in accordance with 
the German law and national guidelines for animal protection. Animals were kept in ICV-
cages with filter caps and sacrificed with isoflurane (Baxter, Munich, Germany).  
7.2.2 Basic laboratory techniques 
7.2.2.1 Protein purification 
AvCystatin and SNAP-tag control protein were expressed in Escherichia coli. Pellets were 
resuspendet in lysis buffer (PBS, 0.1% Triton, pH 8) and incubated with lysozyme (Sigma-
Aldrich, Steinheim, Germany) on ice for 30 minutes. The cell suspension was sonificated (30 
cycles, MS72/D for 2 minutes) and centrifuged with 12000 rpm at 4°C for 15 minutes. 
Supernatants were collected and purified by affinity chromatography using Ni-NTA agarose 
(Qiagen, Hilden, Germany). Proteins were eluted by pH gradient (consecutive treatment with 
PBS, 10% glycerin, pH 6, 5 and 3), neutralized by neutralization buffer (PBS, pH 10) and 
afterwards dialysed against PBS over night and for additional two hours on the following day. 
Endotoxin was removed with EndoTrap red columns (Profos, Regensburg, Germany) and 
final concentrations measured by Limulus amoebocyte lysate (LAL) Kit QCL 1000 (Cambrex, 
Walkersville, USA). Residual endotoxin levels of purified proteins were below 0.1 endotoxin 
units/ml (EU/ml). Protein concentrations were measured by BCA protein assay kit according 
to the manufacturer`s instructions (Pierce Biotechnology, Rockford, USA). AvCystatin was 
heat-inactivated by cooking at 95°C for 10 minutes and used as a control to exclude that 
modulatory effects on macrophages arise from contaminations in the buffer. The control 
protein SNAP-tag constitutes a 20 kDa mutant of the DNA repair protein O6-alkylguanine-
DNA alkyltransferase and does not exert side effects on macrophage cultures as determined 
by own experiments (data not shown). Both controls, denatured AvCystatin and SNAP-tag 
protein, were determined to have similar residual LPS values as AvCystatin protein. 
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7.2.2.2 Activity test 
To test the inhibitory activity of AvCystatin, purified protein was incubated in a dose-
dependent manner with the cysteine protease papain (Sigma-Aldrich, Steinheim, Germany) 
and its substrate Bz-Arg-pNA (Bachem, Bubendorf, Switzerland) in a 96 well flat bottom 
ELISA plate (ThermoFisher Scientific, Schwerte, Germany). Papain was solved in reaction 
buffer (0.2 M K2HPO4, 0.2 M KH2PO4, 0.004 M DTT, 0.004 M EDTA and 0.01% Brij 35) for a 
concentration of 100 µM. Bz-Arg-pNA (BAPNA) was solved in DMSO for a concentration of 
92 µM. 5 µl papain solution (100 µM) was incubated with 10 µl BAPNA (92 µM), different 
concentrations of AvCystatin (0.05 µM, 0.1 µM, 0.25 µM, 0.5 µM, 1 µM, 2 µM and 3 µM) and 
the respective amount PBS for a total volume of 200 µl per well. Plates were incubated for 30 
minutes at 37°C and the substrate absorption measured at a wavelength of 405 nm.    
7.2.2.3 SDS-PAGE and Coomassie staining 
In order to determine protein expression or to perform western blot analysis, proteins were 
separated through sodium-dodecyl-sulfate-polyacrylamid-gelelectrophoresis (SDS-PAGE). 
Total cell extracts were mixed with 2x sample buffer and heated for 5 minutes at 95°C. Gels 
of 14% polyacrylamid were used in combination with a 6% stacking gel and run at 
120V/400mA. Coomassie staining (2 PhastGel blue R tablets dissolved in 20% ethanol and 
10% acetic acid) was performed for 30 minutes at 60°C. Gels were thereafter treated with 
destaining solution (20% ethanol, 10% acetic acid) to remove unbound Coomassie.    
7.2.2.4 Western blot analysis 
Cells were treated with lysis buffer (10 mM Tris-HCl pH 7.2, 1% DOC, 1% Triton X-100, 1 
mM PMSF, 150 mM NaCl, 50 µg/ml leupeptin, 1 mM Na-orthovanadate, 50 mM NaF) and 7-
30 µg cell extract separated by SDS-PAGE. After blotting, Whatman membranes (Schleicher 
& Schuell, Dassel, Germany) were blocked in TBST (10 mM Tris pH 8.0, 150 mM NaCl, 
0.1% Tween 20) with 5% non-fat dry milk (AppliChem, Darmstadt, Germany) for one hour 
and incubated with primary antibodies overnight. On the following day, membranes were 
washed, incubated with secondary peroxidase-conjugated antibodies and signals detected 
via chemiluminescence reaction by using the ECL plus western blotting detection system 
according to the manufacturer`s instructions (Amersham Pharmacia Biotech, Freiburg, 
Germany).      
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7.2.2.5 RNA isolation, reverse transcription and real-time PCR 
Isolation of total RNA and reverse transcription was performed with the innuPREP RNA kit 
(Analytikjena, Jena, Germany) and the High Capacity RNA-to-cDNA kit (Applied Biosystems, 
Darmstadt, Germany). Real-time PCR was performed with the ABI Prism 7300 sequence 
detection system (Applied Biosystems, Darmstadt, Germany) by using SYBR Green PCR 
reagents (FastStart Universal SYBR Green Master (Rox)) according to the manufacturer`s 
guidelines (Roche, Mannheim, Germany). Relative changes in gene expression were 
calculated with the ABI 7300 SDS software (Applied Biosystems, Darmstadt, Germany) and 
transcript levels normalized to ct values of the housekeeping gene peptidylprolyl isomerase A 
(PPIA) using the ∆∆ct method (Livak and Schmittgen, 2001). PCR programme: 95°C for 10 
minutes (1 cycle); 95°C for 15 seconds and 60°C for 30 seconds (40 cycles); 95°C for 15 
seconds, 60°C for 30 seconds and 95°C for 15 seconds (1 cycle). 
7.2.3 AvCystatin labeling and tracking 
7.2.3.1 Uptake of AvCystatin by peritoneal cells 
Recombinant AvCystatin was labelled with DyLight549 (ThermoFischer Scientific, Schwerte, 
Germany; labeling degree of 1 mole dye/mole AvCystatin) and intraperitoneally administered 
into BALB/c mice (40 µg/mouse). Peritoneal exudate cells were isolated 20 minutes after 
intraperitoneal injection and washed twice with cold FACS buffer (Dulbecco`s PBS, 0.2% 
BSA, 2 mM EDTA). PEC were stained with anti-CD4-Pacific Blue (clone RM4-5; BD 
Biosciences, Heidelberg, Germany), anti-CD19-FITC (clone 1D3; eBioscience, Frankfurt am 
Main, Germany), anti-F4/80-APC (clone BM8; eBioscience, Frankfurt am Main, Germany), 
anti-CD11b-FITC (clone M1/70; BD Biosciences, Heidelberg, Germany), anti-CD11c-Pacific 
Blue (clone N418; BD Biosciences, Heidelberg, Germany) and anti-Gr1-Biotin (clone RB6-
8C5; DRFZ, Berlin, Germany), streptavidin-PECy7 (clone Streptavidin; BD Biosciences, 
Heidelberg, Germany). 20 µg/ml anti-mouse-FcγR (clone 2.4G2; DRFZ, Berlin, Germany) 
was added to prevent non-specific binding. Uptake of labelled AvCystatin was detected by 
LSRFortessa flow cytometer (BD Biosciences, Heidelberg, Germany) and analysed via 
FlowJo software version 8.8.7 (Tree Star, Ashland, USA). Moreover, PEC were isolated from 
BALB/c mice 20 minutes after intraperitoneal injection of DyLight594-labelled AvCystatin (40 
µg/animal). Cells were washed with cold FACS buffer, treated with 20 µg/ml anti-mouse-
FcγR (clone 2.4G2; DRFZ, Berlin, Germany) and stained with anti-CD11b-FITC (clone 
M1/70; BD Biosciences, Heidelberg, Germany). Confocal microscopy was performed by 
using Leica TCS SP2 confocal microscope (Leica, Solms, Germany). 
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7.2.3.2 Mode of AvCystatin uptake 
PEC from BALB/c mice were incubated in vitro with 5 µg/ml DyLight549-AvCystatin for 30 
minutes at 37°C or 4°C. After 30 minutes, cells were washed with cold FACS buffer, treated 
with 20 µg/ml anti-mouse-FcγR (clone 2.4G2; DRFZ, Berlin, Germany), stained with anti-
F4/80-APC (clone BM8; eBioscience, Frankfurt am Main, Germany) and DyLight549 signals 
measured by flow cytometry. The kinetics of AvCystatin uptake was performed by western 
blot analysis. 2x106 PEC of BALB/c mice were seeded in 24 well plates (Corning Costar, 
Bodenheim, Germany) and cultured in DMEM containing 1 mM L-glutamine, 100 U/ml 
penicillin G and 100 mg/ml streptomycin without FCS. After two hours, cells were washed 
with fresh and pre-warmed medium to remove non-adherend cells. Remaining cells were 
stimulated with 5 µg/ml AvCystatin at 37°C for various timepoints or at 4°C for 30 minutes. In 
addition, some cells were treated with AvCystatin in the presence of 10 mM cytochalasin D 
(Sigma-Aldrich, Steinheim, Germany) at 37°C for 15, 30 and 60 minutes. After indicated 
timepoints, cells were washed with cold Dulbecco`s PBS, treated with cell lysis buffer and 
whole cell extracts analysed by western blotting using primary antibodies against AvCystatin 
(Dianova, Hamburg, Germany) and β-actin (Cell Signalling Technology, Frankfurt am Main, 
Germany). 
7.2.4 Detection of signalling events in AvCystatin-MФ 
7.2.4.1 Inhibitor studies 
Peritoneal macrophages of naïve BALB/c mice were incubated in vitro with specific inhibitors 
(all inhibitors were tested in advance for cytotoxicity) 60 minutes prior to stimulation with 0.5 
µM AvCystatin or control treatments (denatured AvCystatin or SNAP-tag). Briefly, 
macrophages were cultured with AvCystatin or control applications for 18 hours in the 
presence of PI3K inhibitor (Ly294002), p38 inhibitor (SB203580), MEK1/2 inhibitor (U0126), 
JNK inhibitor (JNK inhibitor II) and tyrosine kinase inhibitor genistein (all from 
Calbiochem/Merck, Darmstadt, Germany) in a dose-dependent manner. Culture 
supernatants were collected after 18 hours and analysed for IL-10 by ELISA according to the 
manufacturer`s instructions (BD Biosciences, Heidelberg, Germany). 
7.2.4.2 Detection of MAPK phosphorylation in AvCystatin-MФ 
Peritoneal macrophages of BALB/c mice were stimulated in vitro for various timepoints with 
AvCystatin or denatured AvCystatin. The cells were washed afterwards with Dulbecco`s PBS 
and treated with cell lysis buffer. Western blot analysis of total cell extracts was performed by 
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using primary antibodies against phospho-p38 (Thr180/Tyr182), total p38, phospho-p44/42 
(Thr202/Tyr204), total-p44/42, phospho-AKT (Ser473), total AKT and β-actin according to the 
manufacturer`s protocol (all from Cell Signalling Technology, Frankfurt am Main, Germany).  
7.2.4.3 Detection of DUSP expression in AvCystatin-MФ 
For in vitro detection of DUSPs, peritoneal macrophages of BALB/c mice were stimulated 
with 0.5 µM AvCystatin or control treatments (denatured AvCystatin or SNAP-tag). After 
various timepoints, cells were washed with cold Dulbecco`s PBS and treated with lysis buffer 
for RNA extraction (Analytikjena, Jena, Germany). Furthermore, DUSP-1-deficient and 
wildtype mice (both C57BL/6) were intraperitoneally injected with 20 µg AvCystatin or 
denatured AvCystatin. Macrophages were purified from the PEC population and treated with 
lysis buffer for RNA extraction (Analytikjena, Jena, Germany). RNA was isolated from cell 
lysates, transversly transcribed into cDNA and used for quantitative real-time PCR to analyse 
the expression of DUSP-1, DUSP-2, DUSP-3, DUSP-5, DUSP-6 and DUSP-10. To 
determine DUSP-1 phosphorylation in naïve BALB/c mice or MAPK phosphorylation in 
DUSP-1-deficient mice and wildtype littermates, whole cell extracts of in vitro-stimulated 
macrophages were analysed by western blotting with primary antibodies against phospho-
DUSP-1 (Ser359), DUSP-1, phospho-p38 (Thr180/Tyr182), phospho-p44/42 
(Thr202/Tyr204) and β-actin. 
7.2.5 Functional and molecular characterization of AvCystatin-MФ 
7.2.5.1 Cell purification and adoptive cell transfer 
Mice were intreaperitoneally treated with 20 µg AvCystatin or control applications. PEC were 
isolated after 18-20 hours and either used directly for cell transfer (3x106 cells/mouse) or 
purified for macrophages and B cells. Purification of B cells was performed by incubating 
PEC with anti-CD19 MicroBeads and subsequent magnetic cell separation by autoMACS 
according to the manufacturer`s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Macrophages were purified by incubating PEC with biotinylated antibodies anti-CD3ε (clone 
145-2C11; Miltenyi Biotec, Bergisch Gladbach, Germany), anti-CD19 (clone eBio1D3; 
eBioscience, Frankfurt am Main, Germany), anti-CD11c (clone N418; eBioscience, Frankfurt 
am Main, Germany), anti-Gr1 (clone RB6-8C5; DRFZ, Berlin, Germany) and anti-Dx5 (clone 
Dx5; eBioscience Frankfurt am Main, Germany). Addition of 40 µg/ml anti-mouse FcγR 
(clone 2.4G2; DRFZ, Berlin, Germany) was used to avoid non-specific binding. Cells were 
washed with Dulbecco`s PBS supplemented with 0.2% BSA and 2 mM EDTA and incubated 
with anti-Biotin MicroBeads as described in the manufacturer`s protocol (Miltenyi Biotec, 
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Bergisch Gladbach, Germany). After incubation, magnetic cell separation was performed by 
using autoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of macrophages (> 
95 %) or B cells (90-95%) was determined by flow cytometry for the expression of F4/80, 
CD11b or CD19. 2x106 purified macrophages or B cells were resuspended in 0.2 ml PBS 
and intravenously transferred into mice one day after access to DSS (model of DSS-induced 
colitis) or on day 24 into ovalbumin-sensitized mice prior to intranasal provocation with 
ovalbumin. To examine macrophage survival in recipient animals, purified macrophages 
were labelled with 5 µM CFSE (Sigma-Aldrich, Steinheim, Germany) for 8 minutes at room 
temperature. Labeling was stopped by adding 100 µl/ml FCS (Biochrom, Berlin, Germany). 
Cells were washed twice with Dulbecco`s PBS and adoptively transferred into recipient mice. 
Seven days after cell transfer, BAL-fluid, lung tissue, splenocytes and peribronchial lymph 
nodes were analysed for CFSE-labelled macrophages by LSRFortessa flow cytometer (BD 
Biosystems, Heidelberg, Germany) and FlowJo Software version 8.8.7 (Tree Star, Ashland, 
USA).  
7.2.5.2 Model of ovalbumin-induced airway hyperreactivity 
Induction of airway inflammation. Female BALB/c mice were sensitized by intraperitoneal 
injections on day 0 and 14 with 20 µg ovalbumin from chicken egg (Sigma-Aldrich, 
Steinheim, Germany) emulsified in 2 mg Imject Alum adjuvant (ThermoFisher Scientific, 
Schwerte, Germany) in 200 µl Dulbecco`s PBS (PAA Laboratories, Cölbe, Germany). Airway 
challenge was performed through intranasal application of 50 µg ovalbumin per animal on 
day 28 and 29. Naïve control mice were sensitized with PBS in Imject Alum adjuvant and 
challenged with PBS instead of ovalbumin. On day 31, blood samples were collected for 
antibody analysis and animals thereafter sacrificed with isoflurane (Baxter, Munich, 
Germany). Lungs were flushed to determine cell numbers and cytokine quantities in the BAL-
fluid and afterwards fixed with 3.5% paraformaldehyde (Carl Roth, Karlsruhe, Germany) for 
histological analysis. In parallel, cryoconservation of lung tissue was performed and samples 
stored in a -80°C freezer. Moreover, the spleen was removed to prepare splenocytes for cell 
culture experiments.    
Bronchoalveolar lavage and histological analysis of lung sections. The trachea of 
sacrificed mice was exposed and flushed twice with 800 µl protease inhibitor cocktail (1 
complete Mini inhibitor cocktail tablet from Roche, Mannheim, Germany dissolved in 10 ml 
Dulbecco`s PBS) through a tracheal drain tube (BD Bioscienses, Heidelberg, Germany). The 
weight of both lavages was measured and the supernatant of the first lavage stored at -20 °C 
for cytokine detection. After a centrifugation step (2000 rpm, 10 min, 4°C), the cell pellets of 
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both lavages were pooled in a total volume of 1 ml Dulbecco`s PBS and counted. Cytospin 
slides were prepared from 100 µl BAL fluid by using the cytospin centrifuge cellspin I 
(Tharmac, Waldsolms, Germany), stained with the Hemacolor® staining set for microscopy 
(Merck, Darmstadt, Germany) and analysed for different cell types in a blinded fashion. 
Lungs were fixed in 3.5% paraformaldehyde for histological analysis and embedded into 
paraffin. PAS and HE staining was performed for preparations of 5 µm slices to determine 
mucus production and inflammatory cell infiltration. Stained slices were analysed through 
light microscopy with 200-fold magnification (Leica DFC480 camera and Leica Application 
Suite Software version 2.8.1 from Leica, Solms, Germany). Staining and analysis of lung 
sections was performed by Christoph Loddenkemper and Anja Kühl, Research Center 
ImmunoSciences, Immunopathology, Charité Hospital, Berlin, Germany. 
Chemokine detection in lung homogenates. Lung tissue was homogenized by using 
FastPrep-24 lysing matrix tubes D and the FastPrep-24 homogenizer according to the 
manufacturer`s guidelines (both MP Biomedicals, Heidelberg, Germany). RNA was extracted 
from lung homogenates, transcribed into cDNA and quantitative real-time PCR performed for 
specific chemokines and chemokine receptors. 
Splenocyte preparation and stimulation. The spleen was isolated from euthanized mice 
under sterile conditions and mashed through a 70 µm nylon cell strainer (BD Biosciences, 
Heidelberg, Germany) in Dulbecco`s PBS containing 0.2% BSA. Cells were centrifuged 
(1200 rpm, 4°C, 10 min) and resuspended in 5-8 ml erythrocyte lysis buffer (0.02 M KHCO3, 
0.155 M NH4Cl, 0.1 mM EDTA). After incubation on ice for 5 minutes, cells were washed, 
counted and adjusted to the favoured cell concentration in RPMI supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin G and 100 µg/ml streptomycin (cRPMI). 3x105 
splenocytes were seeded in 96 well plates (Corning Costar, Bodenheim, Germany) and 
stimulated with 50 µg/ml ovalbumin, 2.5 µg/ml concavalin A (both GE Healthcare, Munich, 
Germany) or 10 µg/ml AvCystatin. After 96 hours, culture supernatants were collected and 
stored at -20°C for cytokine detection.  
Cytokine- and sublass-specific ELISA. Cytokine levels were assessed by sandwich ELISA 
for IFN-γ, IL-4, IL-5, IL-13 (all from eBioscience, Frankfurt am Main, Germany) and IL-10 (BD 
Biosciences, Heidelberg, Germany) in the BAL-fluid and splenocyte culture supernatants. For 
the detection of ovalbumin-specific IgE, 96 well flat bottom ELISA plates (ThermoFisher 
Scientific, Schwerte, Germany) were coated with 10 µg/ml ovalbumin at 4°C overnight and 
unspecific binding blocked by 3% BSA (AppliChem, Darmstadt, Germany) in PBS for one 
hour. After incubation with mouse serum for two hours, anti-mouse IgE-HRP (clone 
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MCA419P; Serotec, Düsseldorf, Germany) was used as detection antibody and specific 
binding visualized by application of the HRP-substrate TMB (Sigma-Aldrich, Steinheim, 
Germany). Ovalbumin-specific IgG1 and IgG2 were measured in an analogical manner 
whereas alkaline phosphatase-conjugated anti-mouse IgG1 and IgG2a (both clone 
Polyclonal; Rockland Immunochemicals, Gilbertsville, USA) were used as detection 
antibodies and nitrophenylphosphat (Sigma-Aldrich, Steinheim, Germany) as substrate. To 
calculate antibody amounts, purchasable anti-mouse IgE, κ- (clone C38-2), IgG1, κ- (clone 
MOPC-31C) and IgG2a, κ- (clone G155-178) standards were used (all from BD Biosciences, 
Heidelberg, Germany). To determine total IgE levels, 96 well flat bottom plates were coated 
with 4 µg/ml anti-mouse IgE capture antibody (clone R35-72; BD Biosciences, Heidelberg, 
Germany) at 4°C overnight and further treated as described for ovalbumin-specific IgE. 
7.2.5.3 Model of DSS-induced colitis 
Colitis was induced by providing 3% DSS (MP Biomedicals, Heidelberg, Germany, Lot No. 
6683K) dissolved in drinking water to female CL57/BL6 mice over a total time period of 8 
days. 3x106 AvCystatin- or control-treated macrophages were intravenously administered 
into mice one day after access to DSS. Changes in body weight were determined during day 
0 and day 8. After dissection on day 8, the colon length of each animal was measured and 
parts of distal colon fixed in 3.5% paraformaldehyde (Carl Roth, Karlsruhe, Germany) for 
histological analysis. Stained colon sections were analysed by light microscopy with 100-fold 
magnification (Leica DFC480 camera and Leica Application Suite Software version 2.8.1 
from Leica, Solms, Germany). Colon tissue was further treated with HBBS containing 1% 
BSA (AppliChem, Darmstadt, Germany) and 2 mM EDTA (AppliChem, Darmstadt, Germany) 
to remove the intestinal epithelial layer and digested with collagenase VIII (Sigma Aldrich, 
Steinheim, Germany) for one hour at 37°C in a water bath. Separation of lamina propria 
mononuclear cells was performed by Percoll gradient (GE Healtcare, Munich, Germany). 
Lamina propria cells were stained with PE-conjugated anti-mouse SiglecF (clone E50-2440; 
BD Biosciences, Heidelberg, Germany) and analysed by flow cytometry (LSRFortessa, BD 
Biosystems, Heidelberg, Germany) and FlowJo software version 8.8.7 (Tree Star, Ashland, 
USA). Quantification of inflammatory cells was performed for F4/80+, MPO7+, CD3+ and 
B220+ cells by counting the respective cells in 10 high power fields of stained colon slices. 
Staining and analysis of distal colon sections was performed by Anja Kühl, Research Center 
ImmunoSciences, Immunopathology, Charité Hospital Berlin, Germany. Histopathology was 
determined by using the following scoring scheme: 
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Scoring = infiltration + tissue damage (0-6) 
inflammation: 
0: no inflammation 
1: increased number of inflammatory cells in lamina propria 
2: inflammatory cells extending into submucosa 
3: transmural inflammatory infiltrates 
tissue damage:  
0: no mucosal damage 
1: discrete epithelial lesion 
2: erosion or focal ulceration  
3: severe mucosal damage with extended ulcerations extending into bowel wall 
7.2.5.4 Macrophage characterization 
Transcriptional profiling. For the characterization of in vitro-stimulated macrophages, PEC 
were isolated from BALB/c mice, seeded in 24 well plastic tissue-culture dishes (Corning 
Star, Bodenheim, Germany) and incubated at 37°C and 5% CO2 in DMEM supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin G and 100 µg/ml streptomycin (cDMEM). 
After 4 hours, non-adhering cells were removed by washing with pre-warmed cDMEM. 
Remaining macrophages were cultured over night in cDMEM and stimulated on the following 
day with either 0.5 µM AvCystatin or control treatments. Macrophages were washed with 
Dulbecco`s PBS after indicated timepoints and frozen at -80°C in lysis buffer for RNA 
extraction (Analytikjena, Jena, Germany). For the characterization of in vivo-stimulated cells, 
macrophages were purified from isolated PEC of AvCystatin- or control-treated animals 18-
20 hours after treatment as described earlier. Purified macrophages were treated with lysis 
buffer for RNA extraction (Analytikjena, Jena, Germany) and frozen at -80°C. 
Surface marker profile. Surface marker expression was determined for F4/80+CD11b+ 
macrophages 18-20 hours after intraperitoneal treatment with AvCystatin or controls by using 
anti-MHC-II-FITC (clone M5/114.15.2; eBioscience, Frankfurt am Main, Germany), anti-
CD274-PE (clone MIH5; BD Biosciences, Heidelberg, Germany), anti-CD273-PE (clone 
TY25; BD Biosciences, Heidelberg, Germany), anti-CD40-PE (clone 1C10; eBioscience, 
Frankfurt am Main, Germany), anti-CD86-Biotin (clone GL1; eBioscience, Frankfurt am Main, 
Germany), streptavidin-PECy7 (clone Streptavidin; BD Biosciences, Heidelberg, Germany), 
anti-CD16/32-APC (clone 2.4G2; DRFZ, Berlin, Germany), anti-CD80-PE (clone 16-10A1; 
eBioscience, Frankfurt am Main, Germany) and anti-ICAM-1-APC (clone KAT1; DRFZ, 
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Berlin, Germany). Non-specific binding was prevented by adding 20 µg/ml anti-mouse FcγR 
(clone 2.4G2; DRZF, Berlin, Germany). After antibody binding, cells were washed with FACS 
buffer and flow cytometry performed by using LSRFortessa flow cytometer (BD Biosciences, 
Heidelberg, Germany) and FlowJo Software version 8.8.7 (Tree Star, Ashland, USA). 
7.2.5.5 In vivo expression of IL-10 in CD4+ T cells 
CD4+ T cells were purified from the spleen of ovalbumin-sensitized and -challenged mice 
seven days after adoptive transfer of macrophages by using the CD4+ T cell isolation kit 
according to the manufacturer`s guidelines (both from Miltenyi Biotec, Bergisch Gladbach, 
Germany). 1x106 purified CD4+ T cells were stimulated with ovalbumin (50 µg/ml) or ConA 
(2.5 µg/ml) for 96 hours in cRPMI. The culture supernatants were collected and frozen for IL-
10 cytokine ELISA (BD Biosciences, Heidelberg, Germany). Cells were treated with lysis 
buffer for RNA extraction (Analytikjena, Jena, Germany). RNA was isolated from cell lysates, 
transcribed into cDNA and IL-10 expression determined by quantitative real-time PCR.  
7.2.5.6 In vitro co-culture assays 
Cell generation and preparation. To generate dendritic cells from BALB/c mice, the bone 
marrow from the femur and tibia of murine hind legs was flushed with RPMI supplemented 
with 100 U/ml penicillin G and 100 mg/ml streptomycin and collected in a pre-cooled sterile 
petri dish (Sarstedt, Nümbrecht, Germany). The marrow was dissociated by slightly pipetting 
up and down and cells filtered through a 70 µM nylon cell strainer (BD Biosciences, 
Heidelberg, Germany). After centrifugation (1200 rpm, 4°C, 10 min), erythrocyte lysis was 
performed for 5 minutes on ice. Cells were washed, counted, seeded in a petri dish with a 
density of 4x106 cells in 10 ml cRPMI supplemented with 20 ng/ml murine GM-CSF 
(PreproTech, Hamburg, Germany) and incubated at 37°C and 5% CO2. Three days later, 10 
ml pre-warmed cRPMI containing 10 ng/ml GM-CSF was added. Dendritic cells were 
harvested on day seven, resuspended in fresh cRPMI and either directly used for co-culture 
assays or pre-treated with 1 µg/ml ovalbumine-peptide 323-339 (GenScript, Piscataway, 
USA). After incubation at 37°C for two hours, the remaining peptide was washed away and 
dendritic cells were used for co-culture experiments. Splenocytes were prepared from the 
spleen of euthanized DO11.10 TGN Jackson mice and ovalbumin-specific CD4+ T cells 
purified by using the CD4+ T cell isolation kit according to the manufacturer`s description 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purification of macrophages from 
AvCystatin- (20 µg/mouse) or control-treated BALB/c mice was performed as described 
previously. 
MATERIAL AND METHODS 
_____________________________________________________________________________ 
110 
In vitro co-culture. Ovalbumin-specific CD4+ T cells were incubated with macrophages and 
ovalbumin-peptide-treated dendritic cells in a ratio of 5:1:1. The assays were performed in a 
mixed population and a transwell approach separating the macrophages from dendritic cells 
and T cells through a 1.0 µm filter membrane (greiner bio-one, Frickenhausen, Germany). 
CD4+ T cells and dendritic cells were additionally incubated in the presence of fresh 
macrophage supernatants. Therefore, macrophages were cultured separately for 18 hours 
and the macrophage culture supernatant was subsequently added to CD4+ T cells and 
dendritic cells. Culture supernatants were collected after 48 hours and analysed by ELISA for 
IL-10 (BD Biosciences, Heidelberg, Germany), IL-2, IFN-γ and IL-13 (all from eBioscience, 
Frankfurt am Main). Remaining cells were intracellularly stained for IL-10. Therefore, cells 
were stimulated with 1 µg/ml PMA/ionomycin (Sigma-Aldrich, Steinheim, Germany) for three 
hours in fresh cRPMI at 37°C and 5% CO2. After 30 minutes, 1 µg/ml brefeldin A (Sigma-
Aldrich, Steinheim, Germany) was added. Cells were washed with FACS buffer, stained with 
anti-CD4-PerCP-eF710 (clone RM4-5; eBioscience, Frankfurt am Main, Germany) and 
incubated for 15 minutes on ice. In addition, 20 µg/ml anti-mouse-FcγR (clone 2.4G2; DRFZ, 
Berlin, Germany) was added to prevent unspecific binding. After being washed, cells were 
permeabilized with the fixation/permeabilization kit from BD Biosciences, Heidelberg, 
Germany according to the manufacturer`s instructions, intracellularly stained with anti-IL-10-
PE (clone JES5-16E3; eBiosciences, Frankfurt am Main, Germany) and analysed by 
LSRFortessa flow cytometer (BD Biosciences, Heidelberg, Germany) and FlowJo software 
version 8.8.7 (Tree Star, Ashland, USA). To evaluate an autocrine impact of IL-10 on CD4+ T 
cell cytokine responses, splenic CD4+ T cells of DO11.10 TGN Jackson mice were pre-
incubated with 10 µg/ml anti-IL-10 receptor antibody (clone 1B1; DRFZ, Berlin, Germany) for 
one hour and finally co-cultured with AvCystatin- or control-stimulated macrophages and 
ovalbumin-peptide-treated dentritic cells as described previously. Levels of IL-10, IL-2, IFN-γ 
and IL-13 were quantified in the culture supernatants by ELISA.  
Co-culture experiments using macrophage populations. Peritoneal macrophages were 
purified from naïve BALB/c mice and in vitro polarized into M1, M2a, M2b and AvCystatin-
macrophages. For M1 polarization, macrophages were treated with 100 U/ml IFN-γ 
(PreproTech, Hamburg, Germany) and 10 ng/ml LPS (Sigma-Aldrich, Steinheim, Germany) 
for 18-20 hours. M2a polarization was performed by pre-treating macrophages with 20 ng/ml 
IL-21 for 6 hours and subsequent incubation with 20 ng/ml IL-4/IL-13 for 18-20 hours (all 
from PreproTech, Hamburg, Germany). For M2b polarization, macrophages were stimulated 
with 150 µg ovalbumin immune complexes (Acris Antibodies, San Diego, USA) and 10 ng/ml 
LPS (Sigma-Aldrich, Steinheim, Germany) for 18-20 hours. AvCystatin- and control-treated 
macrophages were induced either in vitro through stimulation with 0.5 µM AvCystatin or the 
MATERIAL AND METHODS 
_____________________________________________________________________________ 
111 
same amount of denatured AvCystatin or in vivo through intraperitoneal injection of 
AvCystatin or control treatments. All in vitro stimulations were performed in cRPMI at 37°C 
and 5% CO2. Macrophages were afterwards washed with fresh cRPMI to ensure that the 
respective polarizing stimuli do not affect other cells in the co-culture. In vivo-generated 
AvCystatin- and control-macrophages were isolated and purified from the peritoneal cavity 
18-20 hours after intraperitoneal injection. Both in vitro- and in vivo-polarized macrophages 
were either incubated alone for 48 hours to determine IL-10 self-production by the different 
populations or in combination with ovalbumin-specific CD4+ T cells and ovalbumin-peptide-
treated dendritic cells. IL-10 levels were measured by ELISA in the supernatants and 
compared between macrophage cultures and co-cultures of macrophages, CD4+ T cells and 
dendritic cells.    
Analysis of macrophage markers for the induction of CD4+IL-10+ T cells. To investigate 
the effect of sphingosine kinase-1 on the IL-10 induction in T cells, ovalbumin-specific CD4+ 
T cells were pre-treated with different concentrations of the S1PR1 antagonist VPC23019 
(Avanti Polar Lipids, Alabaster, USA) for one hour at 37°C and 5% CO2 and thereafter 
incubated with in vivo-stimulated macrophages and ovalbumin-peptide-treated dendritic cells. 
In parallel, co-cultures of CD4+ T cells and dendritic cells were supplemented with various 
concentrations of S1P (Calbiochem/Merck, Darmstadt, Germany). To determine a possible 
function of ARG-1 or programmed death ligands for the induction of IL-10 in CD4+ T cells, in 
vivo-generated AvCystatin-MФ were treated in a dose-dependent manner with the ARG-1 
inhibitor BEC (Calbiochem/Merck, Darmstadt, Germany) or anti-PD-L1 and anti-PD-L2 
antibodies (both from eBioscience, Frankfurt am Main, Germany) for one hour at 37°C and 
5% CO2 and subsequently cultured with CD4+ T cells and dendritic cells. The activity of BEC 
was tested by measuring urea concentrations in the supernatants of M2a macrophage 
cultures by using the QuantiChrom urea assay kit according to the manufacturer`s protocol 
(BioAssay Systems, Hayward, USA). Both, anti-PD-L1 and anti-PD-L2 were formerly 
evaluated for their inhibitory potential by Terrazas et al. (2005). All co-culture experiments 
were performed in cRPMI.   
7.2.6 Statistical analysis 
Statistical analysis and graphical output was performed with GraphPad Prism Software, 
version 5.02 (GraphPad Software, San Diego, USA). Data is presented as mean ± SEM and 
was first tested with a one-way ANOVA test followed by the Bonferroni´s multiple comparison 
test to retrieve statistical significance between experimental groups. Differences between 
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